UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
Filed by the Registrant |
|
☒ |
Filed by party other than the registrant |
|
☐ |
Check
the appropriate box:
☒ |
|
Preliminary Proxy Statement |
☐ |
|
Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) |
☐ |
|
Definitive Proxy Statement |
☐ |
|
Definitive additional materials |
☐ |
|
Soliciting material under Rule 14a-12 |
180
LIFE SCIENCES CORP.
(Name of Registrant as Specified in Charter)
Payment
of Filing Fee (Check all boxes that apply):
| ☐ | Fee
paid previously with preliminary materials |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
3000
El Camino Rd., Bldg. 4, Suite 200
Palo Alto, California 94306
May
[●], 2023
To
Our Stockholders:
The
Board of Directors (“Board”) and officers of 180 Life Sciences Corp., a Delaware corporation (the “Company”),
join us in extending to you a cordial invitation to attend the 2023 annual meeting of our stockholders, which we refer to as the annual
meeting or the Meeting, to be held (subject to postponement(s) or adjournment(s) thereof):
Date: |
|
Thursday,
July 6, 2023 |
Time: |
|
9:00 a.m.
Pacific Time |
Virtual
Meeting Site: |
|
https://agm.issuerdirect.com/atnf |
You
will not be able to attend the annual meeting physically. The annual meeting will be held via an audio teleconference. Stockholders may
attend, vote and submit questions during the annual meeting via the Internet by logging in at https://agm.issuerdirect.com/atnf (please
note this link is case sensitive), with your Control ID and Request ID, and thereafter following the instructions to join the virtual
meeting. In addition to voting by submitting your proxy prior to the annual meeting and/or voting online as discussed herein, you also
will be able to vote your shares electronically during the annual meeting with your Request ID. Details regarding the business to be
conducted are more fully described in the accompanying Notice of Annual Meeting and Proxy Statement.
As permitted by the rules of the
Securities and Exchange Commission (the “SEC” or the “Commission”), we have provided access to our
proxy materials over the Internet. Accordingly, we are sending a Notice of Internet Availability of Proxy Materials, or E-proxy notice,
on or about May [●], 2023, to our stockholders of record as of the close of business on May 11, 2023. The E-proxy notice contains
instructions for your use of this process, including how to access our proxy statement and annual report and how to authorize your proxy
to vote online. In addition, the E-proxy notice contains instructions on how you may receive a paper copy of the proxy statement
and annual report or elect to receive your proxy statement and annual report over the Internet. We believe these rules allow us to provide
you with the information you need while lowering the costs of delivery and reducing the environmental impact of the annual meeting.
The
Notice of Annual Meeting and Proxy Statement, is also available at https://www.iproxydirect.com/atnf (please note this
link is case sensitive). This website also includes copies of our Annual Report on Form 10-K for the year ended December 31,
2022, which we refer to as the annual report. Stockholders may also request a copy of the proxy statement and our annual report by contacting
our main office at (650) 507-0669.
In
connection with the annual meeting, you will be asked to consider and vote on certain proposals, which are more fully described in the
accompanying proxy statement. Whether or not you plan to attend the annual meeting, we urge you to read the proxy statement (and any
documents incorporated into the proxy statement by reference) and consider such information carefully before voting. The attached Notice
of Annual Meeting and the Proxy Statement describe the business to be considered and acted upon by the stockholders at the annual meeting.
Please review these materials and vote your shares.
Your
vote is very important. Even if you plan to attend the annual meeting, if you are a holder of record of voting stock please submit your
proxy by mail, fax, Internet or telephone as soon as possible to make sure that your shares are represented at the annual meeting. If
you hold your shares of Company stock in “street name” through a bank, broker, or other nominee, you must vote in accordance
with the voting instructions provided to you by such bank, broker, or other nominee, which include instructions for voting by Internet
or telephone.
Our
Board of Directors encourages your participation in 180 Life Sciences Corp.’s electoral process and, to that end, solicits your
proxy with respect to the matters described in the Notice of Meeting and the proxy statement.
We
look forward to seeing you on Thursday, July 6, 2023. Your vote and participation in our governance is very important to us.
Sincerely,
/s/
Marc Feldmann |
|
/s/ Lawrence Steinman |
Prof.
Sir Marc Feldmann, Ph.D. |
|
Lawrence Steinman, M.D. |
Executive
Co-Chairman |
|
Executive
Co-Chairman |
Important
Notice Regarding the Availability of Proxy Materials for the Virtual Annual Meeting of Stockholders to Be Held on July 6, 2023.
Our
proxy statement and Annual Report on Form 10-K for the year ended December 31, 2022 are available at the following cookies-free website
that can be accessed anonymously: https://agm.issuerdirect.com/atnf (please note this link is case sensitive). Stockholders
may also vote prior to the meeting at www.iproxydirect.com/atnf (please note this link is case sensitive).
180
LIFE SCIENCES CORP.
3000 El Camino Rd., Bldg. 4, Suite 200
Palo Alto, California 94306
NOTICE
OF 2023 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON THURSDAY, JULY 6, 2023
To
the Stockholders of 180 Life Sciences Corp.:
We
are pleased to provide you notice of, and to invite you to attend, the 2023 annual meeting of the stockholders of 180 Life Sciences Corp.,
a Delaware corporation (“180 Life”, the “Company”, “we” and “us”),
which will be held on Thursday, July 6, 2023, at 9:00 a.m., Pacific Time (subject to postponement(s) or adjournment(s) thereof),
which we refer to as the annual meeting, or the “Meeting”. The meeting will be held virtually via live audio webcast
at https://agm.issuerdirect.com/atnf (please note this link is case sensitive). See also “Instructions For The
Virtual Annual Meeting”, beginning on page 1. The annual meeting is being held for the following purposes:
| 1. | To
elect four Class I directors to the Board of Directors (the “Board”) each to serve a term of two years
and until their respective successors have been elected and qualified, or until such director’s resignation or removal. The
Board has nominated for re-election the following incumbent Class I directors: Lawrence Steinman, James N. Woody, Russell T.
Ray and Francis Knuettel II. |
| 2. | To
approve the adoption of the First Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan. The
Board of Directors recommends that you approve and ratify the first amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan. |
| 3. | To
approve an advisory resolution on Named Executive Officer compensation. The Board of Directors recommends that you approve and
ratify executive compensation. |
| 4. | To
hold a non-binding vote on the frequency of executive compensation votes. The Board of Directors recommends a vote to hold future
non-binding votes on executive compensation every “1 year”. |
| 5. | To
ratify the appointment of Marcum LLP, an independent registered public accounting firm, as the Company’s independent auditors for
the fiscal year ending December 31, 2023. The Board of Directors recommends that you approve and
ratify the appointment of Marcum LLP as the Company’s independent auditors for the fiscal year ending December 31, 2023. |
| 6. | Approval
of an Amendment to the Company’s Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers
of the Company. The Board of Directors recommends that you approve an amendment to the Company’s Second Amended and Restated
Certificate of Incorporation to limit the liability of certain officers of the Company. |
| 7. | To
transact such other business as may properly come before the annual meeting. |
THE
BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR ALL” FOR PROPOSAL ONE, “FOR” PROPOSALS
TWO, THREE, FIVE, AND SIX, AND FOR “1 YEAR” FOR PROPOSAL FOUR.
Any action may be taken on any
one of the foregoing proposals at the Meeting on the date specified above or on any date or dates to which the Meeting may be postponed
or adjourned. We do not expect to transact any other business at the annual meeting. Our Board of Directors has fixed the close of business
on May 11, 2023, as the record date for determining those stockholders entitled to vote at the annual meeting and any adjournment or postponement
thereof. Accordingly, only common and preferred stock stockholders of record at the close of business on that date are entitled to notice
of, and to vote at, the annual meeting.
We
cordially invite you to attend the annual meeting. However, to ensure your representation at the annual meeting, please authorize the
individuals named on your proxy card to vote your shares by calling the toll-free telephone number, faxing your proxy card or by
using the Internet as described in the instructions included with your proxy card or voting instruction card. Alternatively, if you received
a paper copy of the proxy card by mail, please complete, date, sign and promptly return the proxy card. This will not prevent you from
voting at the meeting, but will help to secure a quorum and avoid added solicitation costs. If your shares are held in “street
name” by your broker or other nominee, only that holder can vote your shares and the vote cannot be cast unless you provide
instructions to your broker. You should follow the directions provided by your broker regarding how to instruct your broker to vote your
shares. Your proxy may be revoked at any time before it is voted. Please review the proxy statement accompanying this notice for more
complete information regarding the matters to be voted on at the meeting.
The
enclosed proxy statement, notice of the availability of which is first being mailed to stockholders on or about May [●], 2023,
is also available at https://www.iproxydirect.com/atnf (please note this link is case sensitive). This website also
includes our Annual Report on Form 10-K for the year ended December 31, 2022, which we refer to as the 2022 Annual Report.
Stockholders may also request a copy of the proxy statement and our annual report by contacting our main office at (650) 507-0669.
Even
if you plan to attend the annual meeting, we request that you submit a proxy by following the instructions on your proxy card as soon
as possible and thus ensure that your shares will be represented at the annual meeting if you are unable to attend.
If
you have any questions or require any assistance with voting your shares, please contact our proxy agent, Issuer Direct Corporation at
(919) 481-4000, or 1-866-752-VOTE (8683).
By
Order of the Board of Directors:
/s/ Marc Feldmann |
|
/s/ Lawrence Steinman |
Prof. Sir Marc Feldmann, Ph.D. |
|
Lawrence Steinman, M.D. |
Executive Co-Chairman |
|
Executive Co-Chairman |
Palo
Alto, California |
|
May
[●], 2023 |
|
IMPORTANT: WHETHER
OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING, WE ASK YOU TO VOTE BY TELEPHONE, MAIL, FAX OR ON THE INTERNET USING THE INSTRUCTIONS
ON THE PROXY CARD. |
TABLE
OF CONTENTS
PROXY
STATEMENT
FOR 2023 ANNUAL MEETING OF STOCKHOLDERS
GENERAL
INFORMATION
180
Life Sciences Corp. (“we,” “us”, “our” or the “Company”)
has made these materials available to you on the Internet or, upon your request, has delivered printed versions of these materials to
you by mail, in connection with the Company’s solicitation of proxies for use at our 2023 annual meeting of stockholders, which
we refer to as our annual meeting, or the “Meeting”, on Thursday, July 6, 2023 at 9 a.m., Pacific time, and at
any postponement(s) or adjournment(s) thereof. The meeting will be held virtually via live audio webcast at https://agm.issuerdirect.com/atnf (please
note this link is case sensitive). See also “Instructions For The Virtual Annual Meeting”, beginning on page 1.
These
materials were first sent or given to stockholders on or about May [●], 2023. You are invited to attend the annual meeting online
and are requested to vote on the proposals described in this Proxy Statement.
Information
Contained in this Proxy Statement
The
information in this proxy statement relates to the proposals to be voted on at the annual meeting, the voting process, the compensation
of our directors and executive officers, corporate governance, and certain other required information. Included with this proxy statement
is a copy of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC
on March 31, 2023 (the “2022 Annual Report”). If you requested printed versions of these materials by mail, these
materials also include the proxy card and vote instruction form for the annual meeting.
Instructions
For The Virtual Annual Meeting
This
year our annual meeting will be a completely virtual meeting. There will be no physical meeting location. The meeting will only be conducted
via live audio webcast.
To
participate in the virtual meeting, visit https://agm.issuerdirect.com/atnf (please note this link is case sensitive)
and enter the control number on your proxy card, or on the instructions that accompanied your proxy materials.
We
recommend you check in/log in to the annual meeting 15 minutes before the meeting is scheduled to start so that any technical difficulties
may be addressed before the meeting begins.
You
may vote during the meeting by following the instructions available on the meeting website during the meeting. To the best of our knowledge,
the virtual meeting platform is fully supported across browsers (Internet Explorer, Firefox, Chrome, and Safari) and devices (desktops,
laptops, tablets, and cell phones) running the most updated version of applicable software and plugins. Participants should ensure they
have a strong Internet connection wherever they intend to participate in the meeting. Participants should also allow plenty of time to
log in and ensure that they can hear streaming audio prior to the start of the meeting.
Questions
During the Annual Meeting
We
plan to hold a question-and-answer session with management immediately following the conclusion of the business to be conducted
at the annual meeting.
You
may submit a question at any time during the meeting by following the instructions provided in the meeting portal at the address described
above. The Chair of the meeting has broad authority to conduct the annual meeting in an orderly manner, including establishing rules
of conduct. A copy of the rules of conduct will be available online at the annual meeting.
Questions
will be relayed to the meeting organizers and forwarded to the Chairman of the meeting for review. Questions regarding matters to be
acted upon at the meeting will be answered after each matter has been presented, as appropriate. Questions from stockholders not relating
to proposals will be grouped by topic with a representative question read aloud and answered as time permits and to the extent such questions
do not relate to material non-public information, off-topic items or other matters which the Chairman in his discretion, believes
should not be addressed at the annual meeting.
Technical
Difficulties or Trouble Accessing the Virtual Meeting Website
Technicians
will be available to assist you if you experience technical difficulties accessing the virtual meeting website. If you encounter any
difficulties accessing the virtual meeting during the check-in or meeting time, please call 844-399-3386 for assistance.
Important
Notice Regarding the Availability of Proxy Materials
Pursuant
to rules adopted by the Securities and Exchange Commission, the Company uses the Internet as the primary means of furnishing proxy materials
to stockholders. Accordingly, the Company is sending a Notice of Internet Availability of Proxy Materials (the “Notice”)
to the Company’s stockholders. All stockholders will have the ability to access the proxy materials (including the Company’s
2022 Annual Report) via the Internet at https://www.iproxydirect.com/atnf (please note this link is case sensitive)
or request a printed set of the proxy materials. Instructions on how to access the proxy materials over the Internet or to request a
printed copy may be found in the Notice. The Notice contains a control number that you will need to vote your shares. Please keep the
Notice for your reference through the meeting date. In addition, stockholders may request to receive proxy materials in printed form
by mail or electronically by email on an ongoing basis. The Company encourages stockholders to take advantage of the availability of
the proxy materials on the Internet to help reduce the environmental impact of its annual meetings.
Record
Date and Shares Entitled to Vote
You are entitled to notice of
and to vote at the annual meeting if you were a stockholder of record as of the close of business on May 11, 2023 (the “Record
Date”).
At
the close of business on the Record Date, there were (a) [5,317,586] shares of our common stock outstanding; (b) no shares
of our Series A Convertible Preferred Stock outstanding; (c) 1 share of our preferred Class C Special Voting Shares
outstanding; and (d) 1 share of our preferred Class K Special Voting Shares outstanding.
The
common stock votes one vote on all stockholder matters, the Class C Special Voting Shares, vote 0 voting shares in aggregate; and
the Class K Special Voting Shares vote 264 voting shares in aggregate. As a result, we had an aggregate of [5,317,850] total voting
shares as of the Record Date.
In
order for us to satisfy our quorum requirements, the holders of at least a majority of the voting power of all outstanding shares of
capital stock entitled to vote at the meeting must be present. You will be deemed to be present if you attend the meeting or if you submit
a proxy (including through the mail, by fax or by telephone or the Internet) that is received at or prior to the meeting (and not revoked).
If
your proxy is properly executed and received by us in time to be voted at our annual meeting, the shares represented by your proxy (including
those given through the mail, by fax or by telephone or the Internet) will be voted in accordance with your instructions. If you execute
your proxy but do not provide us with any instructions, your shares will be voted “for all” for Proposal One, “for”
Proposals Two, Three, Five, and Six, and for “1 Year” for Proposal Four, or otherwise determined by the proxies.
The
only matters that we expect to be presented at our annual meeting are set forth in the notice of annual meeting. If any other matters
properly come before our annual meeting, the persons named in the proxy card will vote the shares represented by all properly executed
proxies on such matters in their best judgment.
Voting
Process
If
you are a stockholder of record, there are five ways to vote:
| ● | At
the virtual annual meeting. You may vote during the meeting by following the instructions available on the
meeting website during the meeting. |
| ● | Via
the Internet. You may vote by proxy via the Internet by following the instructions provided in the notice. |
| ● | By
Telephone. If you request printed copies of the proxy materials by mail, you may vote by proxy by calling
the toll-free number found on the proxy card or notice. |
| ● | By
Fax. If you request printed copies of the proxy materials by mail, you may vote by proxy by faxing your proxy
to the number found on the proxy card or notice. |
| ● | By
Mail. If you request printed copies of the proxy materials by mail, you may vote by proxy by filling out the
proxy card and returning it in the envelope provided. |
If
you hold shares through an account with a bank or broker, the voting of the shares by the bank or broker when you do not provide voting
instructions is governed by the rules of the New York Stock Exchange (the “NYSE”). NYSE rules allow brokers,
banks and other nominees to vote shares on certain “routine” matters for which their customers do not provide voting
instructions. Only Proposal 5 is a “routine” proposal. Therefore, if you do not instruct your broker, bank and
other nominee how to vote, your broker, bank and other nominee will have discretionary authority to vote your shares on Proposal 5. A
broker non-vote occurs when your bank or broker submits a proxy but does not vote on non-routine proposals, absent
specific instructions from you. See also “Voting Requirements for Each of the Proposals”, below.
Providing
and Revoking Proxies
The
presence of a stockholder at our annual meeting will not automatically revoke that stockholder’s proxy. However, a stockholder
may revoke a proxy at any time prior to its exercise by:
| ● | submitting
a written revocation prior to the annual meeting to the Corporate Secretary, 180 Life Sciences Corp., 3000 El Camino Real, Bldg. 4,
Suite 200, Palo Alto, California 94306; |
| ● | submitting
another signed and later dated proxy card and returning it by mail in time to be received before our annual meeting or by submitting
a later dated proxy by the Internet or telephone prior to the annual meeting; or |
| ● | attending
our annual meeting and voting by following the instructions available on the meeting website during the meeting. |
Meeting
Time and Location: Virtual Annual Meeting
Attendance
at the annual meeting is limited to holders of record of our common stock and preferred stock at the close of business on the record
date, May 11, 2023, and our guests. You will be asked to provide your control number in order to be admitted into the annual meeting.
If your shares are held in the name of a bank, broker, or other nominee and you plan to attend the annual meeting, you must obtain your
control number from such bank, broker, or other nominee, or contact Issuer Direct Corporation at (919) 481-4000, or 1-866-752-VOTE (8683) to
obtain your control number, in order to be admitted. No recording of the meeting will be permitted. At the annual meeting, stockholders
of the Company will be afforded a reasonable opportunity to participate in the meeting and to vote on matters submitted to the stockholders,
including an opportunity to communicate, and to read or hear the proceedings of the meetings in a substantially concurrent manner with
such proceedings.
Conduct
at the Meeting
The
Chairman of the meeting has broad responsibility and legal authority to conduct the annual meeting in an orderly and timely manner. This
authority includes establishing rules for stockholders who wish to address the meeting. Only stockholders or their valid proxy holders
may address the meeting. The Chairman may exercise broad discretion in recognizing stockholders who wish to speak and in determining
the extent of discussion on each item of business. In light of the number of stockholders of the Company, the number of items on this
year’s agenda and the need to conclude the meeting within a reasonable period of time, we cannot ensure you that every stockholder
who wishes to speak on an item of business will be able to do so.
Voting
Requirements for Each of the Proposals
Proposal |
|
Vote
Required |
|
Broker
Discretionary
Voting
Allowed* |
1 |
|
Election
of four Class I Directors |
|
Plurality
of Votes Cast |
|
No |
2 |
|
Adoption
of the First Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan |
|
Affirmative
vote of a majority of the votes cast on the proposal |
|
No |
3 |
|
To
approve an advisory resolution on Named Executive Officer compensation |
|
Affirmative
vote of a majority of the votes cast on the proposal |
|
No |
4 |
|
To
hold a non-binding vote on the frequency of executive compensation votes |
|
Plurality
of Votes Cast |
|
No |
5 |
|
Ratify
the appointment of Marcum LLP, an independent registered public accounting firm, as the Company’s independent auditors for
the fiscal year ending December 31, 2023 |
|
Affirmative
vote of a majority of the votes cast on the proposal |
|
Yes |
6 |
|
Approval
of an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to Limit the Liability of Certain
Officers of the Company |
|
Affirmative
vote of a majority of the voting shares entitled to vote generally in the election of directors |
|
No |
| * | See
also “Quorum”, below. |
For
Proposal 1, the four nominees receiving the highest number of affirmative votes of the shares entitled to be voted for them will
be elected as directors to serve for a term of two years and until their successors are duly elected and qualified, unless the elected
director is removed or resigns earlier. This means that the director nominees with the most “for” votes will be elected.
Thus, shares as to which a stockholder “withholds” voting authority and broker non-votes will not be counted towards
any director nominee’s achievement of a plurality and will not affect the outcome of the election of directors. Stockholders may
not cumulate their votes in favor of any one nominee.
Approval
of Proposals 2, 3, and 5 require the affirmative vote of a majority of the votes cast on such proposals present in person or represented
by proxy at the annual meeting and entitled to vote thereon, provided that a quorum exists at the annual meeting, and provided further
that proposal 3 is non-binding. Votes cast “against” Proposals 2, 3, and 5 will count against the approval of the
proposals. Abstentions and broker non-votes will not be counted as votes cast, but will be counted as shares present in person or represented
by proxy at the meeting and entitled to vote thereon, and will therefore be treated as a vote “against” such proposals. Broker
non-votes will not be counted as votes cast, and are not entitled to vote on proposals where shareholders have not provided discretionary
authority, and as such will have no effect on these proposals.
For
Proposal 4, the voting frequency (i.e., every “1 year”, “2 years”, or “3 years”)
receiving the affirmative “for” vote of the greatest number of votes cast by stockholders who are present, either
in person or by proxy, at the annual meeting and entitled to vote on Proposal 4 will be the frequency recommended, on an advisory basis,
by our stockholders. Abstentions and broker non-votes will not be counted as votes cast and will not be counted in favor of any recommendation
of voting frequency.
Approval
of Proposal 6 requires the affirmative “for” vote of a majority of the voting power of the outstanding shares of Company
capital stock entitled to vote generally in the election of directors (as opposed to outstanding shares present, in person or by proxy,
at the meeting). Votes cast “against”, as well as abstentions and broker non-votes, will be counted against the approval
of Proposal 6.
If
a broker indicates on the proxy that it does not have discretionary authority as to certain shares to vote on a particular matter, those
shares will not be considered as present and entitled to vote with respect to that matter. For your vote to be counted, you must submit
your voting instruction form to your broker.
As
described above, although the Company will include abstentions and broker non-votes as present or represented for purposes of establishing
a quorum for the transaction of business, the Company intends to exclude abstentions and broker non-votes from the tabulation of
voting results on the election of directors or on any issues requiring approval of a majority of the votes cast at the annual meeting.
Quorum
In
order for us to satisfy our quorum requirements, the holders of at least a majority of the voting power of all outstanding shares of
capital stock entitled to vote at the meeting must be present. You will be deemed to be present if you attend the meeting or if you submit
a proxy (including through the mail, by fax or by telephone or the Internet) that is received at or prior to the meeting (and not revoked).
Board
of Directors Voting Recommendations
Our
Board recommends that you vote your shares:
| ● | “FOR”
each of the nominees to the Board of Directors (Proposal 1). |
| ● | “FOR”
approval of the First Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan (Proposal 2). |
| ● | “FOR”
the approval of the advisory resolution on Named Executive Officer compensation (Proposal 3). |
| ● | For
“1 Year” for the frequency of future votes on executive compensation (Proposal 4). |
| ● | “FOR”
the ratification of the appointment of Marcum LLP, an independent registered public accounting firm, as the Company’s independent
auditors for the fiscal year ending December 31, 2023 (Proposal 5). |
| ● | “FOR”
the amendment to the Company’s Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers
of the Company (Proposal 6). |
Mailing
Costs and Solicitation of Proxies
We
will pay the cost of soliciting proxies. Proxies may be solicited on behalf of the Company by directors, officers or employees of the
Company in person or by telephone, facsimile or other electronic means. We may also pay Issuer Direct Corporation a fee not to exceed
$10,000 plus costs and expenses. In addition, Issuer Direct Corporation and certain related persons may be indemnified against certain
liabilities arising out of or in connection with the engagement.
Arrangements
may also be made with brokerage firms and other custodians, nominees and fiduciaries for the forwarding of material to, and solicitation
of proxies from, the beneficial owners of our securities held of record at the close of business on the Record Date by such persons.
We will reimburse such brokerage firms, custodians, nominees and fiduciaries for the reasonable out-of-pocket expenses incurred
by them in connection with any such activities.
Inspector
of Voting
It
is anticipated that representatives of Issuer Direct Corporation will tabulate the votes and act as inspector of election for the annual
meeting.
Stockholders
Entitled to Vote at the Meeting
A
complete list of stockholders entitled to vote at the annual meeting will be available at our principal executive offices, for any purpose
germane to the annual meeting, during ordinary business hours, for a period of ten days prior to the annual meeting.
Voting
Instructions
Your
vote is very important. Whether or not you plan to attend the annual meeting, we encourage you to read this proxy statement and submit
your proxy or voting instructions as soon as possible. For specific instructions on how to vote your shares, please refer to the instructions
on the Notice of Internet Availability of Proxy Materials (Notice) you received in the mail, or, if you requested to receive printed
proxy materials, your enclosed proxy card.
Confidential
Voting
Independent
inspectors will count the votes. Your individual vote is kept confidential from us unless special circumstances exist. For example, a
copy of your proxy card will be sent to us if you write comments on the card, as necessary to meet applicable legal requirements, or
to assert or defend claims for or against the Company.
Stockholder
of Record and Shares Held in Brokerage Accounts
If
on the Record Date your shares were registered in your name with the Company’s transfer agent, then you are a stockholder of record
and you may vote in person at the meeting, by proxy or by any other means supported by the Company. If on the Record Date your shares
were held in an account at a brokerage firm, bank, dealer, or other similar organization, then you are the beneficial owner of shares
held in “street name” and these proxy materials (or the Notice) are required to be forwarded to you by that organization.
The organization holding your account is considered the stockholder of record for purposes of voting at the annual meeting. As a beneficial
owner, you have the right to direct your broker or other agent on how to vote the shares in your account. You are also invited to attend
the annual meeting. However, you must obtain your control number from such bank, broker, or other nominee, or contact Issuer Direct Corporation
at (919) 481-4000, or 1-866-752-VOTE (8683) to obtain your control number, in order to be admitted and since you
are not the stockholder of record, you may not vote your shares by following the instructions available on the meeting website during
the meeting unless you request and obtain a valid proxy from your broker or, other agent.
Multiple
Stockholders Sharing the Same Address
The
SEC has adopted rules that permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy materials with
respect to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders.
This process, which is commonly referred to as “householding,” potentially provides extra convenience for stockholders
and cost savings for companies. The Company, as well as some brokers (or other nominees), household the Company’s Proxy Materials,
which means that we or they deliver a single Proxy Statement and 2022 Annual Report to multiple stockholders sharing an address unless
contrary instructions have been received from the affected stockholders. Once you have received notice from your broker (or other nominee)
or from us that they or we will be householding materials to your address, householding will continue until you are notified otherwise
or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate
Proxy Statement or Annual Report in the future, or if you are receiving multiple copies of the Proxy Statement and Annual Report and
wish for only one copy to be delivered to your household in the future, please notify (i) your broker (or other nominee) if your shares
are held in a brokerage or similar account or (ii) the Company if you hold registered shares in your own name. We will promptly deliver
a separate Proxy Statement to record stockholders upon written or oral request. You can notify us of your instructions by telephone at
(650) 507-0669 or by sending a written request to our Corporate Secretary at our principal executive offices at 3000 El Camino Real,
Bldg. 4, Suite 200, Palo Alto, California 94306, or a stockholder may make a request by calling our Investor Relations at (650) 507-0669.
If
you receive more than one Notice of Internet Availability of Proxy Materials, it means that your shares are registered differently and
are held in more than one account. To ensure that all shares are voted, please either vote each account as discussed above under “Voting
Process” on page 3, or sign and return by mail all proxy cards or voting instruction forms.
Voting
Results
The
preliminary voting results will be announced at the annual meeting. The final voting results will be tallied by the inspector of voting
and published in the Company’s Current Report on Form 8-K, which the Company is required to file with the SEC within four business
days following the annual meeting.
Company
Mailing Address
The
mailing address of our principal executive offices is 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, California 94306.
Other
Matters
As
of the date of this proxy statement, the Board of Directors does not know of any business to be presented at the annual meeting other
than as set forth in the notice accompanying this proxy statement. If any other matters should properly come before the annual meeting,
it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the
persons voting the proxies.
BACKGROUND
OF THE COMPANY
On
November 6, 2020, the Company (formerly known as KBL Merger Corp. IV (prior to the closing of the Business Combination (defined
below), sometimes referred to herein as “KBL”) consummated the previously announced business combination (the “Business
Combination”) following a special meeting of stockholders, where the stockholders of the Company considered and approved, among
other matters, a proposal to adopt that certain Business Combination Agreement (as amended, the “Business Combination Agreement”),
dated as of July 25, 2019, entered into by and among the Company, KBL Merger Sub, Inc. (“Merger Sub”), 180 Life
Corp. (f/k/a 180 Life Sciences Corp.) (“180”), Katexco Pharmaceuticals Corp. (“Katexco”), CannBioRex
Pharmaceuticals Corp. (“CBR Pharma”), 180 Therapeutics L.P. (“180 LP” and together with Katexco
and CBR Pharma, the “180 Subsidiaries” and, together with 180, the “180 Parties”), and Lawrence
Pemble, in his capacity as representative of the stockholders of the 180 Parties (the “Stockholder Representative”).
Pursuant to the Business Combination Agreement, among other things, Merger Sub merged with and into 180, with 180 continuing as the surviving
entity and a wholly-owned subsidiary of the Company (the “Merger”). The Merger became effective on November 6,
2020 (the closing of the Merger being referred to herein as the “Closing”). In connection with, and prior to, the
Closing, 180 filed a Certificate of Amendment of its Certificate of Incorporation in Delaware to change its name to 180 Life Corp., and
KBL Merger Corp. IV (the Company) changed its name to 180 Life Sciences Corp.
Reverse
Stock Split
On
December 15, 2022, at a Special Meeting of the stockholders of the Company, the stockholders of the Company approved an amendment to
the Company’s Second Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued
and outstanding shares of our common stock, par value $0.0001 per share, by a ratio of between one-for-four to one-for-twenty, inclusive,
with the exact ratio to be set at a whole number to be determined by our Board of Directors or a duly authorized committee thereof in
its discretion, at any time after approval of the amendment and prior to December 15, 2023 (the “Stockholder Authority”).
On December 15, 2022, the Company’s Board of Directors, with the Stockholder Authority, approved an amendment to our Second Amended
and Restated Certificate of Incorporation to affect a reverse stock split of our common stock at a ratio of 1-for-20 (the “Reverse
Stock Split”).
Immediately
after the Special Meeting and the approval thereof by the Board, on December 15, 2022, we filed a Certificate of Amendment to our Second
Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Reverse Stock Split.
Pursuant
to the Certificate of Amendment, the Reverse Stock Split became effective on December 19, 2022 at 12:01 a.m. Eastern Time (the “Effective
Time”). The Certificate of Amendment did not reduce the number of authorized shares of our common stock, nor alter the par
value of our common stock or modify any voting rights or other terms of our common stock.
No
fractional shares were issued in connection with the Reverse Stock Split and stockholders of record who otherwise would be entitled to
receive fractional shares, were instead entitled to have their fractional shares rounded up to the nearest whole share.
The
effects of the 1-for-20 Reverse Stock Split have been retroactively reflected throughout this Proxy Statement.
DEFINITIONS
Unless
the context requires otherwise, references in this proxy statement to the “Company,” “we,” “us,”
“our,” “180 Life”, “180LS” and “180 Life Sciences Corp.”
refer specifically to 180 Life Sciences Corp. and its consolidated subsidiaries. References to “KBL” refer to the
Company prior to the November 6, 2020 Business Combination.
In
addition, unless the context otherwise requires and for the purposes of this Proxy Statement only:
| ● | “CAD”
refers to Canadian dollars; |
| ● | “Exchange Act”
refers to the Securities Exchange Act of 1934, as amended; |
| ● | “£”
or “GBP” refers to British pounds sterling; |
| ● | “SEC”
or the “Commission” refers to the United States Securities and Exchange Commission; and |
| ● | “Securities
Act” refers to the Securities Act of 1933, as amended. |
FORWARD-LOOKING
STATEMENTS AND WEBSITE LINKS
Statements
in this Proxy Statement that are “forward-looking statements” are based on current expectations and assumptions
that are subject to risks and uncertainties. In some cases, forward-looking statements can be identified by terminology such as
“may,” “should,” “potential,” “continue,” “expects,”
“anticipates,” “intends,” “plans,” “believes,” “estimates,”
and similar expressions. These statements involve risks and uncertainties, and actual results may differ materially from any future results
expressed or implied by the forward-looking statements, including any failure to meet stated goals and commitments, and execute
our strategies in the time frame expected or at all, as a result of many factors, including the need for additional funding, the terms
of such funding, changing government regulations, the outcome of trials and our ability to market and commercialize future products.
More information on risks, uncertainties, and other potential factors that could affect our business and performance is included in our
other filings with the SEC, including in the “Risk Factors”, “Cautionary Note Regarding Forward-Looking Statements”
and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our
most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. These forward-looking statements
are based on our current estimates and assumptions and, as such, involve uncertainty and risk. Actual results could differ materially
from projected results.
We
do not assume any obligation to update information contained in this document, except as required by federal securities laws. Although
this Proxy Statement may remain available on our website or elsewhere, its continued availability does not indicate that we are reaffirming
or confirming any of the information contained herein. Neither our website nor its contents are a part of this Proxy Statement.
Website
links included in this Proxy Statement are for convenience only. The content in any website links included in this Proxy Statement is
not incorporated herein and does not constitute a part of this Proxy Statement.
INCORPORATION
BY REFERENCE
To
the extent that this proxy statement has been or will be specifically incorporated by reference into any other filing of the Company
under the Securities or the Exchange Act, the sections of this proxy statement titled “Audit Committee Report”,
“Pay Versus Performance” and “Relationship Between “Compensation Actually Paid” and Performance”,
to the extent permitted by the rules of the U.S. Securities and Exchange Commission (the “SEC” or the “Commission”),
shall not be deemed to be so incorporated, unless specifically provided otherwise in such filing.
REFERENCES
TO ADDITIONAL INFORMATION
Included
with this proxy statement is a copy of the Company’s Annual Report on Form 10-K for the year ended December 31,
2022, as filed with the SEC on March 31, 2023 (the “2022 Annual Report”).
You
may also request a copy of this proxy statement and the annual report from Issuer Direct Corporation, the Company’s proxy agent,
at the following address and telephone number:
Issuer
Direct Corporation
One Glenwood Ave., Suite 1001, Raleigh, North Carolina, 27603
(919) 481-4000, or 1-866-752-VOTE (8683)
VOTING
RIGHTS AND PRINCIPAL STOCKHOLDERS
Holders
of record of our common stock, Class C Special Voting Shares, and Class K Special Voting Shares, at the close of business on
the Record Date, will be entitled to vote at the annual meeting, on all matters properly presented at the annual meeting and at any adjournment
or postponement thereof.
At
the close of business on the Record Date, there were (a) [5,317,586] shares of our common stock outstanding; (b) no shares
of our Series A Convertible Preferred Stock outstanding; (c) 1 share of our Class C Special Voting Shares outstanding;
and (d) 1 share of our Class K Special Voting Shares outstanding.
The
common stock votes one vote on all stockholder matters, the Class C Special Voting Shares, vote 0 voting shares in aggregate; and
the Class K Special Voting Shares vote 264 voting shares in aggregate. As a result, we had an aggregate of [5,317,850] total voting
shares as of the Record Date.
Our
stockholders do not have dissenters’ rights or similar rights of appraisal with respect to the proposals described herein and,
moreover, do not have cumulative voting rights with respect to the election of directors.
Security
Ownership of Management and Certain Beneficial Owners and Management
The
following table sets forth, as of the Record Date, the number and percentage of outstanding shares of our common stock, Class C
Special Voting Shares; and Class K Special Voting Shares, beneficially owned by: (a) each person who is known by us to be the
beneficial owner of more than 5% of our outstanding shares of common stock; (b) each of our directors; (c) each of our Named
Executive Officers (as defined below under “Executive and Director Compensation — Summary Executive Compensation
Table”); and (d) all current directors and Named Executive Officers, as a group.
Beneficial
ownership has been determined in accordance with Rule 13d-3 under the Exchange Act. Under this rule, certain shares may
be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose
of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire shares (for
example, upon exercise of an option or warrant or upon conversion of a convertible security) within 60 days of the date as of which
the information is provided. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount
of shares beneficially owned by such person by reason of such acquisition rights. As a result, the percentage of outstanding shares of
any person as shown in the following table does not necessarily reflect the person’s actual voting power at any particular date.
Beneficial
ownership as set forth below is based on our review of our record stockholders list and public ownership reports filed by certain stockholders
of the Company, and may not include certain securities held in brokerage accounts or beneficially owned by the stockholders described
below.
Unless
otherwise indicated, we believe that all persons named in the table below have sole voting and investment power with respect to all shares
of common stock beneficially owned by them. Unless otherwise indicated, the business address of each of the entities, directors and executive
officers in this table is 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, California 94306.
Name and Address of Beneficial Owners | |
Number of Common Stock Shares Beneficially Owned | | |
Percent of Common Stock | |
Directors, Executive Officers and Named Executive Officers | |
| | |
| |
James N. Woody | |
| 59,443 | (1) | |
| 1.1 | % |
Jonathan Rothbard | |
| 40,939 | (2) | |
| * | |
Ozan Pamir | |
| 11,221 | (3) | |
| * | |
Quan Anh Vu(a) | |
| 1,025 | | |
| * | |
Lawrence Steinman | |
| 31,379 | (4) | |
| * | |
Marc Feldmann | |
| 141,747 | (4) | |
| 2.7 | % |
Donald A. McGovern, Jr. | |
| 14,761 | (5) | |
| * | |
Larry Gold | |
| 6,246 | (6) | |
| * | |
Francis Knuettel II | |
| 2,269 | (7) | |
| * | |
Pamela G. Marrone | |
| 5,278 | (7) | |
| * | |
Teresa M. DeLuca | |
| 2,894 | (7)(8) | |
| * | |
Russell T. Ray | |
| 5,223 | (7) | |
| * | |
| |
| | | |
| | |
All officers and directors as a group (11 persons)(9) | |
| 321,400 | | |
| 5.9 | % |
| |
| | | |
| | |
5% Stockholders | |
| | | |
| | |
None. | |
| | | |
| | |
| ** | Percentages
based upon 5,317,586 shares of our common stock issued and outstanding at May 11, 2023. |
| (a) | Resigned
effective January 15, 2023, but included as a “Named Executive Officer” for fiscal 2022. |
| (1) | Includes
options to purchase 57,555 shares of common stock at an exercise price of $88.60 per share, which have vested, and/or which vest
within 60 days of the Record Date. |
| (2) | Includes
options to purchase 12,916 shares of common stock at an exercise price of $79.00 per share, which have vested, and/or which vest
within 60 days of the Record Date. |
| (3) | Includes
options to purchase 7,400 shares of common stock at an exercise price of $88.60 per share, which have vested, and/or which vest
within 60 days of the Record Date. |
| (4) | Includes
options to purchase 1,250 shares of common stock at an exercise price of $79.00 per share, which have vested, and/or which vest
within 60 days of the Record Date. |
| (5) | Includes
options to purchase 1,250 shares of common stock at an exercise price of $49.80 per share, options to purchase 1,375 shares
of common stock at an exercise price of $7.56, and options to purchase 6,707 shares of common stock at an exercise price of $27.20 per
share, in each case which have vested, and/or which vest within 60 days of the Record Date. |
| (6) | Includes
options to purchase 1,250 shares of common stock at an exercise price of $49.80 per share, and options to purchase 1,375 shares
of common stock at an exercise price of $7.56, and options to purchase 250 shares of common stock at an exercise price of $27.20 per
share, in each case which have vested, and/or which vest within 60 days of the Record Date. |
| (7) | Includes
options to purchase 1,811 shares of common stock at an exercise price of $151.20 per share, and options to purchase 350 shares
of common stock at an exercise price of $27.20 per share, in each case which have vested, and/or which vest within 60 days of the
Record Date. |
| (8) | Includes
125 shares of common stock held by Teresa M. DeLuca’s spouse, 125 shares of common stock held by The Santina Iraggi
Irrvoc TR, U/A 11/2/20, an irrevocable trust, of which Teresa M. DeLuca is beneficiary and trustee, and 125 shares of common
stock held by the REV TR FBO Teresa M Deluca, a revocable trust, of which Teresa M. DeLuca is beneficiary and trustee, all of which
shares Teresa M. DeLuca is deemed to beneficially own. |
| (9) | Does
not include the ownership of Quan Vu, who is a Named Executive Officer, but who resigned from the Company effective January 18, 2023. |
Change
of Control
The
Company is not aware of any arrangements which may at a subsequent date result in a change of control of the Company.
CORPORATE
GOVERNANCE
The
Company promotes accountability for adherence to honest and ethical conduct; endeavors to provide full, fair, accurate, timely and understandable
disclosure in reports and documents that the Company files with the SEC and in other public communications made by the Company; and strives
to be compliant with applicable governmental laws, rules and regulations.
Board
Leadership Structure
Our
Board of Directors has the responsibility for selecting the appropriate leadership structure for the Company. In making leadership structure
determinations, the Board of Directors considers many factors, including the specific needs of the business and what is in the best interests
of the Company’s stockholders.
Our
current leadership structure is comprised of two Co-Executive Chairmen of the Board, Prof. Sir Marc Feldmann, Ph.D. and Lawrence
Steinman, M.D., and a separate Chief Executive Officer (“CEO”), James N. Woody, M.D. Ph.D. The Board
of Directors believes that this leadership structure is the most effective and efficient for the Company at this time. The Board of Directors
does not have a policy as to whether the Chairman/Chairmen should be an independent director, an affiliated director, or a member of
management. Our Board of Directors believes that the Company’s current leadership structure is appropriate because it effectively
allocates authority, responsibility, and oversight between management (the Company’s CEO, Dr. Woody) and the members of our
Board of Directors. It does this by giving primary responsibility for the operational leadership and strategic direction of the Company
to its CEO, while enabling our Chairmen to facilitate our Board of Directors’ oversight of management, promote communication between
management and our Board of Directors, and support our Board of Directors’ consideration of key governance matters. The Board of
Directors believes that its programs for overseeing risk, as described below, would be effective under a variety of leadership frameworks
and therefore do not materially affect its choice of structure.
The
Board believes that this leadership structure, including our strong independent Lead Director, best serves the Company and its stockholders
at this time by leveraging executive leadership experience while providing effective independent oversight. Independent leadership remains
an important pillar of the Board leadership structure and, as such, the Company continues to have an independent Lead Director with robust,
well-defined responsibilities as set forth below under “Independent Lead Director.”
The
Board evaluates its structure periodically, as well as when warranted by specific circumstances in order to assess which structure is
in the best interests of the Company and its stockholders based on the evolving needs of the Company. This approach provides the Board
appropriate flexibility to determine the leadership structure best suited to support the dynamic demands of our business.
Risk
Oversight
Effective
risk oversight is an important priority of the Board of Directors. Because risks are considered in virtually every business decision,
the Board of Directors discusses risks throughout the year generally or in connection with specific proposed actions. The Board of Directors’
approach to risk oversight includes understanding the critical risks in the Company’s business and strategy, evaluating the Company’s
risk management processes, allocating responsibilities for risk oversight among the full Board of Directors, and fostering an appropriate
culture of integrity and compliance with legal responsibilities.
The
Board of Directors exercises direct oversight of strategic risks to the Company. The Audit Committee reviews and assesses the Company’s
processes to manage business and financial risk and financial reporting risk. It also reviews the Company’s policies for risk assessment
and assesses steps management has taken to control significant risks. The Compensation Committee oversees risks relating to compensation
programs and policies. In each case management periodically reports to our Board or relevant committee, which provides guidance on risk
assessment and mitigation. The Nominating and Corporate Governance Committee recommends the slate of director nominees for election to
the Company’s Board of Directors, identifies and recommends candidates to fill vacancies occurring between annual stockholder meetings,
reviews, evaluates and recommends changes to the Company’s Corporate Governance Guidelines, and establishes the process for conducting
the review of the Chief Executive Officer’s performance. The Risk, Safety and Regulatory Committee oversees our risk management
policies and procedures, reviews our principal risk and compliance policies and our approach to risk management, deals with risk identification
and risk assessment for the principal operational, business, compliance, legal and ethics risks facing our company, whether internal
or external in nature. (The Company’s committees are described in greater detail below).
Our
Co-Executive Chairmen can represent the board in communications with stockholders and other stakeholders but cannot individually (however
the full Board can) override our Chief Executive Officer on, any risk matters. Additionally, our Co-Executive Chairmen have not traditionally
provided input on design of the Board itself, which instead comes from the full Board.
While
the Board and its committees oversee the Company’s strategy, management is charged with its day-to-day execution. To monitor performance
against the Company’s strategy, the Board receives regular updates and actively engages in dialogue with management.
Family
Relationships
There
are no family relationships among executive officers and directors.
Arrangements
between Officers and Directors
There
is no arrangement or understanding between our directors and executive officers and any other person pursuant to which any director or
officer was or is to be selected as a director or officer. There are also no arrangements, agreements or understandings to our knowledge
between non-management stockholders that may directly or indirectly participate in or influence the management of our affairs.
Other
Directorships
None
of the directors of our Company are also directors of issuers with a class of securities registered under Section 12 of the Exchange Act
(or which otherwise are required to file periodic reports under the Exchange Act), other than:
| ● | Mr. McGovern
(who serves on the Board of Directors of Cars.com and as the Chairman of the Audit Committee and Member of the Compensation Committee
of Cars.com), |
| ● | Prof.
Steinman (who serves on the Board of Directors of BioAtla, Inc. (NASDAQ:BCAB), on the Compensation Committee and Nominating and Corporate
Governance Committee of BioAtla and on the Board of Directors of Pasithea Therapeutics Corp. (NASDAQ:KTTA), and also on the Compensation
Committee and Nominating and Corporate Governance Committee of Pasithea), |
| ● | Dr.
DeLuca (who serves on the Board of Directors of Surgery Partners, Inc. (NASDAQ:SGRY) and on the Audit Committee and Chair Compliance
and Ethics Committee of the Board of Directors of Surgery Partners, Inc.), and |
| ● | Mr.
Knuettel (who serves as a member of the Board of Directors, Audit Committee, Nominating and Corporate Governance Committee and Compensation
Committee of Murphy Canyon Acquisition Corp. (MURF), as a member of the Board of Directors, Audit Committee and Nominations and Corporate
Governance Committee of Relativity Acquisition Corp. (NASDAQ:RACY). |
Involvement
in Certain Legal Proceedings
To
the best of our knowledge, during the past ten years, none of our directors or executive officers were involved in any of the following:
(1) any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either
at the time of the bankruptcy or within two years prior to that time; (2) any conviction in a criminal proceeding or being
a named subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) being subject to any
order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily
enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; (4) being
found by a court of competent jurisdiction (in a civil action), the SEC or the Commodities Futures Trading Commission to have violated
a federal or state securities or commodities law; (5) being the subject of, or a party to, any Federal or State judicial or administrative
order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of (i) any
Federal or State securities or commodities law or regulation; (ii) any law or regulation respecting financial institutions or insurance
companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty
or temporary or permanent cease-and-desist order, or removal or prohibition order; or (iii) any law or regulation prohibiting
mail or wire fraud or fraud in connection with any business entity; or (6) being the subject of, or a party to, any sanction or
order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of
the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent
exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.
Board
of Directors Meetings
During
the fiscal year that ended on December 31, 2022, the Board held seven meetings and took various other actions via the unanimous
written consent of the Board of Directors and the various committees described below. Each director attended at least 75% of all of the
Board of Directors meetings and committee meetings of the committees on which they served, during the fiscal year ended December 31,
2022. All of the Company’s directors attended the Company’s 2022 annual meeting. Each director of the Company is expected
to be present at annual meetings of stockholders, absent exigent circumstances that prevent their attendance. Where a director is unable
to attend an annual meeting in person but is able to do so by electronic conferencing, the Company will arrange for the director’s
participation by means where the director can hear, and be heard, by those present at the meeting.
Board
Committee Membership
Our
Board of Directors has four standing committees: an Audit Committee, a Compensation Committee, a Nominating and Corporate Governance
Committee, and a Risk, Safety and Regulatory Committee. All four committees are composed solely of independent directors. We filed a
copy of our Audit Committee charter and our Compensation Committee charter as exhibits to the registration statement that we filed in
connection with our IPO. We filed a copy of our Nominating and Corporate Governance Committee charter as an exhibit to our Current
Report on Form 8-K that we filed with the SEC on November 12, 2020. We filed a copy of our Risk, Safety and Regulatory
Committee charter as an exhibit to our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 that we
filed with the SEC on July 9, 2021. You can review the charters for our standing committees by accessing our public filings at the
SEC’s web site at www.sec.gov or on our website at https://ir.180lifesciences.com/corporate-governance/board-committees.
The
current members of the committees of our Board of Directors are as follows:
Director Name | |
Independent | |
Audit Committee | |
Compensation Committee | |
Nominating and Corporate Governance Committee | |
Risk, Safety and Regulatory Committee |
Lawrence Steinman, M.D.(1) | |
| |
| |
| |
| |
|
Sir Marc Feldmann, Ph.D.(1) | |
| |
| |
| |
| |
|
James N. Woody, M.D., Ph.D. | |
| |
| |
| |
| |
|
Larry Gold, Ph.D. | |
X | |
M | |
| |
C | |
|
Donald A. McGovern, Jr.(2) | |
X | |
C | |
M | |
| |
M |
Russell T. Ray, MBA | |
X | |
M | |
M | |
M | |
|
Teresa DeLuca, M.D., MBA | |
X | |
| |
C | |
M | |
|
Francis Knuettel II, MBA | |
X | |
M | |
| |
| |
M |
Pamela G. Marrone, Ph.D. | |
X | |
| |
M | |
| |
C |
| (1) | Co-Executive Chairman
of the Board of Directors. |
| (2) | Lead
independent director. |
| C | Chairperson
of the Committee. |
| M | Member
of the Committee. |
Each
of these committees has the duties described below and operates under a charter that has been approved by our Board of Directors.
Audit
Committee
NASDAQ
listing standards and applicable SEC rules require that the Audit Committee of a listed company be comprised solely of independent directors.
We have established an Audit Committee of the Board of Directors, which currently consists of Donald A. McGovern, Jr., MBA (Chair),
Larry Gold, Ph.D., Russell T. Ray, MBA and Francis Knuettel II, MBA. Each member of the Audit Committee meets the independent
director standard under NASDAQ’s listing standards and under Rule 10A-3(b)(1) of the Exchange Act. Each member of
the Audit Committee is financially literate and our Board of Directors has determined that Mr. McGovern qualifies as an “audit
committee financial expert” as defined in applicable SEC rules.
Responsibilities
of the Audit Committee include:
| ● | the
appointment, compensation, retention, replacement, and oversight of the work of the independent registered public accounting firm and
any other independent registered public accounting firm engaged by us; |
| ● | pre-approving all
audit and non-audit services to be provided by the independent registered public accounting firm or any other registered public
accounting firm engaged by us, and establishing pre-approval policies and procedures; |
| ● | reviewing
and discussing with the independent registered public accounting firm all relationships the firm has with us in order to evaluate their
continued independence; |
| ● | setting
clear hiring policies for employees or former employees of the independent registered public accounting firm; |
| ● | setting
clear policies for audit partner rotation in compliance with applicable laws and regulations; |
| ● | obtaining
and reviewing a report, at least annually, from the independent registered public accounting firm describing (i) the independent
auditor’s internal quality-control procedures and (ii) any material issues raised by the most recent internal quality-control review,
or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within, the preceding
five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues; |
| ● | reviewing
and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated
by the SEC prior to us entering into such transaction; and |
| ● | reviewing
with management, the independent registered public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or
compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports
that raise material issues regarding our consolidated financial statements or accounting policies and any significant changes in accounting
standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities. |
Compensation
Committee
We
have established a Compensation Committee of the Board of Directors. The members of our Compensation Committee are Teresa DeLuca MD,
Ph.D. (Chair), Donald A. McGovern, Jr., MBA, Russell T. Ray, MBA and Pamela G. Marrone, Ph.D. We have adopted a Compensation
Committee charter, which details the principal functions of the Compensation Committee, including:
| ● | reviewing
and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer’s compensation, evaluating
our Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the remuneration
(if any) of our Chief Executive Officer based on such evaluation in executive session at which the Chief Executive Officer is not present; |
| ● | reviewing
and approving the compensation of all of our other executive officers; |
| ● | reviewing
our executive compensation policies and plans; |
| ● | implementing
and administering our incentive compensation equity-based remuneration plans; |
| ● | assisting
management in complying with our proxy statement and annual report disclosure requirements; |
| ● | approving
all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and
employees; |
| ● | producing
a report on executive compensation to be included in our annual proxy statement; and |
| ● | reviewing,
evaluating and recommending changes, if appropriate, to the remuneration for directors. |
The
Compensation Committee charter also provides that the Compensation Committee may, in its sole discretion, retain or obtain the advice
of a compensation consultant, legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight
of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel
or any other adviser, the Compensation Committee will consider the independence of each such adviser, including the factors required
by NASDAQ and the SEC.
Compensation
Committee Interlocks and Insider Participation
As
described above, the current members of the Compensation Committee are independent members of our Board of Directors. No member of the
Compensation Committee is an employee or a former employee of the Company. During fiscal 2022, none of our executive officers served
on the Compensation Committee (or its equivalent) or Board of Directors of another entity whose executive officer served on our Compensation
Committee. Accordingly, the Compensation Committee members have no interlocking relationships required to be disclosed under SEC rules
and regulations.
Nominating
and Governance Committee
We
have established a nominating and corporate governance committee of the Board of Directors. The members of our Nominating and Governance
Committee are Larry Gold, Ph.D. (Chair), Russell T. Ray, MBA and Teresa DeLuca MD, MBA. Our Board has determined that each
member is independent under applicable NASDAQ listing standards. We have adopted a Compensation Committee charter, which details the
principal functions of the nominating and corporate governance committee. Specific responsibilities of the Nominating and Corporate Governance
Committee include:
| ● | making
recommendations to our Board regarding candidates for directorships; |
| ● | making
recommendations to our Board regarding the size and composition of our Board; |
| ● | overseeing
our corporate governance policies and reporting; and |
| ● | making
recommendations to our Board concerning governance matters. |
Risk,
Safety and Regulatory Committee
In
May 2021, the Board of Directors adopted a charter of a Risk, Safety and Regulatory Committee, which committee is tasked with, among
other things, overseeing our risk management policies and procedures, reviewing our principal risk and compliance policies and our approach
to risk management, dealing with risk identification and risk assessment for the principal operational, business, compliance and ethics
risks facing our company, whether internal or external in nature including, but not limited to, the risks and incident responses associated
with: information security; business continuity and disaster recovery; vendor management; operations risks; supply chain risks; employment
and workplace conduct practices; safety and environmental matters; and legal risks, overseeing our compliance programs, reviewing our
compliance with relevant laws, regulations, and corporate policies (including our Code of Ethics), overseeing significant complaints
and other matters raised through our compliance reporting mechanisms, including the review and investigation of such matters as necessary,
reviewing significant government inquiries or investigations and other significant legal actions, reviewing information about current
and emerging legal and regulatory compliance risks and enforcement trends that may affect our business operations, performance or strategy,
meeting, and reviewing and discussing with management the implementation and enforcement of policies, standards, procedures and risk
management programs, and compliance with applicable laws and regulations, related to the manufacture and supply of products consistent
with applicable high-quality and medical product safety standards. The members of our Risk, Safety and Regulatory Committee are
Pamela G. Marrone, Ph.D. (Chair), Donald A. McGovern, Jr., MBA, and Francis Knuettel II, MBA. Our Board has determined
that each member is independent under applicable NASDAQ listing standards.
Director
Independence
Our
Board of Directors has affirmatively determined that each of Donald A. McGovern, Jr., MBA, Larry Gold, Ph.D., Russell T. Ray,
MBA, Teresa M. DeLuca, M.D., MBA, Pamela G. Marrone, Ph.D. and Francis Knuettel II, MBA is an independent director as
defined under the NASDAQ rules governing members of boards of directors and as defined under Rule 10A-3 of the Exchange Act,
and has no relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.
Furthermore,
the Board has determined that each of the members of our Audit Committee, Compensation Committee, Nominating and Corporate Governance
Committee, and Risk, Safety and Regulatory Committee is independent within the meaning of Nasdaq director independence standards applicable
to members of such committees, as currently in effect.
The
Compensation Committee members also qualify as “non-employee directors” within the meaning of Section 16 of the Exchange
Act.
Board
Diversity Matrix
Beginning
in 2022, we surveyed the Board and asked each director to self-identify their race/ethnicity, gender identity and LGBTQ+ identity. The
results are presented below in the table below, which provides certain highlights of the composition of our board members and nominees.
Each of the categories listed in the below table has the meaning as it is used in Nasdaq Proposed Rule 5605(f).
Board Diversity Matrix (As of May
11, 2023)* |
Total Number of Directors | |
9 | |
| |
Female | | |
Male | | |
Non-Binary | | |
Did Not Disclose Gender | |
Part I: Gender Identity | |
| | |
| | |
| | |
| |
Directors | |
| 2 | | |
| 7 | | |
| — | | |
| — | |
Part II: Demographic Background | |
| | | |
| | | |
| | | |
| | |
African American or Black | |
| — | | |
| — | | |
| — | | |
| — | |
Alaskan Native or Native American | |
| — | | |
| — | | |
| — | | |
| — | |
Asian | |
| — | | |
| — | | |
| — | | |
| — | |
Hispanic or Latinx | |
| — | | |
| — | | |
| — | | |
| — | |
Native Hawaiian or Pacific Islander | |
| — | | |
| — | | |
| — | | |
| — | |
White | |
| 2 | | |
| 7 | | |
| — | | |
| — | |
Two or More Races or Ethnicities | |
| — | | |
| — | | |
| — | | |
| — | |
LGBTQ+ | |
| — | | |
| | | |
| | | |
| | |
Did Not Disclose Demographic Background | |
| — | | |
| | | |
| | | |
| | |
| * | The
Company’s 2021 Board Diversity Matrix was publicly disclosed in the Company’s proxy statement for its 2022 Annual Meeting
of Stockholders. |
Under
the phase-in transition rules, the Company is required to have, or provide an explanation why it does not have, (x) at least one diverse
director by December 31, 2023, and (y) at least two diverse directors by December 31, 2026. Pursuant to applicable Nasdaq rules, because
we are a “smaller reporting company”, and because, as shown in the table above, as of May 11, 2023, we had two directors
who self-identify as female we meet Nasdaq’s diversity objective of having two diverse directors.
Website
Availability of Documents
The
charters of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee and our Code of Business Conducts
and Ethics can be found on our website at https://ir.180lifesciences.com/corporate-governance/governance-documents. Unless
specifically stated herein, documents and information on our website are not incorporated by reference in this proxy statement.
Stockholder
Communications with the Board of Directors
Our
stockholders and other interested parties may communicate with members of the Board of Directors by submitting such communications in
writing to our Corporate Secretary, 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, California 94306, who, upon receipt of any
communication other than one that is clearly marked “Confidential,” will note the date the communication was received,
open the communication, make a copy of it for our files and promptly forward the communication to the director(s) to whom it is
addressed. Upon receipt of any communication that is clearly marked “Confidential,” our Corporate Secretary will not
open the communication, but will note the date the communication was received and promptly forward the communication to the director(s) to
whom it is addressed. If the correspondence is not addressed to any particular board member or members, the communication will be forwarded
to a board member to bring to the attention of the Board of Directors.
Lead
Independent Director
Our
lead independent director has a clearly defined set of responsibilities and provides significant independent Board leadership. Donald
A. McGovern, Jr., MBA, has served as our lead independent director since March 2021.
Our
lead director: will preside at any meetings of the independent directors, including executive sessions, and take the lead role in communicating
to the Co-Chairmen any feedback, as appropriate; will (a) assist in the recruitment of board candidates; (b) have active
involvement in board evaluations; (c) have active involvement in establishing committee membership and committee chairs; and (d) have
active involvement in the evaluation of the chief executive officer; will provide board performance feedback to the Co-Chairmen; will
work with committee chairs as necessary to ensure committee work is conducted at the committee level and appropriately reported to the
board; will communicate with the independent directors between meetings when appropriate; and will recommend consultants and outside
advisors to the board as necessary or appropriate. The lead director may also attend meetings of committees on which the lead director
is not a member.
Executive
Sessions of the Board of Directors
The
independent members of our Board of Directors meet in executive session (with no management directors or management present) from time
to time. The executive sessions include whatever topics the independent directors deem appropriate.
Code
of Ethics
We
have adopted a Code of Ethics applicable to our directors, officers and employees, which we filed as an exhibit to the registration statement
that we filed in connection with our IPO. You can review our Code of Ethics by accessing our public filings at the SEC’s web
site at www.sec.gov. In addition, a copy of our Code of Ethics will be provided without charge upon request from us. We intend
to disclose any amendments to or waivers of certain provisions of our Code of Ethics in a Current Report on Form 8-K. There
have been no waivers granted with respect to our Code of Ethics to any such officers or employees to date.
Policy
on Equity Ownership
The
Company does not have a policy on equity ownership at this time. However, as illustrated in the “Security Ownership of Management
and Certain Beneficial Owners” table on page 10, all current Named Executive Officers and directors are beneficial owners of
stock of the Company.
Compensation
Recovery and Clawback Policies
Under
the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), in the event of misconduct that results in a financial
restatement that would have reduced a previously paid incentive amount, we can recoup those improper payments from our Chief Executive
Officer and Chief Financial Officer (if any). The SEC also recently adopted rules which direct national stock exchanges to require listed
companies to implement policies intended to recoup bonuses paid to executives if the company is found to have misstated its financial
results. We plan to implement a clawback policy in the future, once required, although we have not yet implemented such policy.
Insider
Trading/Anti-Hedging Policies
All
employees, officers and directors of, and consultants and contractors to, us or any of our subsidiaries are subject to our Insider Trading
Policy. The policy prohibits the unauthorized disclosure of any nonpublic information acquired in the workplace, the misuse of material
nonpublic information in securities trading. The policy also includes specific anti-hedging provisions.
To
ensure compliance with the policy and applicable federal and state securities laws, all individuals subject to the policy must refrain
from the purchase or sale of our securities except in designated trading windows or pursuant to preapproved 10b5-1 trading plans.
The anti-hedging provisions prohibit all employees, officers and directors from engaging in “short sales” of
our securities.
Report
of Audit Committee
The
following report of the Audit Committee does not constitute soliciting materials and should not be deemed filed or incorporated by reference
into any other Company filing under the Securities Act, or the Exchange Act, except to the extent we specifically incorporate such
report by reference therein.
AUDIT
COMMITTEE REPORT
The
Audit Committee, which is comprised exclusively of independent directors, represents and assists the Board of Directors in fulfilling
its responsibilities for general oversight of the integrity of the Company’s financial statements, the Company’s compliance
with legal and regulatory requirements, the independent registered public accounting firm’s qualifications and independence, the
performance of the Company’s internal audit function and independent registered public accounting firm, and risk assessment and
risk management. The Audit Committee manages the Company’s relationship with its independent registered public accounting firm
(which reports directly to the Audit Committee). The Audit Committee has the authority to obtain advice and assistance from outside legal,
accounting or other advisors as the Audit Committee deems necessary to carry out its duties and receives appropriate funding, as determined
by the Audit Committee, from the Company for such advice and assistance.
In
connection with the audited financial statements of the Company for the year ended December 31, 2022, the Audit Committee of the
Board of Directors of the Company (1) reviewed and discussed the audited financial statements with the Company’s management
and the Company’s independent auditors; (2) discussed with the Company’s independent auditors the matters required to
be discussed by the applicable requirements of the Public Company Accounting Oversight Board (“PCAOB”) and the Securities
and Exchange Commission; (3) received and reviewed the written disclosures and the letter from the independent auditors required
by the applicable requirements of the PCAOB regarding the independent auditors’ communications with the Audit Committee concerning
independence; (4) discussed with the independent auditors the independent auditors’ independence; and (5) considered
whether the provision of non-audit services by the Company’s principal auditors is compatible with maintaining auditor independence.
Based
upon these reviews and discussions, the Audit Committee recommended to the Board of Directors, and the Board of Directors approved, that
the audited financial statements for the year ended December 31, 2022 be included in the Company’s Annual Report on Form 10-K for
the year ended December 31, 2022 for filing with the Securities and Exchange Commission.
The
undersigned members of the Audit Committee have submitted this Report to the Board of Directors.
Respectfully
submitted,
Audit
Committee
/s/ Donald
A. McGovern, Jr., MBA, Chair
/s/ Larry
Gold, Ph.D.
/s/ Russell
T. Ray, MBA
/s/ Francis
Knuettel II, MBA
INFORMATION
ABOUT OUR EXECUTIVE OFFICERS AND DIRECTORS
Executive
Officers
The
following table sets forth certain information with respect to our executive officers:
Name | |
Position | |
Age |
James N. Woody, M.D., Ph.D. | |
Chief Executive Officer and Director | |
80 |
Ozan Pamir | |
Chief Financial Officer and Secretary | |
32 |
Jonathan Rothbard, Ph.D. | |
Chief Scientific Officer | |
71 |
Below
is information regarding each executive officer’s biographical information, including their principal occupations or employment
for at least the past five years, and the names of other public companies in which such persons hold or have held directorships
during the past five years.
JAMES
N. WOODY, M.D., PH.D. — CHIEF EXECUTIVE OFFICER — Information regarding Dr. Woody is set forth
below under “Classified Board of Directors”.
OZAN
PAMIR — CHIEF FINANCIAL OFFICER AND SECRETARY — Ozan Pamir has served as our Chief Financial Officer
since April 2023, and prior to that, as interim Chief Financial Officer from November 2020 to April 2023. Mr. Pamir has also
served as the Chief Financial Officer and as a member of the Board of Directors of 180, our wholly-owned subsidiary following the
Closing of the Business Combination, since October 2018. Mr. Pamir has also served as the Chief Financial Officer and as a
member of the Board of Directors of Unify Pharmaceuticals between August 2019 and July 2021, and as the Chief Financial Officer
of Enosi Life Sciences between May 2020 and April 2021, both of which are pre-clinical companies focused on autoimmune
diseases. Previously, Mr. Pamir served in various positions with Echelon Wealth Partners, a leading Canadian investment bank, from
June 2014 to October 2018, including Investment Banking Analyst (June 2014 — June 2015), Senior Associate,
Investment Banking (June 2015 — September 2017) and Vice President of Investment Banking (September 2017 — October 2018),
as well as Investment Banking Analyst of OCI Groups from October 2013 to June 2014. Mr. Pamir holds an Economics and Finance
degree from McGill University and is a CFA Charterholder.
JONATHAN
ROTHBARD, PH.D. — CHIEF SCIENTIFIC OFFICER — Jonathan Rothbard, Ph.D. has served as our Chief Scientific
Officer since the Closing of the Business Combination in November 2020. Dr. Rothbard has served as the Chief Executive Officer and Chief
Scientific Officer of Katexco since November 2018. Previously, he was a founder of ImmuLogic Pharmaceutical Corp., in Palo Alto, California,
where he served as Chief Scientific Officer from 1989 to 1995, a founder of Amylin Corporation in San Diego, California in 1989, and
CellGate Incorporated in Redwood City, California, where he served as Chief Scientific Officer from 1998 to 2004. Dr. Rothbard served
on the faculty in the Departments of Neurology (2007-2018), Chemistry (2005-2006), Medicine-division of Rheumatology (1996-1998) at Stanford
University School of Medicine. His first academic faculty position was as the head of the Molecular Immunology Laboratory at the Imperial
Cancer Research Fund in London from 1985-1989. Dr. Rothbard received his BA from Hamilton College in 1973 and his Ph.D. from Columbia
University in 1977 and completed post-doctoral fellowships at The Rockefeller University and Stanford University Medical School.
Classified
Board of Directors
The
Board of Directors is divided into two classes. At each annual general meeting of stockholders, the successors to directors whose terms
then expire will be elected to serve from the time of election and qualification until the second annual meeting following the election.
The directors are divided among the two classes as follows:
| ● | the
Class I directors are Lawrence Steinman, James N. Woody, Russell T. Ray and Francis Knuettel II, and their terms
expire at the annual meeting of stockholders on July 6, 2023 (subject to their re-appointment pursuant to Proposal 1 herein);
and |
| ● | the
Class II directors are Larry Gold, Sir Marc Feldmann, Donald A. McGovern, Jr.,
Teresa M. DeLuca and Pamela G. Marrone, and their terms expire at the annual meeting
of stockholders to be held in 2024. |
Any
additional directorships resulting from an increase in the number of directors will be distributed among the two classes so that, as
nearly as possible, each class will consist of one-half of the directors. The division of the Board of Directors
into two classes with staggered two-year terms may delay or prevent a change of our management or a change in control.
Our
current directors are as follows:
Name
|
|
Age |
|
Position With Company |
|
Date
First
Appointed as
Officer or
Directors |
|
Director Class* |
Class I
Directors |
|
|
|
|
|
|
|
|
Lawrence
Steinman, M.D. |
|
75 |
|
Executive
Co-Chairman |
|
November 2020 |
|
Class I |
James
N. Woody, M.D., Ph.D. |
|
80 |
|
Chief
Executive Officer and Director |
|
November 2020 |
|
Class I |
Russell
T. Ray, MBA |
|
76 |
|
Director |
|
July 2021 |
|
Class I |
Francis
Knuettel II, MBA |
|
57 |
|
Director |
|
July 2021 |
|
Class I |
|
|
|
|
|
|
|
|
|
Class II
Directors |
|
|
|
|
|
|
|
|
Sir
Marc Feldmann, Ph.D. FRS |
|
78 |
|
Executive
Co-Chairman, and Chairman, CEO and Executive Director of CannBioRex |
|
November 2020 |
|
Class II |
Larry
Gold, Ph.D. |
|
81 |
|
Director |
|
November 2020 |
|
Class II |
Donald
A. McGovern, Jr., MBA |
|
72 |
|
Director |
|
November 2020 |
|
Class II |
Teresa
M. DeLuca, M.D., MBA |
|
58 |
|
Director |
|
July 2021 |
|
Class II |
Pamela
G. Marrone, Ph.D. |
|
66 |
|
Director |
|
July 2021 |
|
Class II |
| * | Terms
expire at the 2023 annual meeting of stockholders (Class I) and the annual meeting of stockholders to be held in 2024 (Class II). |
Director
Nominees
At
the annual meeting, four directors are to be re-elected as Class I directors, to hold office until the 2025 annual meeting
of stockholders and until their respective successors are duly elected and qualified. The Nominating and Corporate Governance Committee
has recommended, and the Board of Directors has selected, the following nominees for election: Lawrence Steinman, James N. Woody, Russell
T. Ray and Francis Knuettel II, all of whom are currently directors of our company. Each nominee for director has consented to being
named in this proxy statement and has indicated a willingness to serve if elected.
There
is no arrangement or understanding between our directors and executive officers and any other person pursuant to which any director or
officer was or is to be selected as a director or officer, and there is no arrangement, plan or understanding as to whether non-management stockholders
will exercise their voting rights to continue to elect the current Board. There are also no arrangements, agreements or understandings
to our knowledge between non-management stockholders that may directly or indirectly participate in or influence the management
of our affairs.
Although
we do not anticipate that any nominee will be unavailable for election, if a nominee is unavailable for election, the persons named as
proxyholders will use their discretion to vote for any substitute nominee in accordance with their best judgment as they deem advisable.
Information
regarding the director nominees is provided below:
|
|
LAWRENCE
STEINMAN
CO-EXECUTIVE CHAIRMAN
(CLASS I DIRECTOR NOMINEE) |
Lawrence
Steinman, M.D. has served as Co-Executive Chairman since the Closing of the Business Combination in November 2020. He also has primary
scientific responsibility for our α7nAChR platform. Dr. Steinman served as Co-Chairman of 180 and as a member of its board of directors
since April 2019. Prior to joining 180, he served on the Board of Directors of Centocor Biotech, Inc., from 1989 to 1998, the Board of
Directors of Neurocine Biosciences from 1997 to 2005, the Board of Directors of Atreca from 2010 – 2019, the Board of Directors
of BioAtla, Inc. (NASDAQ:BCAB) from July 2020 to present (he also serves on the Compensation Committee and Nominating and Corporate Governance
Committee of BioAtla), the Board of Directors of Tolerion, Inc. from 2013 to 2020 and the Board of Directors of Alpha5 Integrin from
November 2020 to June 2022, and the Board of Directors of Pasithea Therapeutics Corp. (NASDAQ:KTTA) from August 2020 to the present.
He is currently the George A. Zimmermann Endowed Chair in the Neurology Department at Stanford University and previously served as the
Chair of the Interdepartmental Program in Immunology at Stanford University Medical School from 2003 to 2011. He is a member of the National
Academy of Medicine and the National Academy of Sciences. He also founded the Steinman Laboratory at Stanford University, which is dedicated
to understanding the pathogenesis of autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica. He received the Frederic
Sasse Award from the Free University of Berlin in 1994, the Sen. Jacob Javits Award from the U.S. Congress from 1988 through 2002, the
John Dystel Prize in 2004 from the National MS Society in the U.S., the Charcot Prize for Lifetime Achievement in Multiple Sclerosis
Research in 2011 from the International Federation of MS Societies and the Anthony Cerami Award in Translational Medicine by the Feinstein
Institute of Molecular Medicine in 2015. In 2023, he was honored as a Pioneer in Medicine by the Society for Brain Mapping and Therapeutics.
He also received an honorary Ph.D. from the Hasselt University in 2008, and from the University of Buenos Aires in 2022. He received
his BA (physics) from Dartmouth College in 1968 and his MD from Harvard University in 1973. He also completed a fellowship in chemical
immunology at the Weizmann Institute (1974 – 1977) and was an intern and resident at Stanford University Medical School. We believe
Dr. Steinman’s extensive experience leading the research and development of numerous therapeutics qualify him to serve as a director.
Director
Qualifications:
We
believe Dr. Steinman’s extensive experience leading the research and development of numerous therapeutics for biotechnology
companies qualifies him to serve as a director.
|
|
JAMES
N. WOODY, M.D., PH.D.
CHIEF
EXECUTIVE OFFICER AND CLASS I DIRECTOR NOMINEE |
James
N. Woody, M.D., Ph.D. has served as our Chief Executive Officer and as a director since the Closing of the Business Combination
in November 2020. Dr. Woody has served as the CEO of 180 since July 2020, and as a director of 180 since September 2020.
Dr. Woody was a founder and served as Chairman of the Board of Directors for Viracta Pharmaceuticals, a lymphoma therapeutic company
(July 2014 to December 2020). With the company undergoing a reverse merger into a public company, he resigned his Board member
position and continues as a Board observer. He served as a General Partner of Latterell Venture Partners (February 2006 to December 2019)
then moved to a Venture Partner position, for the one remaining LVP legacy company, PerceptiMed, a Pharmacy management company, where
he continues to serve on the Board as they plan their IPO. He served as an interim CEO for MaraBio Systems Inc., a startup autism
diagnostic company, from November 2018 to December 2022, when a new full time CEO was selected and he continues to serve as Vice
Chairman, on the Board of Directors. He also serves as Chairman of the Board for Enosi Life Sciences, a next generation TNF inhibitor
company, which position he has held since July 2020. He served as a Board member of IntegenX Inc. (2012 to 2018), and Neuraltus
Pharmaceuticals, Inc. (February 2009 to December 2019). Dr. Woody was the founding CEO and Chairman of the Board of OncoMed
Pharmaceuticals, Inc. (2004 to 2014), a NASDAQ listed company with a focus on antibodies targeting cancer stem cells. He previously served
as a member of the Board of Directors of Protein Simple, formerly Cell Biosciences (2005 to 2014), acquired by Bio-Techne; Forte Bio
Corporation, acquired by PALL in 2012 (2005 to 2012); Bayhill Therapeutics, Inc. (2004 to 2012); Femta Pharmaceuticals (2008 to 2012);
and Proteolix, Inc. (2005 to 2009), acquired by Onyx for the multiple myeloma drug Carfilzomib. Dr. Woody also served on the Board
of Directors of Talima Therapeutics, Inc. (2007 to 2011); HemaQuest Pharmaceuticals, Inc. (2009 to 2013); Calistoga (2009 to 2011), acquired
by Gilead for the lymphoma drug Idelalisib (Zydelig); Tetralogic (2008 to 2014), a NASDAQ listed company; and Avidia (2003 to 2006),
acquired by Amgen. From 1996 to 2004, He was President and General Manager of Roche Biosciences, Palo Alto, California (formerly Syntex),
where he had responsibility for all bioscience research and development, ranging from genetics and genomics to clinical development of
numerous new pharmaceuticals, as well as former Syntex administrative matters. From 1991 to 1996, Dr. Woody served as Senior Vice
President of Research and Development and Chief Scientific Officer of Centocor, Inc., Malvern, Pennsylvania, where he assisted in the
development of several new major antibody-based therapeutics in the fields of oncology and autoimmune and cardiovascular disease,
including Remicade®, a multi-billion dollar pharmaceutical. Prior to that time, he served as a Medical Officer in the U.S. Navy,
retiring as a CAPT (06) and as Commanding Officer of the Naval Medical Research and Development Command in 1991. Dr. Woody
and his colleagues, with U.S. Navy and Congressional approval, founded the National Marrow Donor Program. He is a member of the
Research Advisory Committee for the Veterans Gulf War Illness. Dr. Woody was a member of the Board of Directors of the Lucille Packard
(Stanford) Children’s Hospital (LPCH) in Palo Alto, California, (July 2002 to December 2020), serving as Chairman of
the LPCH Quality Service and Safety Committee and a Member of the Patient Safety Oversight Committee. Dr. Woody also is a member
of the Stanford Medical School Dean’s Research Committee and Stanford “SPARK” research initiatives program.
Dr. Woody received a B.S. in Chemistry from Andrews University, Berrien Springs, Michigan, an M.D. from Loma Linda University and
Pediatric Subspecialty Training at Duke University School of Medicine and Harvard University School of Medicine. He received a Ph.D.
in Immunology from the University of London, England. We believe that his expertise and experience in the life sciences and venture capital
industries and his educational background make him qualified to serve as a director.
Director
Qualifications:
We
believe that his expertise and experience in the life sciences and venture capital industries, and his educational background make him
qualified to serve as a director.
|
|
RUSSELL
T. RAY, MBA
CLASS I
DIRECTOR NOMINEE |
Russell
T. Ray, MBA has served as a director of our Company since July 9, 2021. Mr. Ray was a Senior Advisor to HLM Venture Partners,
a health care venture capital firm, from February 2017 to December 2017 and from January 2014 to December 2015. From January 2016 to
February 2017, Mr. Ray was a Managing Director and Vice Chairman of Healthcare Investment Banking at Stifel, Nicolaus & Company,
Incorporated, an investment banking firm, with a focus on health care investments. From September 2003 to September 2015, Mr. Ray served
as a Partner and Senior Advisor with HLM Venture Partners, a health care focused venture capital firm that invests in health care services,
health care information technology and medical technology companies. Prior to his work with HLM, he served as Managing Director and President
of Chesapeake Strategic Advisors (2002 to 2003), which invested in health care services, health care information technology and medical
technology companies. Mr. Ray was formerly Managing Director and Co-Head of Global Health Care Investment Banking at Credit Suisse First
Boston Corporation (1999 to 2002) where he led a 50-person team with offices in Baltimore, Chicago, London, New York and San Francisco
focused on providing corporate finance and M&A advisory services to private and public companies in the biotechnology, health care
services and health care information technology sectors. From 1987 to 1999, Mr. Ray was a Managing Director and Global Co-Head of Healthcare
Investment Banking at Deutsche Bank and its predecessor entities, BT Alex. Brown and Alex. Brown & Sons. Mr. Ray served on the board
of directors of Allergan, Inc. from 2003 to 2015. Mr. Ray also served as Chairman of the Audit and Finance Committee of Merrimack
Pharmaceuticals, Inc. (NASDAQ:MACK) (which position he held between January 2015 and June 2022), which specializes in developing
drugs for the treatment of cancer.
Mr.
Ray is a former Captain in the United States Army and recipient of the Bronze Star Medal, two Air Medals and two Army Commendation Medals
for Meritorious Service. He obtained a Bachelor’s of Science degree in Engineering from the United States Military Academy at West
Point, a Bachelor’s of Science degree in Ecology and Evolutionary Biology from the University of Washington, a Master of Science
degree from the University of Pennsylvania in Ecology and Evolutionary Biology and received a Master of Business Administration degree
in Finance from the Wharton School of Business at the University of Pennsylvania.
Director
Qualifications:
We
believe that his expertise and experience in the life sciences industry, venture capital and M&A advisory services to private and
public biotechnology clients, and his educational background make him qualified to serve as a director.
|
|
FRANCIS
KNUETTEL II, MBA
CLASS I
DIRECTOR NOMINEE |
Francis
Knuettel II, MBA has been a director of our Company since July 2, 2021. Mr. Knuettel has over 25 years of management experience
in venture and private-equity backed public companies, and has advised public and private companies on financial management and controls,
mergers and acquisitions, capital markets transactions and operating and financial restructurings. Since April 2022, he has been managing
Camden Capital LLC, where he provides fractional and interim Chief Financial Officer and board services, including serving as Chief Financial
Officer of OceanTech Acquisition Corp (Nasdaq:OTEC) since March 2023. From December 2020 to July 2021, Mr. Knuettel served as the President
of Unrivaled Brands, Inc. (OTCQX:UNRV), a vertically integrated company focused on the cannabis sector with operations in California
and Nevada, from December 2020 to March 2021, he served as the Interim Chief Executive Officer of Unrivaled and he served as Chief Executive
Officer of Unrivaled from March 2021 to March 2022 and as a director from December 2020 through April 2022. Mr. Knuettel has served as
a member of the Board of Directors, Audit Committee, Nominating and Corporate Governance Committee and Compensation Committee of Murphy
Canyon Acquisition Corp. (MURF) since February 2022, and as a member of the Board of Directors, Audit Committee and Nominations and Corporate
Governance Committee of Relativity Acquisition Corp. (NASDAQ:RACY), since February 2022, both Special Purpose Acquisition Companies.
Mr. Knuettel was formerly Director of Capital and Advisory at Viridian Capital Advisors, a position he held from June 2020 to January
2021, following the sale but prior to the close of the acquisition of One Cannabis Group, Inc. (“OCG”) by an OTCQX listed
company. At OCG, Mr. Knuettel served from June 2019 to January 2021 as Chief Financial Officer of the company, a leading cannabis dispensary
franchisor, with over thirty cannabis dispensaries across seven states. Prior to joining OCG, Mr. Knuettel was Chief Financial Officer
at MJardin Group, Inc. (“MJardin”) (August 2018 to January 2019), a Denver-based cannabis cultivation and dispensary management
company, where he led the company’s IPO on the Canadian Securities Exchange. Following the IPO, Mr. Knuettel managed the merger
with GrowForce, a Toronto-based cannabis cultivator, after which he moved over to the Chief Strategy Role (January 2019 to June 2019).
In his role as CSO, he managed the acquisition of several private companies before recommending and executing the consolidation of management
and other operations to Toronto and the closure of the executive office in Denver. From April to August 2018, Mr. Knuettel served as
Chief Financial Officer of Aqua Metals, Inc. (NASDAQ:AQMS), an advanced materials firm that developed technology in battery recycling.
Prior to that, from April 2014 to April, 2018, Mr. Knuettel served as Chief Financial Officer at Marathon Patent Group, Inc. (NASDAQ:MARA),
a patent enforcement and licensing company. Before that, Mr. Knuettel held numerous CFO and CEO positions at early-stage companies where
he had significant experience both building and restructuring businesses. In addition to the Board of Director positions set forth above,
he currently serves as the Chairman of the Board of Directors of a MedTech company focused on smart intubation devices. Mr. Knuettel
graduated cum laude from Tufts University with a B.A. degree in Economics and from The Wharton School at the University of Pennsylvania
with an M.B.A. in Finance and Entrepreneurial Management.
Director
Qualifications:
We
believe that his expertise and experience in the life sciences and venture capital industries, roles in executive management as both
CEO and CFO, and his educational background make him qualified to serve as a director.
Director
Qualifications
The
Board believes that each of our directors is highly qualified to serve as a member of the Board. Each of the directors has contributed
to the mix of skills, core competencies and qualifications of the Board. When evaluating candidates for election to the Board, the Board
seeks candidates with certain qualities that it believes are important, including integrity, an objective perspective, good judgment,
and leadership skills. Our directors are highly educated and have diverse backgrounds and talents and extensive track records of success
in what we believe are highly relevant positions.
Directors
Whose Terms Extend Beyond the 2023 annual Meeting
|
|
PROF.
SIR MARC FELDMANN, PH.D. FRS
EXECUTIVE
CO-CHAIRMAN (CLASS II DIRECTOR)
CHAIRMAN,
CEO AND EXECUTIVE DIRECTOR OF CANNBIOREX |
Prof.
Sir Marc Feldmann, Ph.D. FRS has served as Co-Executive Chairman since the Closing of the Business Combination in November 2020.
He also has primary scientific responsibility for our synthetic cannabidiol (“CBD”) analogues programs. Prof. Sir Feldmann
has served as Co-Chairman of 180 and as a member of its board of directors since April 2018. Since June 1, 2018, Prof. Sir Feldmann has
served as Chairman, CEO and Executive Director of CannBioRex. Since August 2018, Prof. Sir Feldmann has also served as a director of
Enosi Therapeutics Corp., a company which he founded that is a pre-clinical company focused on cancer and autoimmune deficiencies. He
is an Emeritus Prof. at the Kennedy Institute of Rheumatology, Department of Orthopedics, Rheumatology and Musculoskeletal Sciences at
the University of Oxford. He is renowned as an expert in the development of anti-inflammatory therapeutics and has published over 700
papers reflecting a long term commitment to the cellular and molecular aspects of inflammatory autoimmune diseases, cytokines and their
therapeutic applications. In 1983, he published a new hypothesis explaining the mechanism of induction of autoimmune diseases, highlighting
the role of cytokines, potent signaling proteins which drive the important processes of inflammation, immunity and cell growth. In collaboration
with Sir Ravinder Maini, he showed that tumor necrosis factor (“TNF”) was a key driver of rheumatoid arthritis, and that
blocking it was beneficial, first in novel test tube systems (in vitro) using human disease tissue from rheumatoid joints, then animal
models and in a series of clinical trials. Maini and Feldmann developed a key patent for the optimal use of antibodies for TNF, which
was licensed to Centocor and AbbVie, and eventually led to the acquisition of Centocor by Johnson & Johnson. Medically he is a Fellow
of the Royal College of Physicians, the Royal College of Pathologists of London. In recognition of his scientific work, which has led
to anti-TNF currently being the best-selling drug class in the world, Prof. Sir Feldmann was elected to the Academy of Medical Sciences
and the Royal Society in London, is a Fellow of the Australian Academy of Science, and is an International Member of the National Academy
of Sciences, USA. He was knighted by Queen Elizabeth II in 2010 for his outstanding services to medicine, and also received the Australian
equivalent, the Companion of Honour (AC). He was awarded the Crafoord Prize in 2000, the Albert Lasker Award for Clinical Medical Research
in 2003, the Cameron Prize for Therapeutics by the University of Edinburgh in 2004, the John Curtin Medal of the Australian National
University in 2007 and the Dr. Paul Janssen Award for Biomedical Research in 2008, the Ernst Schering Prize in 2010 and the Gairdner
International Award in 2014, together with Sir Ravinder Maini, and separately the European Inventor Award (Lifetime Achievement) by the
European Patent Office in 2007, and the Tang Prize in 2020. He graduated with an MBBS degree from the University of Melbourne in 1967
and earned a Ph.D. in Immunology at the Walter and Eliza Hall Institute of Medical Research in 1972. He undertook postdoctoral research
at the Imperial Cancer Research Fund’s Tumour Immunology Unit in 1972 before moving to the Charing Cross Sunley Research Centre
in 1985, which later merged with the Kennedy Institute of Rheumatology which then joined the Faculty of Medicine at Imperial College
in 2000 and was transferred to the University of Oxford in 2011.
Director
Qualifications:
We
believe Prof. Sir Feldmann’s significant and successful experience leading the research and development of numerous therapeutics
make him qualified to serve as a director.
|
|
LARRY
GOLD, PH.D.
CLASS II
DIRECTOR |
Larry
Gold, Ph.D. has served as a director of our Company since the Closing of the Business Combination in November 2020. Dr. Gold
is the Founder and Chairman Emeritus of the Board, and former CEO of SomaLogic, Inc. Prior to SomaLogic, he also founded and was the
Chairman of NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstar merged with Gilead Sciences, Inc. to form
a global organization committed to the discovery, development and commercialization of novel products that treat infectious diseases.
During his nearly 10 years at NeXstar, Dr. Gold held numerous executive positions including Chairman of the Board, Executive Vice President
of R&D, and Chief Science Officer. Before forming NeXagen, he also co-founded and served as Co-Director of Research at Synergen,
Inc., a biotechnology company later acquired by Amgen, Inc. Dr. Gold became the Chairman of Lab79, a new biotech company in Boulder,
Colorado in 2014. Since 1970, Dr. Gold has been a professor at the University of Colorado at Boulder. While at the University, he served
as the Chairman of the Molecular, Cellular and Developmental Biology Department from 1988 to 1992. Between 1995 and 2013, Dr. Gold received
the CU Distinguished Lectureship Award, the National Institutes of Health Merit Award, the Career Development Award, the Lifetime Achievement
Award from the Colorado Biosciences Association, and the Chiron Prize for Biotechnology. Dr. Gold was also awarded the 8th International
Steven Hoogendijk Prize by the Dutch Batavian Society of Experimental Philosophy in 2018. In addition, Dr. Gold has been a member of
the American Academy of Arts and Sciences since 1993 and the National Academy of Sciences since 1995. He is a fellow of the National
Academy of Inventors. Dr. Gold also serves on the Board of Directors for Lab79, Deck Therapeutics, COLS (a charitable foundation) and
a new pain company, TenZero, each private companies. Dr. Gold established the Gold Lab at the University of Colorado Boulder in 1971.
Starting with basic research on bacteria and bacteriophage, the lab shifted its focus to human disease following the invention of the
SELEX process in 1989. The Gold Lab today focuses on the utilization of biological and information technology to improve healthcare.
Dr. Gold also began holding the GoldLab Symposia in 2010, an annual event that tackles big questions in healthcare. He is determined
to change healthcare for the better through teaching, research, and debate among scientists and citizens throughout the world. Dr. Gold
received a BA in 1963 in Biochemistry from Yale University, a Ph.D. in 1967 in Biochemistry from the University of Connecticut, and was
an NIH Postdoctoral Fellow until 1969 at Rockefeller University.
Director
Qualifications:
We
believe Dr. Gold’s significant experience and successful development and commercialization of products make him qualified
to serve as a director.
|
|
DONALD
A. MCGOVERN, JR., MBA
CLASS II
DIRECTOR |
Donald
A. McGovern, Jr., MBA has served as a director of our Company since the Closing of the Business Combination in November
2020 and became our lead director on March 30, 2021. Mr. McGovern is a retired Vice Chairman, Global Assurance, of PricewaterhouseCoopers
LLP (PwC). Through decades of leadership at PwC and board experience, Mr. McGovern brings wide-ranging operational, financial, accounting
and audit and public company experience. He currently serves on the board of Cars.com (NYSE: CARS). Mr. McGovern joined the Board of
Cars.com in May 2017 upon the spinout of Cars.com from Tegna creating a new public company listed on the NYSE. Cars.com is a leading
two-sided digital automotive marketplace. Mr. McGovern is chair of the Audit Committee, an audit committee financial expert under SEC
regulations, and a member of the Compensation Committee of Cars.com. His past public board experience has been with CRH, plc. Mr. McGovern
served two three-year terms (2013 – 2019) on the board of directors of CRH. During his tenure, he was Senior Independent Director,
chair of the Remuneration Committee, a member of the Nomination Committee and of the Audit Committee and an audit committee financial
expert under U.S. SEC and U.K. FRC regulations. CRH is headquartered in Dublin, Ireland and listed on the London, Irish and New York
Stock Exchanges. His past private company board experience includes Neuraltus Pharmaceuticals (2014 – 2019) and eASIC Corp (2016
– 2018). Mr. McGovern joined the Board of Neuraltus in preparation for Neuraltus doing a potential IPO. Neuraltus was a privately
held, venture capital backed biopharmaceutical company dedicated to the development of therapeutics to treat neurological disorders.
Mr. McGovern was chair of the Audit Committee and Compensation Committee. Mr. McGovern joined the Board of eASIC as the Company was in
the process of filing a Form S-1 registration statement for an IPO. eASIC, a privately held, venture capital backed, fabless semiconductor
company, was acquired by Intel Corporation. Mr. McGovern was chair of the Audit Committee and member of the Nomination Committee.
He
is by background a High Technology Industry Assurance partner and served as the global engagement partner, lead audit partner, or concurring
partner, for numerous Silicon Valley and other U.S. public companies such as Cisco Systems, Applied Materials, Schlumberger, Ltd., Hewlett-Packard,
Agilent Technologies, Nvidia, eBay, and Varian Medical. He also has served Silicon Valley pre-IPO companies and during his career had
been involved in over 35 IPOs. He has extensive experience for SEC current reporting and securities filings related to initial public
offerings and other SEC registration statements, due diligence, mergers and acquisitions, restructurings, divestitures and risk management.
Mr.
McGovern spent 39 years at PwC including 26 years as a partner. Mr. McGovern was Vice Chairman, Global Assurance Leader and a member
of the PwC Global Network Executive Team, from July 2008 until his retirement from PwC on June 30, 2013. He had been the Managing Partner
of the firm’s Silicon Valley Office from July 2001 to June 2007 and previously held other operating roles. In April 2001, Mr. McGovern
was elected to the PwC Board of Partners and Principals of the U.S. firm as well as to PwC’s Global Board. He was the first ever
lead director for the U.S. Board (2001 – 2005) and was elected to serve 2 terms on each Board.
Mr.
McGovern is a member of the American Institute of Certified Public Accountants and has an active CPA license to practice in California,
Illinois and New York. He received a BA from Marquette University in 1972 and received an MBA from DePaul University in 1975. He also
attended the Executive Program for Growing Companies of the Stanford University Graduate School of Business in 1992.
Director
Qualifications:
We
believe Mr. McGovern’s significant auditing, accounting and financial experience, and his being an audit committee financial
expert, as well as his Board experience make him qualified to serve as a director.
|
|
TERESA
M. DELUCA, M.D., MBA
CLASS II
DIRECTOR |
Teresa
M. DeLuca, M.D., MBA, has served as a director of our Company since July 9, 2021. Dr. DeLuca is a physician executive and psychiatrist
in New York, New York, resuming her own practice, since January 2020. Dr. DeLuca previously served as a Managing Director at Columbia
University’s NY Life Science Venture Fund from January 2018 to December 2019. Her responsibilities as Managing Director included
leading a consortium of 12 private/public institutions (Cold Spring Harbor Laboratory, Columbia, CUNY, Einstein, Hospital for Special
Surgery, Memorial Sloan Kettering Cancer Center, Mount Sinai, NYU, Rockefeller University, SUNY Downstate Medical Center, Stony Brook,
Weil Cornell), and providing due diligence support for potential investments, partnerships, acquisitions, commercialization, licensing,
and IPOs. Before that she served as Assistant Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New
York City from August 2014 to December 2017 and as the Chief Medical Officer of Magellan Pharmacy Solutions at Magellan Health from December
2012 to July 2014. Prior to that, she served as SVP of Pharmacy Health Solutions at Humana, VP of Clinical Sales Solutions & National
Medical Director at Walgreen Co., and VP of Personalized Medicine as well as VP of Medical Policy & Clinical Quality at Medco. Prior
to taking on these executive leadership roles, Dr. DeLuca was a Senior Medical Scientist at GlaxoSmithKline. Dr. DeLuca served as a director
at North Bud Farms, Inc., a pharmaceutical company from May 2018 to February 2020 (CSE:NBUD) and has served as a director of Surgery
Partners, Inc. (NASDAQ:SGRY), a leading operator of surgical facilities and ancillary services, since September 2016, and also currently
serves on the Audit Committee and Chair Compliance and Ethics Committee of the Board of Directors of Surgery Partners, Inc. In March
2022, Dr. DeLuca joined the Board of Directors of Rejuveron, a private Swiss drug discovery company and serves on the Audit Committee
and Chair of Governance and Remuneration Committees of such company.
Dr.
DeLuca received a Bachelor’s degree from the University of Rochester / LIU. Dr. DeLuca received her M.B.A. from Drexel University
and her M.D. from St. Georges University School of Medicine, before undertaking her residency at Thomas Jefferson University Medical
School. A strong advocate for good board governance, in 2016, Dr. DeLuca earned the Carnegie Mellon Cybersecurity certificate and in
2022 passed the Digital Directors Network Cyber Risk Masterclass examination. She continues to maintain good standing with the National
Association of Corporate Directors (NACD) as a Board Leadership Fellow (Masters Level), and in 2020 Dr. DeLuca passed the NACD’s
“Directorship Certified” examination (NACD.DC). In addition, in 2022, Dr. DeLuca became a NACD “Subject Matter Expert”
in examination development and a Board Advisory Faculty Member and also earned the American College of Corporate Directors (ACCD) “Advanced
Professional Director” credential. Dr. DeLuca was also named “2020 Director to Watch” in the Directors & Board
Annual Report and named “2022 Director of the Month” in Chief Executive Magazine. Dr. DeLuca is also the Co-Chair and Leadership
Council Member for the international organization, Women Corporate Directors (WCD).
Director
Qualifications:
The
Board of Directors believes that Dr. DeLuca’s public company experience and background as both a practicing MD and former
senior executive Chief Medical Officer with significant P&L business line ownership at global Fortune 50 companies, make her well
qualified to serve on the Board of Directors in the determination of the Board.
|
|
PAMELA
G. MARRONE, PH.D.
CLASS II
DIRECTOR |
Pamela
G. Marrone, Ph.D. has been a director of our Company since July 2, 2021. Dr. Marrone is currently co-founder and Executive
Chair of the Invasive Species Corporation, bringing biological solutions to control difficult invasive species in water, forestry and
agriculture. She was founder and was Chief Executive Officer of Marrone Bio Innovations, Inc. (NASDAQ:MBII), a natural products company
producing pest management and plant health products, from April 2006 until her retirement in August 2020, and then served on the Board
of Directors until its sale to Bioceres Crop Solutions in July 2022. In July 2022, she was elected Chair of the Board of Directors of
Elicit Plant, a French venture capital-backed company developing and selling plant natural products to reduce crop stress. In July 2021,
she was appointed as senior fellow of Arizona State University’s Swette Center for Sustainable Food Systems. She also currently
serves on the board of Stem Express LLC. Prior to founding Marrone Bio, in 1995 Dr. Marrone founded AgraQuest, Inc. (acquired by Bayer),
where she served as board member, president and chief executive officer until May 2004 and as board member, president or chair from such
time until March 2006 and she remained on the board until March 2007. While there, she led teams that discovered and commercialized several
bio-based pest management products. She served as founding president and business unit head for Entotech, Inc., a biopesticide subsidiary
of Denmark-based Novo Nordisk A/S (acquired by Abbott Laboratories), from 1990 to 1995, and held various positions at the Monsanto Company
from 1983 until 1990, where she led the Insect Biology Group, which was involved in pioneering projects in transgenic crops, natural
products and microbial pesticides. Dr. Marrone is an author of over twenty invited publications, an inventor on more than 400 patents
and is in demand as a speaker and has served on the boards and advisory councils of numerous professional and academic organizations.
In 2016, Dr. Marrone was elected to the Cornell University Board of Trustees and completed her four-year term in July 2020. In 2013,
Dr. Marrone was named the Sacramento region’s “Executive of the Year” by the Sacramento Business Journal and “Cleantech
Innovator of the Year” by the Sacramento Area Regional Technology Alliance and Best Manager with Strategic Vision by Agrow in 2014.
In January 2019, she was awarded the “Sustie” award by the Ecological Farming Association for her decades-long leadership
in sustainable agriculture. In March 2020, she was awarded the Most Admired CEO, Distinguished Career Award by the Sacramento Business
Journal. In 2022, she was the first woman to receive the Kathryn C. Hach Award for Entrepreneurial Success from the American Chemical
Society. Dr. Marrone earned a B.S. in Entomology from Cornell University and a Ph.D. in Entomology from North Carolina State University.
Director
Qualifications:
We
believe Dr. Marrone’s strong background with public companies and her considerable management, technical and commercialization
expertise, make her well qualified to serve on the Board of Directors in the determination of the Board.
EXECUTIVE
AND DIRECTOR COMPENSATION
Executive
Compensation
General
Upon
the Closing of the Business Combination, James N. Woody, M.D., Ph.D., the Chief Executive Officer of 180, was appointed to serve
as the Chief Executive Officer of our Company, and Jonathan Rothbard, Ph.D., the Chief Executive Officer and Chief Scientific Officer
of Katexco, was appointed to serve as the Chief Scientific Officer of our Company. Also following the Closing of the Business Combination,
Ozan Pamir, the Chief Financial Officer of 180, continued to serve in that position for 180, and on November 27, 2020, he was appointed
to serve as the Interim Chief Financial Officer of our Company. In April 2023, Mr. Pamir was appointed as Chief Financial Officer of
the Company. Effective on October 29, 2021, the Board appointed Mr. Quan Anh Vu as Chief Operating Officer/Chief
Business Officer (“COO/CBO”) of the Company and he served in that role until his resignation on January 18, 2023.
A
description of the employment or services agreements with each of the foregoing persons is set forth below.
Description
of Employment Agreements
Each
of the salaries of the executives described below and certain of the compensation payable to the consultants described below, are subject
to the increases in salary and the temporary salary accruals discussed below under “Salary Increases and Temporary Salary and Compensation
Accruals”.
James
N. Woody 180 Employment Agreement
James
N. Woody, M.D., Ph.D. and 180 entered into an employment agreement on July 1, 2020 (which agreement was amended on September 18,
2020), effective as of July 1, 2020, whereby Dr. Woody served as the Chief Executive Officer of 180 and began serving as our
Chief Executive Officer following the Closing of the Business Combination. The initial term of the employment agreement started on July 1,
2020, was for a period of one (1) year, and was subject to automatic renewal for consecutive one (1) year terms unless either
party provided 60 days’ notice. Dr. Woody’s annual base salary was initially $250,000 per year from July 1,
2020 to September 1, 2020, and increased to $360,000 per year on September 1, 2020. The agreement provided that Dr. Woody’s
salary was to be renegotiated with the completion of the next qualified financing of over $20 million. Dr. Woody is eligible
to participate in any stock option plans and receive other equity awards, as determined from time to time.
James
N. Woody Amended and Restated Employment Agreement
On
February 25, 2021, the Company entered into an Amended and Restated Employment Agreement with James N. Woody (the “A&R
Agreement”), dated February 24, 2021, and effective November 6, 2020, which replaced and superseded the July 2020
agreement with 180 as discussed above. Pursuant to the A&R Agreement, Dr. Woody agreed to serve as the Chief Executive Officer
of the Company. The A&R Agreement has a term of three years from its effective date (through November 6, 2023) and is automatically
renewable thereafter for additional one-year periods, unless either party provides the other at least 90 days written notice
of their intent to not renew the agreement. Dr. Woody’s annual base salary under the agreement was initially increased to
$450,000 per year, subject to automatic 5% yearly increases. For the 2021 year, Dr. Woody’s salary was $450,000, for 2022,
and for 2023, Dr. Woody’s salary will be $490,000 (see also “Payment of Back Pay; 2021 Bonuses and Increases in Salaries”,
below). The Board of Directors, as recommended by the Compensation Committee, may increase Dr. Woody’s salary from time to time,
which increases do not require an amendment to his agreement.
Dr. Woody
is also eligible to receive an annual bonus, with a target bonus equal to 45% of his then-current base salary, based upon the
Company’s achievement of performance and management objectives as set and approved by the Board of Directors and/or Compensation
Committee in consultation with Dr. Woody. At Dr. Woody’s option, the annual bonus can be paid in cash or the equivalent
value of the Company’s common stock or a combination therefore. The Board of Directors, as recommended by the Compensation Committee
or separately, may also award Dr. Woody bonuses from time to time (in stock, options, cash, or other forms of consideration) in
its discretion.
Under
the employment agreement, Dr. Woody is eligible to participate in any stock option plans and receive other equity awards, as determined
by the Board of Directors from time to time.
The
agreement can be terminated any time by the Company for cause (subject to the cure provisions of the agreement), or without cause (with
60 days prior written notice to Dr. Woody), by Dr. Woody for good reason (as described in the agreement, and subject to
the cure provisions of the agreement), or by Dr. Woody without good reason. The agreement also expires automatically at the end
of the initial term or any renewal term if either party provides notice of non-renewal as discussed above.
In
the event the A&R Agreement is terminated without cause by the Company, or by Dr. Woody for good reason, the Company agreed
to pay him the lesser of 18 months of salary or the remaining term of the agreement, the payment of any accrued bonus from the prior
year, his pro rata portion of any current year’s bonus and health insurance premiums for the same period that he is to receive
severance payments (as discussed above).
The
A&R Agreement contains standard and customary invention assignment, indemnification, confidentiality and non-solicitation provisions,
which remain in effect for a period of 24 months following the termination of his agreement.
Dr. Rothbard’s
Employment Agreement
On
August 21, 2019, 180 entered into an Employment Agreement with Dr. Rothbard which replaced a prior agreement, which was not
effective until the Closing Date, but became effective on such date. The Employment Agreement has a term of three years from the
Closing Date (i.e., until November 6, 2023), automatically extending for additional one-year terms thereafter unless either
party terminates the agreement with at least 90 days prior written notice before the next renewal date.
The
Employment Agreement provides for Dr. Rothbard to be paid a salary of $375,000 per year, with automatic increases in salary, on
the first anniversary of the effective date, and each anniversary thereafter, of 10%. For the 2021 year, Dr. Rothbard’s salary
was $375,000, for the 2022 year, Dr. Rothbard’s salary was $268,906, and for 2023, Dr. Rothbard’s salary will be $200,000
(see also “Payment of Back Pay; 2021 Bonuses and Increases in Salaries”, below). The salary for the 2023 year represents
Dr. Rothbard’s commitment of 50% of his work-related time to the Company. The Board of Directors, as recommended by the Compensation
Committee, may increase Dr. Rothbard’s salary from time to time, which increases do not require an amendment to his agreement.
The
Employment Agreement provides for Dr. Rothbard to receive an annual bonus subject to meeting certain objectives set by the Board
of Directors, with a targeted bonus amount of 50% of his then salary, payable on or before February 15th of each
year.
The
Employment Agreement also provides for Dr. Rothbard to earn equity compensation in the discretion of the Board of Directors. Dr. Rothbard
may also be issued bonuses, from time to time, in the discretion of the Board of Directors, which may be payable in cash, stock or options.
In
the event Dr. Rothbard’s employment is terminated by the Company without cause, by Dr. Rothbard for good reason (as discussed
in the employment agreement), or the agreement is not renewed by the Company, he is required to be paid 36 months of severance pay
(if such termination occurs during the first year of the term); 24 months of severance pay (if such termination occurs during the
second year of the term); and 12 months of severance pay (if such termination occurs after the second year of the term), along with
any accrued bonus amount and a pro rata annual bonus based on the targeted bonus, as well as the payment of health insurance premiums
for the same period over which he is required to be paid severance pay.
The
Employment Agreement was amended effective January 1, 2022, to override the automatic annual salary increases of 10% per annum and instead
provide for future increases in the sole determination of the Board of Directors. The Employment Agreement was further amended effective
June 1, 2022, to adjust the base salary of Dr. Rothbard to $193,125, permanently, subject to further amendments approved by the Board
of Directors (see also “Payment of Back Pay; 2021 Bonuses and Increases in Salaries”, below). The Employment Agreement
was further amended effective June 1, 2022, to adjust the base salary of Dr. Rothbard to $193,125.
Ozan
Pamir Katexco Employment Agreement
Our
indirect wholly-owned subsidiary Katexco entered into an employment agreement with Mr. Pamir on October 22, 2018. The
agreement provides for an indefinite term that continues until termination. The initial annual base salary set forth in the agreement
was CAD $120,000, with annual increases as determined by the Board of Directors. The agreement also provided Mr. Pamir with a CAD
$20,000 signing bonus. Any bonuses, including stock options, are in the sole discretion of Katexco, depending on financial circumstances
and the performance of the services under the agreement. In 2019, the compensation was increased to $120,000 per annum in US dollars.
On
February 1, 2020, there was an amendment to Mr. Pamir’s consulting agreement with Katexco, whereby the contract was transferred
from Katexco to Katexco Pharmaceuticals Corp. — US.
Ozan
Pamir Company Employment Agreement
On
February 25, 2021, the Company entered into an Employment Agreement dated February 24, 2021, and effective November 6,
2020, which agreement was amended and corrected on March 1, 2021, to be effective as of the effective date of the original agreement
(which amendment and correction is retroactively updated in the discussion of the agreement), with Ozan Pamir, the Company’s then
Interim Chief Financial Officer, which replaced and superseded Mr. Pamir’s agreement with Katexco, as discussed above. Pursuant
to the agreement, Mr. Pamir agreed to serve as the Interim Chief Financial Officer of the Company; and the Company agreed to pay
Mr. Pamir $300,000 per year for 2021, which was increased to $309,000 for the 2022 year, and, based on his appointment as Chief
Financial Officer in April 2023, and $380,000 for the 2023 year (see also “Payment of Back Pay; 2021 Bonuses and Increases in
Salaries”, below)). Such salary is to be increased to a mutually determined amount upon the closing of a new financing, and
shall also be increased on a yearly basis. The Board of Directors, as recommended by the Compensation Committee, may increase Mr. Pamir’s
salary from time to time, which increases do not require an amendment to his agreement.
Under
the agreement, Mr. Pamir is eligible to receive an annual bonus, in a targeted amount of 30% of his then salary for the 2021 and
2022 years, and 40% for the 2023 year (see also “Payment of Back Pay; 2021 Bonuses and Increases in Salaries”, below)),
based upon the Company’s achievement of performance and management objectives as set and approved by the Chief Executive Officer,
in consultation with Mr. Pamir. The bonus amount is subject to adjustment. The Board of Directors, as recommended by the Compensation
Committee of the Company (and/or the Compensation Committee) or separately, may also award Mr. Pamir bonuses from time to time (in
stock, options, cash, or other forms of consideration) in its discretion.
Under
the employment agreement, Mr. Pamir is also eligible to participate in any stock option plans and receive other equity awards, as
determined by the Board of Directors from time to time.
The
agreement can be terminated at any time by the Company with or without cause with 60 days prior written notice and may be terminated
by Mr. Pamir at any time with 60 days prior written notice. The agreement may also be terminated by the Company with six days’
notice in the event the agreement is terminated for cause under certain circumstances. Upon the termination of Mr. Pamir’s
agreement by the Company without cause or by Mr. Pamir for good reason, the Company agreed to pay him three months of severance
pay.
The
agreement contains standard and customary invention assignment, indemnification, confidentiality and non-solicitation provisions,
which remain in effect for a period of 24 months following the termination of his agreement.
On
May 27, 2021, the Company entered into a Second Amendment to Employment Agreement with Ozan Pamir (the “Second Amendment”).
The Second Amendment amended the terms of Mr. Pamir’s employment solely to provide that all compensation payable to Mr. Pamir
under such agreement would be paid directly by the Company.
On
September 14, 2021, the Board authorized a discretionary bonus of $30,000 to Mr. Pamir in consideration for services rendered.
Quan
Anh Vu Executive Employment Agreement (terminated); and Separation Agreement
On
October 27, 2021, and effective on November 1, 2021, the Company entered into an Employment Agreement with Quan Anh Vu, its
then Chief Operating Officer/Chief Business Officer.
Pursuant
to the employment agreement, Mr. Vu agreed to serve as Chief Operating Officer/Chief Business Officer for the Company. In consideration
therefore, the Company agreed to pay Mr. Vu a starting salary of $390,000 per year, subject to annual increases of up to 5% (on
each November 1st, but effective as of the following January 1st, including a 3% increase to $401,700
for 2022, as discussed below under “Salary Increases and Temporary Salary and Compensation Accruals”). In addition to the
base salary, Mr. Vu was eligible to receive an annual bonus, with a target bonus opportunity of 50% of the then-current base
salary, based on achievement of performance and management objectives established by the CEO and the Compensation Committee, in consultation
with Mr. Vu, payable on or before March 31st of the year following the year in which the bonus is earned. Mr. Vu
could elect the Annual Bonus to be paid in cash or the equivalent value in the Company’s common stock, or a combination of the
two.
The
Employment Agreement contains standard and customary invention assignment, indemnification, confidentiality and non-solicitation provisions,
which remain in effect for a period of 24 months following the termination of the agreement.
On
January 18, 2023, Mr. Vu resigned as Chief Operating/Chief Business Officer of the Company effective the same date, and entered into
a Separation and Release Agreement with the Company (as amended, the “Separation Agreement”).
Under
the Separation Agreement, the Company agreed to pay Mr. Vu (a) $297,440, less all applicable withholdings and required deductions; and
(b) reimburse up to $1,100 a month for eight months for Mr. Vu’s health insurance expenses, whether under COBRA or otherwise (collectively,
(a) and (b), the “Severance Payment”). The Severance Payment (except for the amounts payable pursuant to (b) which
shall be paid by the 15th day of each calendar month during the applicable eight-month period) is required to be paid within 30 days
of the Separation Date (the “Payment Date”). In addition to the Severance Payment, by the Payment Date, the Company
agreed to pay Mr. Vu $73,645 for accrued backpay and $36,050 for accrued paid time off. Under the Separation Agreement, Mr. Vu agreed
that his resignation was voluntary, provided a customary general release to the Company and also agreed to certain confidentiality, non-disclosure,
non-solicitation, non-disparagement, and cooperation covenants in favor of the Company.
On
March 29, 2023, an error in the Separation Agreement was corrected by the parties’ entry into a First Amendment to Separation Agreement
(the “First Amendment”), effective as of the date of the original agreement, which clarified that none of the amount
received by Mr. Vu pursuant to the Separation Agreement related to a bonus for 2021.
Description
of Material Consulting Agreements
Inflammation
consultancy Agreements with each of Prof. Sir Marc Feldmann and Prof. Jagdeep Nanchahal
On
November 1, 2013, our wholly-owned subsidiary 180 LP entered into letter agreements regarding inflammation consultancy services
(each, an “Inflammation Consultancy Agreement”, and, collectively, the “Inflammation Consultancy Agreements”)
with Isis Innovation Limited for the services of each of Prof. Sir Marc Feldmann and Prof. Jagdeep Nanchahal (each, an “Inflammation
Consultant”). Pursuant to the Inflammation Consultancy Agreements, each Inflammation Consultant agreed to provide advice and
expertise on inflammatory and degenerative diseases including fibrosis as exemplified by Dupuytren’s Disease and osteoinduction
(bone formation), in relation to the technology, programs and products of 180 LP, and, specifically, to provide general and specific
advice and guidance on how 180 LP might further develop its different programs that are ongoing, contemplated, or conceived at or by
180 LP (the “Inflammation Consulting Services”).
In
consideration of the Inflammation Consulting Services, Prof. Sir Marc Feldmann and Prof. Jagdeep Nanchahal were paid a fixed fee
of $500 and $10,000 per annum, respectively.
The
initial term of each Advisory Services Agreement was until November 1, 2015. On November 8, 2015, each of the Advisory Services
Agreement was extended until November 1, 2020. A new contract with Prof. Jagdeep Nanchahal is described below which replaced the
prior Advisory Services Agreement with Prof. Nanchahal. Prof. Sir Marc Feldmann’s agreement was terminated on November 1,
2020.
Service
Agreement with Prof. Sir Marc Feldmann
On
June 1, 2018, CannBioRex Pharma Limited (“CannBioRex”) and Prof. Sir Marc Feldmann Ph.D., our Executive Co-Chairman,
entered into a Service Agreement (the “Feldmann Employment Agreement”). Pursuant to the Feldmann Employment Agreement,
Prof. Sir Feldmann serves as the Chairman, CEO and Executive Director of CannBioRex or in such other capacity consistent with his status.
Prof. Sir Feldmann’s responsibilities include those customary for the roles in which he serves. Prof. Sir Feldmann originally received
compensation of £115,000 per year, with annual compensation reviewed by the Board and eligibility for discretionary bonuses, as
determined by the Board. CannBioRex also reimburses Prof. Sir Feldmann’s travelling and other business expenses.
Pursuant
to the Feldmann Employment Agreement, all intellectual property rights created by Prof. Sir Feldmann or related to his employment belong
to and vest in CannBioRex.
The
Feldmann Employment Agreement contains a customary non-compete clause prohibiting Prof. Sir Feldmann from working for any competing
businesses during the term of his employment, or holding equity in other businesses, except he may hold or beneficially own securities
of publicly-traded companies if the aggregate beneficial interests of him and his family does not exceed 5% of that class of securities.
Prof.
Sir Feldmann is also prohibited for 12 months following termination (the “Post-Termination Period”) to be
involved in any capacity with a competing business or potential joint venturer in the United Kingdom or in any other country. During
the Post-Termination Period, he may not solicit business from CannBioRex and its affiliates’ customers; or any company with
whom he was actively involved in the course of his employment; or about which he holds confidential information. Prof. Sir Feldmann further
covenants to not interfere with CannBioRex’s business relationships by inducing or attempting to induce suppliers to take adverse
actions during the Post-Termination Period. He also agreed not to induce or attempt to induce any CannBioRex employee to leave the
company during the Post-Termination Period.
The
Feldmann Employment Agreement contains customary non-disclosure and confidentiality obligations, sick leave and vacation time.
The
Feldmann Employment Agreement does not have a fixed term. Either party may terminate the agreement by delivering written notice 9 months
in advance. CannBioRex may also terminate the Feldmann Employment Agreement at any time with immediate effect by giving written notice.
If CannBioRex terminates Prof. Sir Feldmann’s employment without providing 9 months written notice, he will become entitled
to a payment equal to his basic salary he would have been entitled to receive if 9 months’ notice were given. The governing
law for the Feldmann Employment Agreement is the law of England.
The
Board of Directors, as recommended by the Compensation Committee of the Company (and/or the Compensation Committee) or separately, may
also award Prof. Sir Feldmann bonuses from time to time (in stock, options, cash, or other forms of consideration) in its discretion.
On
November 17, 2021, the Board of Directors, as recommended by the Compensation Committee of the Company, increased the annual compensation
of Prof. Sir Feldmann to $225,000 per year.
Consultancy
Agreement with Prof. Lawrence Steinman
On
May 31, 2018, CannBioRex Pharma Limited (“CannBioRex”) and Prof. Lawrence Steinman, our Executive Co-Chairman,
entered into a Consultancy Agreement (the “Steinman Agreement”). Prof. Steinman committed to making himself available
to provide services to CannBioRex that may require Prof. Steinman’s expertise. In consideration for the services provided, CannBioRex
will pay Prof. Steinman approximately $50,000 per year, in monthly installments. Prof. Steinman is also entitled to reimbursement of
all business expenses, including travel.
Although
Prof. Steinman is not prohibited from engaging in other business activities during the term of the agreement, he must remain compliant
with the terms of the agreement and seek prior written consent before conducting business with a business similar to, or competitive
with, CannBioRex. The Steinman Agreement contains customary confidentiality and assignment of intellectual property provisions.
The
Steinman Agreement had a two-year term. The agreement may be terminated earlier by Prof. Steinman or CannBioRex with six months’
written notice. CannBioRex may terminate the agreement at any time with immediate effect if Prof. Steinman fails or neglects to efficiently
and diligently perform services pursuant to the agreement or breaches its terms; is guilty of fraud, dishonesty or acts in a manner which
the Company reasonably deems is likely to disparage himself or the Company; becomes unable to provide services for ten working days
in any month; or Prof. Steinman becomes bankrupt or arranges for compromises with his creditors. Upon termination of the Steinman Agreement,
Prof. Steinman must return property related to the consultancy and delete his own electronic records. The parties have continued to operate
under the terms of the agreement even though the agreement expired.
In
addition, Prof. Steinman had a verbal agreement with Katexco Pharmaceuticals Corp., a wholly-owned subsidiary of the Company to
provide services for $100,000 per year, since Katexco’s incorporation in 2018. This agreement was replaced and superseded by the
consulting agreement discussed below.
Consulting
Agreement with Prof. Lawrence Steinman
On
November 17, 2021, and effective on November 1, 2021, the Company entered into a Consulting Agreement with Lawrence Steinman,
M.D., the Company’s Executive Co-Chairman (the “Consulting Agreement”). Pursuant to the Consulting Agreement,
Dr. Steinman agreed to provide certain consulting services to the Company, including, but not limited to, participating in defining
and setting strategic objectives of the Company; actively seeking out acquisition and merger candidates; and having primary scientific
responsibility for the Company’s α7nAChR platform (collectively, the “Services”). The term of the
agreement was for one year (the “Initial Term”); provided that the agreement automatically extends for additional
one year periods after the Initial Term (each an “Automatic Renewal Term” and the Initial Term together with all Automatic
Renewal Terms, if any, the “Term”), subject to the Renewal Requirements (described below), in the event that neither
party provided the other written notice of their intent not to automatically extend the term of the agreement at least 30 days prior
to the end of the Initial Term or any Automatic Renewal Term, and as such, since neither party has terminated the agreement, , the agreement
is currently in effect until November 1, 2023, subject to further Automatic Renewal Terms. The Term can only be extended for an Automatic
Renewal Term, provided that (i) Dr. Steinman is re-elected to the Board of Directors at the Annual Meeting of Stockholders
of the Company immediately preceding the date that such Automatic Renewal Term begins; (ii) the Board affirms his appointment as
Co-Chairman for the applicable Automatic Renewal Term (or fails to appoint someone else as Co-Chairman prior to such applicable
Automatic Renewal Term); and (iii) Dr. Steinman is continuing in his role of having the responsibility for the scientific development
for the Company’s α7nAChR platform (the “Renewal Requirements”). The Consulting Agreement also expires
immediately upon the earlier of: (i) the date upon which Dr. Steinman no longer serves as Co-Chairman and no longer has
primary scientific responsibility for our α7nAChR platform; and (ii) any earlier date requested by either (1) the
Company (as evidenced by a vote of a majority of the Board (excluding Dr. Steinman) at a meeting of the Board), or (2) Dr. Steinman
(as evidenced by written notice from Dr. Steinman to the Board). Additionally, the Company may terminate the Consulting Agreement
immediately and without prior notice if Dr. Steinman is unable or refuses to perform the Services, and either party may terminate
the Consulting Agreement immediately and without prior notice if the other party is in breach of any material provision of the Consulting
Agreement.
The
Company agreed to pay Dr. Steinman $225,000 per year during the term of the agreement, along with a one-time payment of $43,750,
representing the difference between his old compensation and new compensation, dating back to April 1, 2021. Pursuant to the Consulting
Agreement, Dr. Steinman agreed to not compete against the Company, unless approved in writing by the Board of Directors, during
the term of the agreement, and also agreed to certain customary confidentiality provisions and assignment of inventions requirements.
The Consulting Agreement also has a 12 month non-solicitation prohibition following its termination.
Beginning
in calendar year 2022, for each year during the Term of the Consulting Agreement, the Company will, subject to future approval by the
Board, grant Dr. Steinman $125,000 of value of equity compensation. Future equity grants will vest over a 48 month period and
be in accordance with the Plan. Timing of the future grants, nature of the equity grants (e.g., RSU, PSU, restricted stock, etc.) and
any changes in the value of future equity will be recommended by the Company’s Compensation Committee and/or Audit Committee and
approved by the Board.
The
Board of Directors, as recommended by the Compensation Committee of the Company (and/or the Compensation Committee) or separately, may
also award Dr. Steinman bonuses from time to time (in stock, options, cash, or other forms of consideration) in its discretion.
Prof.
Jagdeep Nanchahal Consulting Agreement
On
February 25, 2021, we (and CannBioRex Pharma Limited, which was added as a party to the agreement later), entered into a Consultancy
Agreement dated February 22, 2021, and effective December 1, 2020, with Prof. Jagdeep Nanchahal (as amended, the “Consulting
Agreement”). Prof. Nanchahal has been providing services to the Company and/or its subsidiaries since 2014, and is currently
a greater than 5% stockholder of the Company and the Chairman of our Clinical Advisory Board.
On
March 31, 2021, we entered into a First Amendment to Consultancy Agreement with Prof. Jagdeep Nanchahal, which amended the
Consultancy Agreement entered into with Prof. Nanchahal on February 25, 2021, to include CannBioRex Pharma Limited, a corporation
incorporated and registered in England and Wales (“CannBioRex”), and an indirect wholly-owned subsidiary of the
Company, as a party thereto, and to update the prior Consultancy Agreement to provide for cash payments due to Prof. Nanchahal to be
paid by CannBioRex, for tax purposes, provide for CannBioRex to be party to certain other provisions of the agreement and to provide
for the timing of certain cash bonuses due under the terms of the agreement.
Prof.
Nanchahal is a surgeon scientist focusing on defining the molecular mechanisms of common diseases and translating his findings through
to early phase clinical trials. He undertook his Ph.D., funded by the U.K. Medical Research Council, whilst a medical student in
London and led a lab group funded by external grants throughout his surgical training. After completing fellowships in microsurgery and
hand surgery in the USA and Australia, he was appointed as a senior lecturer at Imperial College. His research is focused on promoting
tissue regeneration by targeting endogenous stem cells and reducing fibrosis. In 2013, his group identified anti-tumor necrosis
factor (TNF) as a therapeutic target for Dupuytren’s disease, a common fibrotic condition of the hand. He is currently leading
a phase 2b clinical trial funded by the Wellcome Trust and Department of Health to assess the efficacy of local administration of anti-TNF in
patients with early-stage Dupuytren’s disease. He is a proponent of evidence-based medicine and was the only plastic
surgery member of the NICE Guidance Development Groups on complex and non-complex fractures. He was a member of the group that wrote
the Standards for the Management of Open Fractures published in 2020. This is an open-source publication to facilitate the care
of patients with these severe injuries.
Pursuant
to the Consulting Agreement, Prof. Nanchahal agreed, during the term of the agreement, to serve as a consultant to the Company and provide
such services as the Chief Executive Officer and/or the Board of Directors of the Company shall request from time to time, including
but not be limited to: (1) conducting clinical trials in the fields of Dupuytren’s disease, frozen shoulder and post-operative delirium/cognitive
decline; and (2) conducting laboratory research in other fibrotic disorders, including fibrosis of the liver and lung (collectively,
the “Services”).
In
consideration for providing the Services, the Company (through CannBioRex Pharma Limited) agreed to pay Prof. Nanchahal 15,000 British
Pounds (GBP) per month (approximately $20,800) during the term of the agreement, increasing to GBP 23,000 (approximately $32,000) on
the date (a) of publication of the data from the phase 2b clinical trial for Dupuytren’s disease (RIDD) and (b) the
date that the Company has successfully raised over $15 million in capital. The fee will increase annually thereafter to reflect
progression in other clinical trials and laboratory research as approved by the Board of Directors. The Company also agreed to pay Prof.
Nanchahal a bonus (“Bonus 1”) in the sum of GBP 100,000 upon submission of the Dupuytren’s disease clinical
trial data for publication in a peer-reviewed journal. In addition, for prior work performed, including completion of the recruitment
to the RIDD (Dupuytren’s) trial, the Company agreed to pay Prof. Nanchahal GBP 434,673 (approximately $596,545)(“Bonus
2”). At the election of Prof. Nanchahal, Bonus 2 could be paid at least 50% (fifty percent) or more, as Prof. Nanchahal elected,
in shares of the Company’s common stock, at a share price of $60.00 per share, or the share price on the date of the grant, whichever
is lower, with the remainder paid in GBP. Bonus 2 was deemed earned and payable upon the Company raising a minimum of $15 million
in additional funding, through the sale of debt or equity, after December 1, 2020 (the “Vesting Date”) and
was not to be accrued, due or payable prior to such Vesting Date (which funding was raised on August 23, 2021). Finally, Prof. Nanchahal
shall receive another one-time bonus (“Bonus 3”) of GBP 5,000 (approximately $7,000) on enrollment
of the first patient to the phase 2 frozen shoulder trial, and another one-time bonus (“Bonus 4”) of GBP
5,000 (approximately $7,000) for enrollment of the first patient to the phase 2 delirium/POCD trial.
Effective
March 30, 2021, in satisfaction of amounts owed to Prof. Nanchahal for 50% of Bonus 2, the Company issued 5,035 shares
of the Company’s common stock to Prof. Nanchahal. Additionally, on April 15, 2021, in satisfaction of amounts owed to Prof.
Nanchahal for an additional 19% of Bonus 2, the Company issued 1,886 of the Company’s common stock to Prof. Nanchahal. Both
issuances were made under the Company’s 2020 Omnibus Incentive Plan.
On
August 23, 2021, at the request of Prof. Nanchahal, the Company agreed to issue Prof. Nanchahal 3,077 shares of common stock
in consideration for the remaining 31% (or 134,748.63 GBP, or $184,605.62) of Bonus 2 (the “Nanchahal Shares”),
based on a $60.00 per share price, which shares were issued on August 23, 2021. The shares will be issued under the Company’s
2020 Omnibus Incentive Plan.
On
December 28, 2022, the Company and CannBioRex Pharma Limited, a corporation incorporated and registered in England and Wales (“CannBioRex”),
and an indirect wholly-owned subsidiary of the Company, entered into a Third Amendment to Consultancy Agreement (the “Third
Amendment”) with Prof. Jagdeep Nanchahal, which amended the Consultancy Agreement with Prof. Nanchahal.
The
Third Amendment amended the Consultancy Agreement to provide that the monthly cash fee payable to Prof. Nanchahal pursuant to such agreement
would remain at its current rate, £23,000 per month, through December 31, 2022, and then increase to £35,000 per month during
the term of the Consultancy Agreement from January 1, 2023, until the end of the term of the Consultancy Agreement (collectively, the
“Fee”). The Third Amendment also provided that the Fee will be adjusted yearly with the recommendation of the Board
of Directors or the Compensation Committee of the Company, which will consider in its determination of the amount of such increase, the
UK consumer price index and Prof. Nanchahal’s contributions to advancing the Company’s mission, among other things. The Third
Amendment also provided that in the event the Consultancy Agreement is terminated by the Company for any reason other than cause, Prof.
Nanchahal is entitled to a lump sum payment of 12 months of his monthly fee as at the date of termination.
Notwithstanding
the above, the Board of Directors or Compensation Committee of the Company may grant Prof. Nanchahal additional bonuses from time to
time in their discretion, in cash, stock or options.
The
Consulting Agreement has an initial term of three years, and renews thereafter for additional three-year terms, until terminated
as provided in the agreement. The Consulting Agreement can be terminated by either party with 12 months prior written notice (provided
the Company’s right to terminate the agreement may only be exercised if Prof. Nanchahal fails to perform his required duties under
the Consulting Agreement), or by the Company immediately if (a) Prof. Nanchahal fails or neglects efficiently and diligently to
perform the Services or is guilty of any breach of its or his obligations under the agreement (including any consent granted under it);
(b) Prof. Nanchahal is guilty of any fraud or dishonesty or acts in a manner (whether in the performance of the Services or otherwise) which,
in the reasonable opinion of the Company, has brought or is likely to bring Prof. Nanchahal, the Company or any of its affiliates into
disrepute or is convicted of an arrestable offence (other than a road traffic offence for which a non-custodial penalty is imposed);
or (c) Prof. Nanchahal becomes bankrupt or makes any arrangement or composition with his creditors. If the Consulting Agreement
is terminated by the Company for any reason other than cause, Prof. Nanchahal is entitled to a lump sum payment of 12 months of
his fee as at the date of termination.
The
Consulting Agreement includes a 12 month non-compete and non-solicitation obligation of Prof. Nanchahal, preventing him
from competing against the Company in any part of any country in which he was actively engaged in the Company’s business, subject
to certain exceptions, including research conducted at the University of Oxford. The Consulting Agreement also includes customary confidentiality
and assignment of inventions provisions, in each case subject to the Company’s previously existing agreements with various universities,
including the University of Oxford, where Prof. Nanchahal serves as a Professor of Hand, Plastic and Reconstructive Surgery.
Salary
Increases and Temporary Salary and Compensation Accruals
Effective
on April 27, 2022, the Company (directly or through an indirectly wholly-owned subsidiary of the Company) entered into (a) a
First Amendment to Amended and Restated Employment Agreement with Dr. Woody (the “First Woody Amendment”); (b) a
First Amendment to Employment Agreement with Mr. Vu (the “First Vu Amendment”); (c) a First Amendment to
Employment Agreement with Dr. Rothbard (“First Rothbard Amendment”); (d) a First Amendment to Employment
Agreement with Prof. Sir Feldmann (the “First Feldmann Amendment”); (e) a First Amendment to Consulting Agreement
with Prof. Steinman (the “First Steinman Amendment”); and (f) a Second Amendment to Consulting Agreement with
Prof. Nanchahal (the “Second Nanchahal Amendment”), which each amended the agreements currently in place with such
individuals as discussed above.
Pursuant
to the First Woody Amendment, First Vu Amendment and First Rothbard Amendment, each of Dr. Woody, Mr. Vu and Dr. Rothbard,
agreed that effective January 1, 2022, their base salaries of $450,000, $390,000 and $375,000, respectively (their “Base
Salaries”) (as provided for in their employment agreements) were amended to increase such amounts by 3% (the “Increase
in Salary”) and effective March 1, 2022, their base salaries were reduced by 20% each ($92,700, $80,340 and $96,563, respectively)
and that such reduced amounts (the “Accrued Amounts”) shall be accrued until such time as the Board of Directors determines
that the Company has sufficient cash on hand to pay such Accrued Amounts, which the Company expects will not be until it has raised a
minimum of $15,000,000 (the “Funding Determination Date”); and that $370,800, $321,360, and $289,688 of such base
salaries, shall be payable per the payroll practices of the Company in cash by the Company to each of Dr. Woody, Mr. Vu and
Dr. Rothbard, respectively, starting effective March 1, 2022 until the Funding Determination Date, and that on the Funding
Determination Date, their salaries shall increase to the new base salary taking into account the Increase in Salary (with no accrual)
($463,500, $401,700 and $386,250, respectively) and the Accrued Amounts shall be paid by the Company, provided that in addition, at the
discretion of the Board of the Directors, the base salaries on the Funding Determination Date of each executive may be further increased
by 2%. Additionally, Mr. Rothbard agreed that any future increases to salary will be determined on an annual basis by the Company’s
Board of Directors at the recommendation of the Compensation Committee, and the annual 10% increases provided in his agreement shall
be overridden by such future determinations by the Board of Directors.
Pursuant
to the First Feldmann Amendment and First Steinman Amendment, Prof. Sir Feldmann and Prof. Steinman agreed effective March 1, 2022,
that their salary would be reduced by $225,000 (100%) and $56,250 (25%), respectively, and that such reduced amounts shall be accrued
and paid on the Final Determination Date.
Pursuant
to the Second Nanchahal Amendment, Prof. Nanchahal agreed that upon acceptance of the data for the phase 2b clinical trial for Dupuytren’s
disease for publication (which occurred March 1, 2022, subject to editing and final approvals), his monthly fee was increased to
£23,000, provided that £4,000 of such increase shall be accrued and £19,000 per month of such fees shall be payable
per the payroll practices of the Company in cash by the Company starting effective March 1, 2022, and until the earlier of (a) November 1,
2022 and (b) the Funding Determination Date, at which time all accrued amounts shall be due.
On
May 26, 2022, and effective on June 1, 2022, the Company entered into (a) a Second Amendment to Employment Agreement with James N. Woody,
M.D., Ph.D., the Chief Executive Officer and Director of the Company; (b) a Second Amendment to Employment Agreement with Quan Anh Vu,
the former Chief Operating Officer and Chief Business Officer of the Company; (c) a Second Amendment to Employment Agreement with
Jonathan Rothbard, Ph.D., Chief Scientific Officer of the Company; and (d) a Second Amendment to Consulting Agreement with Lawrence
Steinman, M.D., the Executive Co-Chairman of the Company (collectively, the “Second Amendments”).
Pursuant
to the Second Amendments, each of Dr. Woody, Mr. Vu, Dr. Steinman, and Dr. Rothbard, effective as of June 1, 2022, agreed to a further
reduction of the base salaries set forth in their respective amended employment and consulting agreements (the “Base Salaries”)
by an amount which, after taking into account the First Accrued Amounts, equals 50% of their respective Base Salaries ($231,750, $200,850,
$112,500, and $193,125, in total respectively). The reductions to the base salaries of Dr. Woody, Mr. Vu, and Dr. Steinman as affected
by the Second Amendments ($139,050, $120,510, $56,250, respectively) (the “Second Accrued Amounts”), are to accrue
until such time as the Company has raised a minimum of $1,000,000 (the “Second Accrued Amount Funding Determination Date”).
There will be no accrual of the $96,562.50 reduction to the base salary of Dr. Rothbard which was affected by his Second Amendment, provided
that Dr. Rothbard’s accrued salary through the effective date of his Second Amendment will continue to remain accrued and will
be paid on the Funding Determination Date.
Payment
of Back Pay; 2021 Bonuses and Increases in Salaries
On
April 27, 2023, and effective on January 1, 2023, the Company entered into (a) a Third Amendment to Employment Agreement with James N.
Woody, M.D., Ph.D., the Chief Executive Officer and Director of the Company; (b) a Third Amendment to Employment Agreement with Ozan
Pamir, the Chief Financial Officer of the Company (which was subsequently amended and corrected); and (c) a Third Amendment to Employment
Agreement with Jonathan Rothbard, Ph.D., Chief Scientific Officer of the Company (collectively, the “Third Amendments”),
which each amended the compensation agreements currently in place with such individuals.
The
Third Amendments reflected (a) an increase in the salary of each of Dr. Woody, Mr. Pamir and Dr. Rothbard of 3.5%, effective as of January
1, 2023; and (b) in the case of Mr. Pamir, a further increase in salary to $380,000 per annum and an increase in his target bonus to
40%, effective April 1, 2023, as well as a change in his title to Chief Financial Officer.
On
April 27, 2023, based on the recommendation of the Compensation Committee, the Board of Directors determined discretionary bonus compensation
for the year ended December 31, 2021 for Dr. Woody ($50,000); Mr. Pamir ($22,500, which is in addition to $30,000 previously paid during
2021); and Dr. Rothbard ($10,000). The Board of Directors also determined that no other bonuses would be paid to any executive officer
of the Company for fiscal 2021.
Effective
April 27, 2023, the Board of Directors, with the recommendation of the Compensation Committee of the Board of Directors, approved the
payment of $111,675 to Dr. Woody; $24,154 to Mr. Pamir; and $50,343 to Dr. Rothbard, in back pay owed to such officers. As a result,
no back pay is currently owed to Dr. Woody, Mr. Pamir or Dr. Rothbard.
Summary
Executive Compensation Table
The
following table sets forth certain information concerning compensation earned by or paid to certain persons who we refer to as our “Named
Executive Officers” for services provided for the fiscal years ended December 31, 2022 and 2021. Our Named Executive
Officers include persons who (i) served as our, or 180’s, principal executive officer or acted in a similar capacity during
the years ended December 31, 2022 and 2021, (ii) were serving at fiscal year-end as our two most highly compensated
executive officers, other than the principal executive officer, whose total compensation exceeded $100,000, and (iii) if applicable,
up to two additional individuals for whom disclosure would have been provided as a most highly compensated executive officer, but for
the fact that the individual was not serving as an executive officer at fiscal year-end.
As
noted above, none of the executive officers of KBL prior to the Closing of the Business Combination, including our former Chief Executive
Officer, received any cash compensation for their services.
Name and Principal Position | |
Year | |
Salary
($) | | |
Bonus
($) | | |
Stock
Awards
($) | | |
Option
Awards
($) | | |
Non-Equity
Incentive
Plan
Compensation | | |
All Other
Compensation
($) | | |
Total
($) | |
James N. Woody | |
2022 | |
$ | 463,500 | | |
$ | (* | ) | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 463,500 | |
CEO and Director | |
2021 | |
$ | 448,270 | | |
$ | 50,000 | | |
$ | — | | |
$ | 4,262,492 | (a) | |
$ | — | | |
$ | — | | |
$ | 4,760,762 | |
Ozan Pamir | |
2022 | |
$ | 309,000 | | |
$ | (* | ) | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 309,000 | |
CFO | |
2021 | |
$ | 304,355 | | |
$ | 52,500 | | |
$ | — | | |
$ | 548,035 | (b) | |
$ | — | | |
$ | — | | |
$ | 904,890 | |
Quan Anh Vu(1) | |
2022 | |
$ | 401,700 | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 333,490 | (2) | |
$ | 735,190 | |
Former COO and CBO | |
2021 | |
$ | 65,000 | | |
$ | — | | |
$ | — | | |
$ | 846,573 | (c) | |
$ | — | | |
$ | — | | |
$ | 911,573 | |
Jonathan Rothbard | |
2022 | |
$ | 268,906 | | |
$ | (* | ) | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 268,906 | |
Chief Scientific Officer | |
2021 | |
$ | 372,034 | | |
$ | 10,000 | | |
$ | 160,671 | (d) | |
$ | 923,534 | (e) | |
$ | — | | |
$ | — | | |
$ | 1,466,239 | |
Does
not include perquisites and other personal benefits or property, unless the aggregate amount of such compensation is more than $10,000.
No executive officer earned non-equity incentive plan compensation or nonqualified deferred compensation during the periods reported
above. Option Awards and Stock Awards represent the aggregate grant date fair value of awards computed in accordance with Financial Accounting
Standards Board Accounting Standard Codification Topic 718. For additional information on the valuation assumptions with respect
to the restricted stock grants, refer to “Note 12 — Stockholders’ Equity” to the audited financial statements
included herein. No executive officer serving as a director received any compensation for services on the Board of Directors separate
from the compensation paid as an executive for the periods above.
| * | The
amount of each executive’s 2022 bonuses have not yet been determined by the Compensation Committee and/or the Board of Directors
as of the date of this filing, and are therefore not included in the table above. The amount of each executive’s bonuses for fiscal
2022, if any, will be disclosed in a separate filing under Item 5.02(f) of Form 8-K within four days of the
date finalized by the Compensation Committee and/or the Board of Directors. Such bonuses may be in the form of cash or equity or a combination
of cash and equity. |
| (1) | On
October 29, 2021, the Board appointed Mr. Quan Anh Vu as Chief Operating Officer/Chief Business Officer (“COO/CBO”)
of the Company. On October 27, 2021, and effective on November 1, 2021, the Company entered into an Employment Agreement with
Quan Ahn Vu. In consideration for performing services under the agreement, the Company agreed to pay Mr. Vu a starting salary of
$390,000 per year. As of the date of this proxy statement, all of the amounts owed to Mr. Vu have been fully paid. Mr. Vu’s
employment agreement was terminated effective January 15, 2023. |
| (2) | Represents
amounts paid to Mr. Vu for the termination of his employment agreement. |
| (a) | Represents
the value of ten year options to purchase 70 ,000 shares of common stock with an exercise price of $88.60 per share which were
granted on February 26, 2021. |
| (b) | Represents
the value of ten year options to purchase 9,000 shares of common stock with an exercise price of $88.60 per share which were
granted on February 26, 2021. |
| (c) | Represents
the value of ten year options to purchase 13,750 shares of common stock with an exercise price of $79.00 per share which were
granted on December 8, 2021. |
| (d) | Represents
the value of 1,215 shares of common stock issued to Dr. Rothbard in consideration for services rendered to the Company as Chief
Scientific Officer on April 7, 2021. |
| (e) | Represents
the value of ten year options to purchase 15,000 shares of common stock with an exercise price of $79.00 per share which were
granted on December 8, 2021. |
Bonuses
No
bonuses were paid to the officers named in the table above during the fiscal years ended December 31, 2022 or 2021, except
as disclosed in the table above.
Pay
Versus Performance
Year | |
Summary
Compensation
Table Total
for Principal
Executive
Officer
(“PEO”)(1) | | |
Compensation
Actually Paid
to PEO(2) | | |
Average
Summary
Compensation
Table Total
for Non-PEO
Named
Executive
Officers
(“NEOs”)(3) | | |
Average
Compensation
Actually Paid
to Non-PEO
NEOs(4) | | |
Value
of
Initial Fixed
$100
Investment
Based on
Total
shareholder
Return
(“TSR”)(5) | | |
Net
Loss
(in thousands)(6) | |
(a) | |
(b) | | |
(c) | | |
(d) | | |
(e) | | |
(f) | | |
(g) | |
2022 | |
$ | 463,500 | | |
$ | (1,366,665 | ) | |
$ | 437,699 | | |
$ | 8,909 | | |
$ | 6.21 | | |
$ | (38,726 | ) |
2021 | |
$ | 4,760,762 | | |
$ | 6,109,641 | | |
$ | 1,094,234 | | |
$ | 1,130,359 | | |
$ | 142.86 | | |
$ | (20,325 | ) |
| (1) | The dollar amounts reported in column (b) are the amounts of
total compensation reported for James N. Woody (our Chief Executive Officer) for each corresponding year in the “Total” column
of the Summary Executive Compensation Table. Refer to “Executive and Director Compensation—Summary Executive Compensation
Table”. |
| (2) | The dollar amounts reported in column (c) represent the amount
of “compensation actually paid” to Dr. Woody, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts
do not reflect the actual amount of compensation earned by or paid to Dr. Woody during the applicable year. In accordance with the requirements
of Item 402(v) of Regulation S-K, the following adjustments were made to Dr. Woody’s total compensation for each year to determine
the compensation actually paid: |
Year | |
Reported
Summary
Compensation
Table Total
for PEO | | |
Reported
Value of
Equity
Awards (A) | | |
Equity
Award
Adjustments
(B) | | |
Compensation
Actually Paid
to PEO | |
2022 | |
$ | 463,500 | | |
$ | — | | |
$ | (1,830,165 | ) | |
$ | (1,366,665 | ) |
2021 | |
$ | 4,760,762 | | |
$ | (4,262,492 | ) | |
$ | 5,611,371 | | |
$ | 6,109,641 | |
| (A) | The grant date fair value of equity awards represents the sum
of the totals of the amounts reported in the “Stock Awards” and “Option Awards” columns in the Summary Executive
Compensation Table for the applicable year. |
| (B) | The equity award adjustments for each applicable year include
the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable
year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from
the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end
of the applicable year; (iii) for awards that are granted and vest in same applicable year, the fair value as of the vesting date; (iv)
for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end
of the prior fiscal year) in fair value; (v) for awards granted in prior years that are determined to fail to meet the applicable vesting
conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi)
the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that
are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable
year. The amounts deducted or added in calculating the equity award adjustments are as follows: |
Year | |
Year End
Fair Value
of
Outstanding
and
Unvested
Equity
Awards
Granted in
Year | | |
Year over
Year
Change in
Fair Value
of
Outstanding
and
Unvested
Equity
Awards
Granted in
Prior Years | | |
Fair Value
as of
Vesting
Date of
Equity
Awards
Granted
and
Vested in
the Year | | |
Year over
Year
Change
in Fair
Value of
Equity
Awards
Granted
in Prior
Years
that
Vested
in the
Year | | |
Fair Value
at the End
of the
Prior
Year of
Equity
Awards
that Failed
to Meet
Vesting
Conditions
in the
Year | | |
Value of
Dividends or
other
Earnings
Paid on Stock
or Option
Awards not
Otherwise
Reflected in
Fair Value or
Total
Compensation | | |
Total Equity
Award
Adjustments | |
2022 | |
$ | 40,138 | | |
$ | (1,426,068 | ) | |
$ | 406,256 | | |
$ | (850,492 | ) | |
$ | — | | |
$ | — | | |
$ | (1,830,165 | ) |
2021 | |
$ | 2,722,954 | | |
$ | — | | |
$ | 2,888,417 | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 5,611,371 | |
| (3) | The dollar amounts reported in column (d) represent the average
of the amounts reported for our company’s named executive officers as a group (excluding Dr. Woody) in the “Total”
column of the Summary Executive Compensation Table in each applicable year. During 2022 and 2021, our non-CEO Named Executive Officers
(NEOs) consisted of Ozan Pamir, then Interim Chief Financial Officer; Quan Anh Vu, Chief Operating Officer and Chief Business Officer;
and Jonathan Rothbard, Chief Scientific Officer. |
| (4) | The dollar amounts reported in column (e) represent the average
amount of “compensation actually paid” to the named executive officers as a group (excluding Dr. Woody), as computed in accordance
with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to
the named executive officers as a group (excluding Dr. Woody) during the applicable year. In accordance with the requirements of Item
402(v) of Regulation S-K, the following adjustments were made to average total compensation for the named executive officers as a group
(excluding Dr. Woody) for each year to determine the compensation actually paid, using the same methodology described above in Note (2): |
Year | |
Average
Reported
Summary
Compensation
Table Total
for Non-PEO
NEOs | | |
Average
Reported
Value of
Equity
Awards | | |
Average
Equity
Award
Adjustments (a) | | |
Average
Compensation
Actually Paid
to Non-PEO
NEOs | |
2022 | |
$ | 437,699 | | |
$ | — | | |
$ | (428,790 | ) | |
$ | 8,909 | |
2021 | |
$ | 1,094,234 | | |
$ | (826,271 | ) | |
$ | 862,396 | | |
$ | 1,130,359 | |
| (a) | The amounts deducted or added in calculating the total average
equity award adjustments are as follows: |
Year | |
Average
Year End
Fair Value
of
Outstanding
and
Unvested
Equity
Awards
Granted in
the Year | | |
Year over Year Average Change in Fair Value of
Outstanding
and
Unvested
Equity
Awards
Granted in
Prior Years | | |
Average
Fair
Value
as of
Vesting
Date of
Equity
Awards
Granted
and
Vested
in the
Year | | |
Year
over
Year
Average
Change
in Fair
Value of
Equity
Awards
Granted
in Prior
Years
that
Vested
in the
Year | | |
Average
Fair Value
at the End
of the
Prior
Year of
Equity
Awards
that Failed
to Meet
Vesting
Conditions
in the
Year | | |
Average
Value of
Dividends or
other
Earnings
Paid on Stock
or Option
Awards not
Otherwise
Reflected in
Fair Value or
Total Compensation | | |
Total
Average
Equity
Award
Adjustments | |
2022 | |
$ | 11,774 | | |
$ | (367,087 | ) | |
$ | 81,450 | | |
$ | (154,927 | ) | |
$ | — | | |
$ | — | | |
$ | (428,790 | ) |
2021 | |
$ | 615,239 | | |
$ | — | | |
$ | 247,157 | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 862,396 | |
| (5) | Assumes $100 invested in our common shares on December 31, 2020,
and calculated based on the difference between the share price of our common stock at the end and the beginning of the measurement period,
and reinvestment of all dividends. No cash dividends were paid in 2021 or 2022. |
| (6) | The dollar amounts reported represent the amount of net loss
reflected in our consolidated audited financial statements for the applicable year. |
Relationship Between “Compensation
Actually Paid” and Performance
We generally seek to incentivize
long-term performance, and therefore do not specifically align our performance measures with “compensation actually paid”
(as computed in accordance with Item 402(v) of Regulation S-K) for a particular year. In accordance with Item 402(v) of Regulation S-K,
we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table.
Compensation
Actually Paid and Net Loss
Our
company has not historically looked to net loss as a performance measure for our executive compensation program. Our net loss was $20.3
million in 2021 and $38.7 million in 2022.
Compensation
Actually Paid and Cumulative TSR
As
shown in the following graph, the compensation actually paid to Dr. Woody and the average amount of compensation actually paid to our
non-PEO NEOs as a group (excluding Dr. Woody) during the periods presented do have some correlation because a significant portion of
their compensation is in the form of long-term equity awards. The equity awards values are significantly impacted by changes in our stock
price each period. These equity awards strongly align our executive officers’ interests with those of our stockholders by providing
a continuing financial incentive to maximize long-term value for our stockholders and by encouraging our executive officers to continue
in our employment for the long-term.
All
information provided above under the “Pay Versus Performance” and “Relationship Between “Compensation Actually
Paid” and Performance”, headings will not be deemed to be incorporated by reference in any filing of our company under the
Securities Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
Outstanding
Equity Awards at Fiscal Year End
| |
Option
Awards
|
Name | |
Number of
securities
underlying
unexercised
options (#)
exercisable | | |
Number of
securities
underlying
unexercised
options (#)
unexercisable | | |
Option
exercise
price ($) | | |
Option
expiration
date |
James N. Woody | |
| 48,222 | | |
| 21,778 | (1) | |
$ | 88.60 | | |
2/26/2031 |
Ozan Pamir | |
| 6,200 | | |
| 2,800 | (1) | |
$ | 88.60 | | |
2/26/2031 |
Quan Anh Vu* | |
| 3,724 | | |
| 10,026 | (2) | |
$ | 79.00 | | |
12/8/2031 |
Jonathan Rothbard | |
| 10,417 | | |
| 4,583 | (3) | |
$ | 79.00 | | |
12/8/2031 |
* | Employment
terminated effective January 15, 2023 and options expired unexercised 90 days thereafter. |
(1) | (a) 1/5th of
such options vesting on the grant date (February 26, 2021); and (b) 4/5ths of such options vesting ratably on a monthly basis
over the following 36 months on the last day of each calendar month. |
(2) | The
options vest in 48 equal monthly installments, beginning on the last day of November 2021, and continuing on the last day
of each calendar month thereafter, subject to the holder’s continued service to the Company on such vesting dates. |
(3) | The
options vest at the rate of 1/3rd of such options at the date of grant (December 8, 2021) with the remaining options
vesting at the rate of 24 equal monthly installments, beginning on the last day of December 31, 2021, and continuing on the
last day of each calendar month thereafter, subject to the Reporting Person’s continued service to the Company on such vesting
dates. |
There
were no outstanding unvested stock awards as of December 31, 2022.
Potential
Payments Upon Termination
Pursuant
to the employment agreements for Dr. Woody, Dr. Rothbard, and Mr. Pamir, severance benefits will be paid in the event
of a termination without “just cause” (as defined in such agreements). Dr. Woody, in the event of such termination,
is entitled to severance payments in the form of continued base salary, for the lesser of eighteen (18) months or the then remaining
term of the agreement, (ii) payment of any accrued and unpaid annual bonus for any year preceding the year in which the employment
terminates; (iii) payment of a pro rata annual bonus for the year in which the employment terminates calculated by multiplying the
target bonus amount by a fraction, the numerator of which is the number of calendar days elapsed in the year as of the effective
date of termination of employment and the denominator of which is 365; and (iv) payment by the Company of Dr. Woody’s
monthly health insurance premiums. For Dr. Rothbard, in the event of such termination during his first year, Dr. Rothbard would
be entitled to his then base salary for a period of 36 months, during his second year, Dr Rothbard would be entitled to his then
base salary for a period of 24 months, and 12 months if the termination happens in the third year of Dr. Rothbard’s
employment or thereafter; (ii) payment of any accrued and unpaid annual bonus for any year preceding the year in which the employment
terminates; (iii) payment of a pro rata annual bonus for the year in which the employment terminates calculated by multiplying the
target bonus amount by a fraction, the numerator of which is the number of calendar days elapsed in the year as of the effective
date of termination of employment and the denominator of which is 365; and (iv) payment by the Company of monthly health insurance
premiums. For Mr. Pamir, in the event of such termination, he would be entitled to an amount equal to his then current base salary
for a period of (3) months.
Director
Compensation
The
following table sets forth compensation information with respect to our non-employee directors during our fiscal year ended December 31,
2022:
Name | |
Fees earned or paid in cash ($) | | |
Stock awards ($)(4) | | |
Option Awards ($)(4) | | |
All other compensation ($) | | |
Total ($) | |
Lawrence Steinman | |
$ | 225,000 | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 225,000 | |
Sir Marc Feldmann, Ph.D., M.D. | |
$ | 225,000 | (5) | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 225,000 | |
Larry Gold, Ph.D. | |
$ | 14,375 | | |
$ | 43,125 | (6) | |
$ | 15,255 | (1) | |
$ | — | | |
$ | 72,755 | |
Donald A. McGovern, Jr. | |
$ | 16,875 | | |
$ | 50,625 | (6) | |
$ | 145,254 | (1)(3) | |
$ | — | | |
$ | 212,754 | |
Russell T. Ray, MBA | |
$ | 14,375 | | |
$ | 43,125 | (6) | |
$ | 21,357 | (2) | |
$ | — | | |
$ | 78,857 | |
Teresa DeLuca, M.D., MBA | |
$ | 55,000 | | |
$ | — | | |
$ | 21,357 | (2) | |
$ | — | | |
$ | 76,357 | |
Francis Knuettel II, MBA | |
$ | 55,000 | | |
$ | — | | |
$ | 21,357 | (2) | |
$ | — | | |
$ | 76,357 | |
Pamela G. Marrone, Ph.D. | |
$ | 15,000 | | |
$ | 45,000 | (6) | |
$ | 21,357 | (2) | |
$ | — | | |
$ | 81,357 | |
* |
The
table above does not include the amount of any expense reimbursements paid to the above directors. No directors received any Non-Equity Incentive
Plan Compensation or Nonqualified Deferred Compensation. Does not include perquisites and other personal benefits, or property, unless
the aggregate amount of such compensation is more than $10,000. |
(1) |
On
May 19, 2022, we granted to each of Dr. Gold and Mr. McGovern, options to purchase up to 750 shares of our common stock
at an exercise price of $20.34 per share. The options vest in equal monthly instalments over the 39 months beginning on May
31, 2022, subject to such director’s continued service to our company on such vesting dates. |
(2) |
On
May 19, 2022, we granted to each of Mr. Ray, Dr. DeLuca, Mr. Knuettel, and Dr. Marrone, options to purchase up to 1,050 shares of
our common stock at an exercise price of $20.34 per share. The options vest in equal monthly instalments over the 39 months beginning
on May 31, 2022, subject to such director’s continued service to our company on such vesting dates. |
(3) |
On
May 19, 2022, we granted to Mr. McGovern options to purchase up to 6,706 shares of our common stock at an exercise price of $27.20
per share. The options vested immediately upon grant. |
(4) |
Represents
the aggregate grant date fair value of the award computed in accordance with the provisions of Financial Accounting Standards Board
(FASB) Accounting Standards Codification (ASC) Topic 718. The assumptions used in calculating the aggregate grant date
fair value of the awards reported in this column are set forth in our consolidated financial statements included in this prospectus.
The values provided for these awards are based on applicable accounting standards and do not necessarily reflect the actual amounts
realized or realizable. As of December 31, 2022, the aggregate number of option awards outstanding held by each non-employee director
(including vested and unvested awards) serving on that date was as follows: Lawrence Steinman — 1,250; Prof. Sir
Marc Feldmann — 1,250; Larry Gold — 5,000; Donald A. McGovern, Jr. — 11,706; Russell
T. Ray — 5,000; Teresa DeLuca — 5,000; Francis Knuettel II — 5,000; and
Pamela G. Marrone — 5,000. None of the non-executive directors held any unvested stock awards as of December 31,
2021. |
(5) |
Amounts
paid were for services rendered as the Chairman, CEO and Executive Director of CannBioRex, pursuant to the June 2018 Service
Agreement (as amended), discussed in greater detail above under “Executive and Director Compensation — Executive
Compensation — Compensation of Officers by 180 Life Sciences Corp. following the Closing of the Business Combination — General — Employment
Agreements — Service Agreement with Prof. Sir Marc Feldmann”. |
(6) |
On
May 19, 2022, the Company issued 529 shares of common stock to Dr. Gold, 621 shares of common stock to Mr. McGovern, 529 shares of
common stock to Mr. Ray, and 552 shares of common stock to Dr. Marrone, in lieu of quarterly cash fees earned by each director for
the quarter ended March 31, 2022. On July 27, 2022, the Company issued 654 shares of common stock to Dr. Gold, 767 shares of common
stock to Mr. McGovern, 654 shares of common stock to Mr. Ray, and 682 shares of common stock to Dr. Marrone, in lieu of quarterly
cash fees earned by each director for the quarter ended June 30, 2022. On October 31, 2022, the Company issued 1,536 shares of common
stock to Dr. Gold, 1,803 shares of common stock to Mr. McGovern, 1,536 shares of common stock to Mr. Ray, and 1,602 shares of common
stock to Dr. Marrone, in lieu of quarterly cash fees earned by each director for the quarter ended September 30, 2022. |
In
connection with each of Mr. Ray’s, Dr. DeLuca’s, Mr. Knuettel’s and Dr. Marrone’s appointment
to the Board, such persons entered into offer letters with the Company, dated on or around May 21, 2021 (collectively, the “Offer
Letters”). The Offer Letters set forth the compensation that Mr. Ray, Dr. DeLuca, Mr. Knuettel and Dr. Marrone
are entitled to receive, including a grant of options to purchase $425,000 of value of shares of the Company’s common stock (value
per share and number of shares determined by the Black-Scholes calculation on the date of grant)(i.e., options to purchase 3,950 shares
of common stock)(the “Initial Option Grant”), which have been granted to date, and which will vest as to 1/48 of the
balance of the option shares upon each month of service after the date of grant and have an exercise price per share equal to the closing
sales price of a share of common stock on the grant date.
Board
of Director Fees
The
current policy of the Board is to pay each independent Board Member, in addition to equity compensation as may be approved from time
to time by the Board and/or Compensation Committee, $40,000 per compensation year as an annual retainer fee payable to each member of
the Board, plus additional committee fees of $5,000 for each member of the Compensation Committee or Nomination and Corporate Governance
Committee, and $7,500 for each member of the Audit Committee or Risk Committee; $10,000 for the Chairperson of the Compensation Committee
and the Nomination and Corporate Governance Committee and $15,000 for the Chairperson of the Audit Committee and of the Risk Committee.
Additionally, the Lead Director (currently Mr. McGovern) is to receive an additional equity grant each year valued at $30,000. For
independent directors, cash fees are earned and paid one quarter in arrears. The Board also currently grants each new independent director
an option to purchase 5,000 shares of common stock, at the exercise price equal to the fair market value on the date of grant as
calculated pursuant to the Plan, and such options vesting in equal monthly installments over the 48 months after the grant date,
subject to the holder’s continued service to the Company on such vesting dates. Due to limitations on the amount of compensation
that can be paid to directors in a compensation year, as defined, new independent directors in 2021 were issued an option to purchase
3,950 shares of common stock in 2021 and were issued options to purchase an additional 1,050 shares of common stock in 2022 as part of
a new independent director grant. In addition, in 2022 Dr. Gold and Mr. McGovern were issued an option to purchase 750 shares
of common stock in 2022 representing the remaining balance of their initial new independent director grant.
The
Board has not yet initiated a recurring yearly equity compensation grant for independent directors.
Equity
Compensation Plan Information
The
following table sets forth information, as of December 31, 2022, with respect to our compensation plans under which common stock
is authorized for issuance.
Plan Category | |
Number of
securities to be
issued upon
exercise of
outstanding
options,
warrants and
rights (A) | | |
Weighted-
average exercise price of
outstanding
options,
warrants
and rights (B) | | |
Number of
securities
remaining
available for
future issuance
under equity
compensation
plans (excluding
securities
reflected in
Column A) (C) | |
Equity compensation plans approved by stockholders(1) | |
| 149,207 | | |
$ | 85.15 | | |
| 129,388 | |
Equity compensation plans not approved by stockholders(2) | |
| 3,183 | | |
$ | 105.60 | | |
| — | |
Total | |
| 179,703 | | |
| | | |
| 129,388 | |
(1) | Options
granted and awards available for future issuance under the 2020 OIP (defined below) and 2022 OIP (defined below), each discussed below. |
(2) | This
relates to five-year warrants granted on March 12, 2021, for the purchase of 3,183 shares of the Company’s common stock
at an exercise price of $105.60 held by Alliance Global Partners (“AGP”). |
2020
Omnibus Incentive Plan
We
have reserved 185,907 shares of our common stock for grant under our 2020 Omnibus Incentive Plan (“2020 OIP”),
of which 16,747 shares are available for future awards as of the date of this proxy statement.
The
purpose of the 2020 OIP is to promote the interests of the Company and its subsidiaries and its stockholders by (i) attracting and
retaining directors, executive officers, employees and consultants of outstanding ability; (ii) motivating such individuals by means
of performance-related incentives to achieve the longer-range performance goals of the Company and its subsidiaries; and (iii) enabling
such individuals to participate in the long-term growth and financial success of the Company.
Awards
under the 2020 OIP may be made in the form of performance awards, restricted stock, restricted stock units, stock options, which may
be either incentive stock options or non-qualified stock options, stock appreciation rights, other stock-based awards and dividend
equivalents. Awards are generally non-transferable.
2022
Omnibus Incentive Plan
We
have reserved 120,000 shares of our common stock for grant under our 2022 Omnibus Incentive Plan (“2022 OIP”),
of which 113,526 shares are available for future awards as of the date of this proxy statement.
The
purpose of the 2022 OIP is to promote the interests of the Company and its subsidiaries and its stockholders by (i) attracting and
retaining directors, executive officers, employees and consultants of outstanding ability; (ii) motivating such individuals by means
of performance-related incentives to achieve the longer-range performance goals of the Company and its subsidiaries; and (iii) enabling
such individuals to participate in the long-term growth and financial success of the Company.
Awards
under the 2022 OIP may be made in the form of performance awards, restricted stock, restricted stock units, stock options, which may
be either incentive stock options or non-qualified stock options, stock appreciation rights, other stock-based awards and dividend
equivalents. Awards are generally non-transferable.
CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Except
as discussed below or otherwise disclosed above under “Executive and Director Compensation”, beginning on page 32, there
have been no transactions over the last two fiscal years, and there is not currently any proposed transaction, in which the Company
was or is to be a participant, where the amount involved exceeds the lesser of (a) $120,000 or (b) one percent of the Company’s
total assets at year-end for the last two completed fiscal years, and in which any officer, director, or any stockholder owning
greater than five percent (5%) of our outstanding voting shares, nor any member of the above referenced individual’s immediate
family, had or will have a direct or indirect material interest.
360
Life Sciences Corp. Agreement — Related Party (Acquisition of ReFormation Pharmaceuticals Corp.)
On
July 1, 2020, the Company entered into an amended agreement with ReFormation Pharmaceuticals, Corp. (“ReFormation”)
and 360 Life Sciences Corp. (“360”), whereby 360 has entered into an agreement to acquire 100% ownership of ReFormation,
on or before July 31, 2020 (“Closing Date”). The Company used to share a director with each of ReFormation and
360. On March 25, 2022, our director resigned from serving on the Board of 360 and he had previously resigned from serving on the
Board of Reformation. Upon the Closing Date, 360 agreed to make tranche payments in tranches to 180 LP in the aggregate amount of $300,000.
The parties agreed that the obligations will be paid by 360 to 180 LP by payments of $100,000 for every $1,000,000 raised through the
financing activities of 360, up to a total of $300,000, however, not less than 10% of all net financing proceeds received by 360 shall
be put towards the obligation to the Company until paid in full. This transaction closed on July 31, 2020.
On
February 26, 2019, 180 LP entered into a one-year agreement (the “Pharmaceutical Agreement”) with ReFormation,
a related party that shares directors and officers of 180 LP, pursuant to which ReFormation agreed to pay 180 LP $1.2 million for
rights of first negotiation to provide for an acquisition of any arising intellectual property or an exclusive licensing, partnering,
or collaboration transaction to use any arising intellectual property with respect to a contemplated research agreement between the Company
and Oxford (see Oxford University Agreements, above), which was signed on March 22, 2019 and therefore is the start date of the
project. Of the $1.2 million receivable from Reformation pursuant to the Pharmaceutical Agreement, $0.9 million was received
by the Company on March 14, 2019 and the remaining $0.3 million was expected to be received over the one-year term of
the agreement.
180
LP is recognizing the income earned in connection with the Pharmaceutical Agreement on a straight-line basis over the term of the
agreement. During the years ended December 31, 2022 and 2021, 180 LP recognized no income related to the Pharmaceutical Agreement, which
is included in other income in the accompanying consolidated statement of operations and other comprehensive income loss. As of December
31, 2021, the Company charged the $300,000 receivable to bad debt expense.
On
November 17, 2021, the Company provided notice to 360, which initiated the right of first negotiation term, which expired unexercised
on February 1, 2022. As such, the Company is no longer under any obligation to negotiate with 360.
Notice
of Acceleration
On
December 29, 2020, we received notice from Marlene Krauss, M.D., the former Chief Executive Officer and director of KBL, alleging
the occurrence of an event of default of the terms of a certain promissory note in the amount of $371,178, dated March 15, 2019,
evidencing amounts owed by the Company to KBL IV Sponsor LLC (of which Dr. Krauss serves as sole managing member), for failure
to repay such note within five days of the release of funds from escrow in connection with the terms of a purchase agreement. Dr. Krauss
has declared the entire amount of the note to be immediately due and payable. The note, pursuant to its terms, accrues damages of $2,000
per day until paid in full (subject to a maximum amount of damages equal to the principal amount of the note upon the occurrence
of the event of default thereunder). There are continuing disputes regarding amounts that may be due to Dr. Krauss under the note.
Inflammation
consultancy Agreements with each of Prof. Sir Marc Feldmann and Prof. Jagdeep Nanchahal
See
“Inflammation consultancy Agreements with each of Prof. Sir Marc Feldmann and Prof. Jagdeep Nanchahal” under “Description
of Material Consulting Agreements”, under “Executive and Director Compensation”, above.
Service
Agreement with Prof. Sir Marc Feldmann
See
“Service Agreement with Prof. Sir Marc Feldmann” under “Description of Material Consulting Agreements”,
under “Executive and Director Compensation”, above.
Prof.
Jagdeep Nanchahal Consulting Agreement
See
“Prof. Jagdeep Nanchahal Consulting Agreement” under “Description of Material Consulting Agreements”,
under “Executive and Director Compensation”, above.
During
the year ended December 31, 2022, we incurred research and development expenses – related parties of $240,731 compared to $2,947,536
incurred for the year ended December 31, 2021, representing a decrease of $2,706,805 or 92%. The decrease includes a decrease in stock-based
compensation expense of $2,300,000; this decrease is comprised of approximately $800,000 paid to Jagdeep Nanchahal in the prior year
for his research in the Phase 2b clinical trial for Dupuytren’s Contracture (RIDD), as well as stock-based compensation expense
of approximately $1,400,000 paid to Mr. Nanchahal in the prior year as well. There was also a decrease in consulting expenses of $460,000.
Prof.
Lawrence Steinman Consultancy Agreement and Consulting Agreement
See
“Consultancy Agreement with Prof. Lawrence Steinman” and “Consulting Agreement with Prof. Lawrence Steinman under
“Description of Material Consulting Agreements”, under “Executive and Director Compensation”, above.
General
and Administrative – Related Parties
During
the year ended December 31, 2022, we incurred general and administrative expenses – related parties of $5,612 compared to $462,580
incurred for the year ended December 31, 2021, representing a decrease of $456,968, or 99%. Of the expenses incurred during 2022, these
primarily relate to professional fees paid to current or former officers, directors or greater than 10% investors, or affiliates thereof.
Of the expenses incurred during 2021, approximately $338,000 represents bad debt expense incurred in connection with a receivable from
related parties, and approximately $124,000 represents professional fees paid to current or former officers, directors or greater than
10% investors, or affiliates thereof.
Interest
Expense on Loans Payable
For
the year ended December 31, 2022, the Company recognized interest expense and interest income — related parties associated with
outstanding loans, of $14,156 and $1,490, respectively.
For
the year ended December 31, 2021, the Company recognized interest expense and interest expense — related parties associated with
outstanding loans, of $24,019 and $38,874, respectively.
As
of December 31, 2022, the Company had accrued interest and accrued interest — related parties associated with outstanding loans,
of $37,960 and $16,770, respectively.
As
of December 31, 2021, the Company had accrued interest and accrued interest — related parties associated with outstanding loans,
of $24,212 and $812, respectively.
Accrued
Expenses - Related Parties
Accrued
expenses - related parties was $188,159 as of December 31, 2022 and consists of deferred compensation for certain executives. Accrued
expenses - related parties was $18,370 as of December 31, 2021 and consists of interest accrued on loans and convertible notes due to
certain officers and directors of the Company.
The
aggregate amount of accrued expenses due to related parties as of December 31, 2022, is comprised of amounts due to Prof. Feldmann, Dr.
Steinman, Dr. Rothbard, Dr. Woody and Mr. Pamir for deferred compensation.
Research
and Development Expenses - Related Parties
Research
and Development Expenses – Related Parties of $240,731 and $2,947,536 during the years ended December 31, 2022 and 2021, respectively,
is related to consulting and professional fees paid to current or former officers, directors, or affiliates thereof.
Interest
Expense - Related Parties
During
the year ended December 31, 2022, the Company recorded $1,508 of interest expense – related parties, which related to interest
expense on loans with officers and directors of the Company.
During
the year ended December 31, 2021, the Company recorded $50,255 of interest expense – related parties, of which $11,380 related
to the convertible notes with officers and directors of the Company and $38,875 related to interest expense on loans with officers, directors
and a greater than 10% investor of the Company.
Exchanges
of Related Party Loans and Convertible Notes
On
September 30, 2021, Dr. Lawrence Steinman and Prof. Sir Marc Feldmann, Ph.D., each of whom serve as Co-Executive Chairmen
of the Company’s Board of Directors, agreed with the Company to convert amounts owed under outstanding loans with an aggregate
principal balance of $693,371 and an aggregate accrued interest balance of $157,741 into an aggregate of 7,093 shares of the Company’s
common stock at the conversion price of $120.00 per share, pursuant to the terms of the agreement, which conversion rate was above the
closing consolidated bid price of the Company’s common stock on the date the binding agreement was entered into.
Notes
and Debt Conversion Agreement
The
Company assumed $270,000 of debt related to convertible notes payable; during the second quarter of 2021 in connection with a reorganization,
the Company repaid the former CEO of 180 Therapeutics L.P., our wholly-owned subsidiary, a convertible note payable in cash for the principal
amount of $10,000 and $1,873 of accrued interest. During the third quarter of 2021, the $260,000 remaining principal balance of convertible
notes payable owed to an Executive Co-Chairman of the Company, plus $96,208 of related accrued interest, was converted into 2,969 shares
of the Company’s common stock, pursuant to a debt conversion agreement dated September 30, 2021.
On
February 10, 2021, the Company entered into amended loan agreements to modify the terms of certain loan agreements in the aggregate
principal amount of $432,699, previously entered into with Prof. Sir Marc Feldmann and Dr. Lawrence Steinman, the Co-Executive Chairmen
of the Board of Directors. The loan agreements were extended and modified to be paid back at the Company’s discretion, either by
1) repayment in cash, or 2) by converting the outstanding amounts into shares of common stock at the same price per share as the next
financing transaction. Subsequently, on February 25, 2021, and effective as of the date of the original February 10, 2021 amendments,
the Company determined that such amendments were entered into in error and each of Prof. Sir Feldmann and Dr. Steinman rescinded
such February 10, 2021 amendments pursuant to their entry into Confirmations of Rescission acknowledgements. On April 12,
2021, the Company entered into amended loan agreements with each of Prof. Sir Feldmann and Dr. Steinman, which extended the date
of all of their outstanding loan agreements to September 30, 2021. On September 30, 2021, we entered into a Debt Conversion
Agreement with Dr. Steinman and Prof. Sir Feldmann, pursuant to which: (x) we and Dr. Steinman agreed to convert an aggregate
of $31,297 owed by us to Dr. Steinman into an aggregate of 261 shares of our common stock; and (y) we and Prof. Sir Feldmann
agreed to convert an aggregate of $819,818 owed by us to Prof. Sir Feldmann into an aggregate of 6,832 shares of our common
stock. Pursuant to the Debt Conversion Agreement, each of Dr. Steinman and Prof. Sir Feldmann agreed that the shares of common stock
issuable in connection therewith were in full and complete satisfaction of amounts owed to such persons.
During
the years ended December 31, 2021, the Company recorded interest expense of $109,767 related to convertible notes payable, In November 2020,
3,164 restricted shares of common stock were issued to insiders (Prof. Sir Feldmann and Dr. Lawrence Steinman) as a result of conversion
of $239,320 of convertible debt.
As
of December 31, 2021, a total of $81,277 of related party loans were outstanding.
Registration
Rights
The
holders of the founder shares and private placement units (and their component securities) and their permitted transferees are entitled
to registration rights pursuant to a registration rights agreement signed on the effective date of our initial public offering (“IPO”).
The holders of these securities and their permitted transferees are entitled to make up to three demands, excluding short form demands,
that we register such securities. In addition, the holders and their permitted transferees have certain “piggy-back” registration
rights with respect to registration statements filed subsequent to our completion of our initial business combination and rights to require
us to register for resale such securities pursuant to Rule 415 under the Securities Act. Notwithstanding the foregoing, the underwriters
may not exercise their demand and “piggyback” registration rights after five (5) and seven (7) years after the
effective date of the registration statement relating to our IPO and may not exercise their demand rights on more than one occasion.
Further, the holders and their permitted transferees have certain “piggy-back” registration rights regarding the shares of
our common stock issuable upon the conversion of a promissory note with respect to the registration statement(s) that we may file
pursuant to the Registration Rights Agreement that we entered into in connection with the June 2020 offering. We satisfied the foregoing
registration rights through the filing of a Registration Statement on Form S-1 (No. 333-248539), which registration statement
was declared effective on November 2, 2020; provided, however, that such registration statement became stale and an updated registration
went effective on August 24, 2021. The Company has an obligation to register shares held by KBL IV Sponsor LLC which shares
have not been registered.
Related
Party Litigation
Action
Against Former Executive of KBL
On
September 1, 2021, the Company initiated legal action in the Chancery Court of Delaware against Dr. Marlene Krauss, the Company’s
former Chief Executive Officer and director (“Dr. Krauss”) and two of her affiliated companies, KBL IV Sponsor, LLC
and KBL Healthcare Management, Inc. (collectively, the “KBL Affiliates”) for, among other things, engaging in
unauthorized monetary transfers of the Company’s assets, non-disclosure of financial liabilities within the Company’s Consolidated
Financial Statements, issuing shares of stock without proper authorization; and improperly allowing stockholder redemptions to take place.
The Company’s complaint alleges causes of action against Dr. Krauss and/or the KBL Affiliates for breach of fiduciary duties, ultra
vires acts, unjust enrichment, negligence and declaratory relief, and seeks compensatory damages in excess of $11,286,570, together with
interest, attorneys’ fees and costs. There can be no assurance that the Company will be successful in its legal actions. As of
December 31, 2022, the Company has a legal accrual of $125,255 recorded to cover the legal expenses of the former executives of KBL.
On
October 5, 2021, Dr. Krauss and the KBL Affiliates filed an Answer, Counterclaims and Third-Party Complaint (the “Krauss Counterclaims”)
against the Company and twelve individuals who are, or were, directors and/or officers of the Company, i.e., Marc Feldmann, Lawrence
Steinman, James N. Woody, Teresa DeLuca, Frank Knuettel II, Pamela Marrone, Lawrence Gold, Donald A. McGovern, Jr., Russell
T. Ray, Richard W. Barker, Shoshana Shendelman and Ozan Pamir (collectively, the “Third-Party Defendants”). On
October 27, 2021, the Company and Ozan Pamir filed an Answer to the Krauss Counterclaims, and all of the other Third-Party Defendants
filed a Motion to Dismiss as to the Third-Party Complaint.
On
January 28, 2022, in lieu of filing an opposition to the Motion to Dismiss, Dr. Krauss and the KBL Affiliates filed a Motion for leave
to file amended counterclaims and third-party complaint, and to dismiss six of the current and former directors previously named, i.e.,
to dismiss Teresa DeLuca, Frank Knuettel II, Pamela Marrone, Russell T. Ray, Richard W. Barker and Shoshana Shendelman. The
Motion was granted by stipulation and, on February 24, 2022, Dr. Krauss filed an amended Answer, Counterclaims and Third-Party Complaint
(the “Amended Counterclaims”). In essence, the Amended Counterclaims allege (a) that the Company and the remaining
Third-Party Defendants breached fiduciary duties to Dr. Krauss by making alleged misstatements against Dr. Krauss in SEC filings and
failing to register her shares in the Company so that they could be traded, and (b) the Company breached contracts between the Company
and Dr. Krauss for registration of such shares, and also failed to pay to Dr. Krauss the amounts alleged to be owing under a promissory
note in the principal amount of $371,178, plus an additional $300,000 under Dr. Krauss’s resignation agreement. The
Amended Counterclaims seek unspecified amounts of monetary damages, declaratory relief, equitable and injunctive relief, and attorney’s
fees and costs.
On
March 16, 2022, Donald A. McGovern, Jr. and Lawrence Gold filed a Motion to Dismiss the Amended Counterclaims against them, and
the Company and the remaining Third-Party Defendants filed an Answer to the Amended Counterclaims denying the same. On April 19,
2022, Dr. Krauss stipulated to dismiss all of her counterclaims and allegations against both Donald A. McGovern, Jr. and Lawrence Gold,
thereby mooting their Motion to Dismiss the Amended Counterclaims against them. The Company and the Third-Party Defendants intend
to continue to vigorously defend against all of the Amended Counterclaims, however, there can be no assurance that they will be successful
in the legal defense of such Amended Counterclaims. In April 2022, Donald A. McGovern, Jr. and Lawrence Gold were dismissed from the
lawsuit as parties. Discovery has not yet commenced in the case. The Company and the Third-Party Defendants intend to continue to
vigorously defend against all of the Amended Counterclaims, however, there can be no assurance that they will be successful in the legal
defense of such Amended Counterclaims.
Action
Against the Company by Dr. Krauss
On
August 19, 2021, Dr. Krauss initiated legal action in the Chancery Court of Delaware against the Company. The original Complaint
sought expedited relief and made the following two claims: (1) it alleged that the Company is obligated to advance expenses including,
attorney’s fees, to Dr. Krauss for the costs of defending against the SEC and certain Subpoenas served by the SEC on Dr. Krauss;
and (2) it alleged that the Company is also required to reimburse Dr. Krauss for the costs of bringing this lawsuit against the Company. On
or about September 3, 2021, Dr. Krauss filed an Amended and Supplemental Complaint (the “Amended Complaint”) in this
action, which added the further claims that Dr. Krauss is also allegedly entitled to advancement by the Company of her expenses, including
attorney’s fees, for the costs of defending against the Third-Party Complaint in the Tyche Capital LLC action referenced below,
and the costs of defending against the Company’s own Complaint against Dr. Krauss as described above. On or about September
23, 2021, the Company filed its Answer to the Amended Complaint in which the Company denied each of Dr. Krauss’ claims and further
raised numerous affirmative defenses with respect thereto.
On
November 15, 2021, Dr. Krauss filed a Motion for Summary Adjudication as to certain of the issues in the case, which was opposed by the
Company. A hearing on such Motion was held on December 7, 2021, and, on March 7, 2022, the Court issued a decision in
the matter denying the Motion for Summary Adjudication in part and granting it in part. The Court then issued an Order implementing
such a decision on March 29, 2022. The parties are now engaging in proceedings set forth in that implementing Order. The Court
granted Dr. Krauss’s request for advancement of some of the legal fees which Dr. Krauss requested in her Motion, and the Company
was required to pay a portion of those fees while it objects to the remaining portion of disputed fees. These legal fees have been accrued
on the Company’s balance sheet.
On
October 10, 2022, Dr. Krauss filed an Application to compel the Company to pay the full amount of fees requested by Dr. Krauss for May-July
2022, and to modify the Court’s Order. The Company filed its Opposition thereto. On January 18, 2023, Dr. Krauss filed
a Second Application to compel the Company to pay the full amount of fees requested by Dr. Krauss for August-October 2022, and to modify
the Court's Order. The Company filed its Opposition thereto. Although the Court has indicated that it would consider and rule on
both of such Applications concurrently, no hearing has yet been scheduled by the Court. Notwithstanding any requirement by the Court
for the Company to advance attorneys’ fees to Dr. Krauss, no adjudication has yet been made as to whether Dr. Krauss will ultimately
be entitled to permanently retain such advancements. The Company is seeking payment for a substantial portion of such amounts from its
director and officers’ insurance policy, of which no assurance can be provided that the directors and officers insurance policy
will cover such amounts. See “Declaratory Relief Action Against the Company by AmTrust International” below.
On
April 29, 2022 and May 24, 2022, we made payments of $975,122 and $849,122, respectively ($1,824,244 in aggregate) to our former Chief
Executive Officer, Dr. Marlene Krauss, a then greater than 5% stockholder, in settlement of certain claims by Dr. Krauss for the advancement
of expenses incurred by Dr. Krauss in certain pending legal matters to which Dr. Krauss, pursuant to our organizational documents and
Delaware law, was determined to be owed indemnification for. The
Company is seeking payment for a substantial portion of such amounts from its director and officers’ insurance policy, of which
no assurance can be provided that the directors and officers insurance policy will cover such amounts.
Action
Against Tyche Capital LLC
The
Company commenced and filed an action against defendant Tyche Capital LLC (“Tyche”) in the Supreme Court of New York, in
the County of New York, on April 15, 2021. In its Complaint, the Company alleged claims against Tyche arising out of Tyche’s
breach of its written contractual obligations to the Company as set forth in a “Guarantee And Commitment Agreement” dated
July 25, 2019, and a “Term Sheet For KBL Business Combination With CannBioRex” dated April 10, 2019 (collectively, the “Subject
Guarantee”). The Company alleges in its Complaint that, notwithstanding demand having been made on Tyche to perform its
obligations under the Subject Guarantee, Tyche has failed and refused to do so, and is currently in debt to the Company for such failure
in the amount of $6,776,686, together with interest accruing thereon at the rate set forth in the Subject Guarantee.
On
or about May 17, 2021, Tyche responded to the Company’s Complaint by filing an Answer and Counterclaims against the Company alleging
that it was the Company, rather than Tyche, that had breached the Subject Guarantee. Tyche also filed a Third-Party Complaint against
six third-party defendants, including three members of the Company’s management, Prof. Sir Marc Feldmann, Dr. James Woody, and
Ozan Pamir (collectively, the “Individual Company Defendants”), claiming that they allegedly breached fiduciary duties
to Tyche with regards to the Subject Guarantee. In that regard, on June 25, 2021, each of the Individual Company Defendants
filed a Motion to Dismiss Tyche’s Third-Party Complaint against them.
On
November 23, 2021, the Court granted the Company’s request to issue an Order of attachment against all of Tyche’s shares
of the Company’s stock that had been held in escrow. In so doing, the Court found that the Company had demonstrated a likelihood
of success on the merits of the case based on the facts alleged in the Company’s Complaint.
On
February 18, 2022, Tyche filed an Amended Answer, Counterclaims and Third-Party Complaint. On March 22, 2022, the Company and each
of the Individual Company Defendants filed a Motion to Dismiss all of Tyche’s claims. A hearing on such Motion to Dismiss
was held on August 25, 2022, and the Court granted the Motion to Dismiss entirely as to each of the Individual Company Defendants, and
also as to three of the four Counterclaims brought against the Company, only leaving Tyche’s declaratory relief claim. On September
9, 2022, Tyche filed a Notice of Appeal as to the Court’s decision, which has not yet been briefed or adjudicated. On August 26,
2022, Tyche filed a Motion to vacate or modify the Company’s existing attachment Order against Tyche’s shares of the Company’s
stock held in escrow. The Company has filed its Opposition thereto, and the Court summarily denied such Motion without hearing on January
3, 2023. Tyche subsequently filed a Notice of Appeal as to that denial and filed its Opening Brief on January 30, 2023.
The Company filed its opposition brief on March 2, 2023, and no hearing date has been set.
On
January 30, 2023, the Company filed a Notice of Motion for Summary Judgment and to Dismiss Affirmative Defenses against
Tyche. Tyche has not yet filed its opposition thereto, and no hearing has yet been set on this matter. The Company and the
Individual Company Defendants intend to continue to vigorously defend against all of Tyche’s claims, however, there can
be no assurance that they will be successful in the legal defense of such claims. Written discovery proceedings and depositions have
occurred among the parties.
Action
Against Ronald Bauer & Samantha Bauer
The
Company and two of its wholly-owned subsidiaries, Katexco Pharmaceuticals Corp. and CannBioRex Pharmaceuticals Corp. (collectively, the
“Company Plaintiffs”), initiated legal action against Ronald Bauer and Samantha Bauer, as well as two of their companies,
Theseus Capital Ltd. and Astatine Capital Ltd. (collectively, the “Bauer Defendants”), in the Supreme Court of British Columbia
on February 25, 2022. The Company Plaintiffs are seeking damages against the Bauer Defendants for misappropriated funds and stock shares,
unauthorized stock sales, and improper travel expenses, in the combined sum of at least $4,395,000 CAD [$3,178,025 USD] plus the additional
sum of $2,721,036 USD. The Bauer Defendants filed an answer to the Company Plaintiffs’ claims on May 6, 2022. There can be no assurance
that the Company Plaintiffs will be successful in this legal action.
Declaratory
Relief Action Against the Company by AmTrust International
On
June 29, 2022, AmTrust International Underwriters DAC (“AmTrust”), which was the premerger directors’ and officers’
insurance policy underwriter for KBL, filed a declaratory relief action against the Company in the U.S. District Court for
the Northern District of California (the “Declaratory Relief Action”) seeking declaration of AmTrust’s obligations
under the directors’ and officers’ insurance policy. In the Declaratory Relief Action, AmTrust is claiming that as a
result of the merger the Company is no longer the insured under the subject insurance policy, notwithstanding the fact that
the fees which the Company seeks to recover from AmTrust relate to matters occurring prior to the merger.
On
September 20, 2022, the Company filed its Answer and Counterclaims against AmTrust for bad faith breach of AmTrust’s insurance
coverage obligations to the Company under the subject directors’ and officers’ insurance policy, and seeking damages of at
least $2 million in compensatory damages, together with applicable punitive damages. In addition, the Company brought a Third-Party Complaint
against its excess insurance carrier, Freedom Specialty Insurance Company (“Freedom”) seeking declaratory relief that Freedom
will also be required to honor its policy coverage as soon as the amount of AmTrust’s insurance coverage obligations to the Company
have been exhausted. On October 25, 2022, AmTrust filed its Answer to the Company’s Counterclaims and, on October 27, 2022,
Freedom filed its Answer to the Third-Party Complaint.
On
November 22, 2022, the Company filed a Motion for Summary Adjudication against both AmTrust and Freedom. The Motion was fully briefed,
and a hearing was held on March 9, 2023. The standard to prevail on a Motion for Summary Adjudication in the Court is high to prevail
and requires a judge to find that there are no disputed issues of fact so that they can rule on the issues as a matter of law. In this
instance the judge found three major issues could be decided as a matter of law in the Company’s favor and that one issue, the
Change in Control exclusion, requires further discovery.
On
April 21, 2023, the Court issued an Order Granting in Part and Denying in Part the Company’s Motion for Partial Summary Judgment.
Specifically, the Court granted summary adjudication in favor of the Company on the following issues: (a) that the Company is, in fact,
an insured under both the AmTrust and Freedom insurance policies; (b) that certain SEC subpoena related expenses for defendants Dr. Marlene
Krauss, the Company’s former Chief Executive Officer and Director, and George Hornig, the former Chairman of the Board, are within
the basic scope of coverage under both the AmTrust and Freedom insurance policies; and (c) that the Insured vs. Insured exclusion relied
upon by AmTrust and Freedom is not applicable to bar any such coverage.
The
Court also found that there were issues of disputed facts as to the Change in Control exclusion contained within the policies, which
therefore precluded the Court from granting the remainder of the Company’s requests for summary adjudication as a matter of law.
Accordingly, the Court, at this time, denied the Company’s further requests for summary adjudication and deemed that for the time
being, the Change in Control issue is to be determined at the time of trial, in order to find that the policies (i) provide coverage
for the fees which the Company has advanced and will advance to Dr. Marlene Krauss and George Hornig; (ii) that AmTrust has breached
the policy; (iii) that AmTrust must pay such expenses of the Company; and that, once the AmTrust policy has been exhausted, (iv) Freedom
will be obligated to pay such expenses of the Company pursuant to its policy. The Company intends to continue to vigorously pursue this
final matter in order to establish the Company’s entitlement to full payment by both AmTrust and Freedom of the subject advancement
expenses of the Company.
While
the Company continues to believe it has a strong case against both AmTrust and Freedom, and believes the Court ruling in its favor in
regards to the matters discussed above is a significant positive outcome for the Company, there can be no assurance that the Company
will prevail in this action.
Indemnification
Agreements
We
have entered into indemnification agreements with each of our directors and officers. The indemnification agreements and our Certificate
of Incorporation and Bylaws require us to indemnify our directors and officers to the fullest extent permitted by Delaware law.
Related
Party Transaction Policy
Our
Audit Committee must review and approve any related party transaction we propose to enter into. Our Audit Committee charter details the
policies and procedures relating to transactions that may present actual, potential or perceived conflicts of interest and may raise
questions as to whether such transactions are consistent with the best interest of our company and our stockholders. A summary of such
policies and procedures is set forth below.
Any
potential related party transaction that is brought to the Audit Committee’s attention will be analyzed by the Audit Committee,
in consultation with outside counsel or members of management, as appropriate, to determine whether the transaction or relationship does,
in fact, constitute a related party transaction. At its meetings, the Audit Committee will be provided with the details of each new,
existing or proposed related party transaction, including the terms of the transaction, the business purpose of the transaction and the
benefits to us and to the relevant related party.
In
determining whether to approve a related party transaction, the Audit Committee must consider, among other factors, the following factors
to the extent relevant:
| ● | whether
the terms of the transaction are fair to us and on the same basis as would apply if the transaction did not involve a related party; |
| ● | whether
there are business reasons for us to enter into the transaction; |
| ● | whether
the transaction would impair the independence of an outside director; and |
| ● | whether
the transaction would present an improper conflict of interest for any director or executive officer. |
Any
member of the Audit Committee who has an interest in the transaction under discussion must abstain from any voting regarding the transaction,
but may, if so, requested by the Chairman of the Audit Committee, participate in some or all of the Audit Committee’s discussions
of the transaction. Upon completion of its review of the transaction, the Audit Committee may determine to permit or to prohibit the
transaction.
DELINQUENT
SECTION 16(A) REPORTS
Section 16(a) of
the Exchange Act requires our directors and officers, and persons who beneficially own more than 10% of a registered class of the
Registrant’s equity securities, to file reports of beneficial ownership and changes in beneficial ownership of our securities with
the SEC on Forms 3, 4 and 5. Officers, directors and greater than 10% stockholders are required by SEC regulation to furnish us
with copies of all Section 16(a) forms they file.
Based
solely upon our review of the Section 16(a) filings that have been furnished to us and filed publicly, we believe that during
the year ended December 31, 2022, that no director, executive officer, or beneficial owner of more than 10% of our common stock
failed to file a report on a timely basis, except that: Larry Gold, our director, inadvertently failed to timely disclose one transaction
on Form 4, and as a result, one Form 4 was untimely filed.
Pursuant
to SEC rules, we are not required to disclose in this filing any failure to timely file a Section 16(a) report that has been
disclosed by us in a prior annual report or proxy statement.
PROPOSAL 1
ELECTION OF DIRECTORS
General
At
the annual meeting, four Class I directors are to be elected for a two-year term, to hold office until the 2025 annual meeting of
stockholders and until their respective successors are duly elected and qualified. The Nominating and Corporate Governance Committee
has recommended, and the Board of Directors has selected, the following nominees for election: Lawrence Steinman, James N. Woody,
Russell T. Ray and Francis Knuettel II, all of whom are currently directors of our company. If any nominee for any reason is
unable to serve or for good cause will not serve, the proxies may be voted for such substitute nominee as the proxy holder may determine.
The Company is not aware of any nominee who will be unable to, or for good cause will not, serve as a director.
The
Company’s Nominating Committee has reviewed the qualifications of the director nominees and has recommended each of the nominees
for election to the Board.
General
Director Qualifications
The
Board of Directors believes that each of our director nominees is highly qualified to serve as a member of the Board of Directors. Each
of the director nominees has contributed to the mix of skills, core competencies and qualifications of the Board of Directors. When evaluating
candidates for election to the Board of Directors, the Board of Directors seeks candidates with certain qualities that it believes are
important, including integrity, an objective perspective, good judgment, and leadership skills. Our director nominees are highly educated
and have diverse backgrounds and talents and extensive track records of success in what we believe are highly relevant positions.
What
Vote Is Required To Elect the Director Nominees
A
plurality of the votes cast in person or by proxy by the holders of our common stock, Class C Special Voting Shares, and Class K
Special Voting Shares, together voting in one class, entitled to vote at the annual meeting are required to elect each director. A plurality
of the votes cast means (1) the director nominee with the most votes for a particular seat is elected for that seat; and (2) votes
cast shall not include votes to “withhold authority” (shown as “AGAINST” on the enclosed form of
proxy) and exclude abstentions with respect to that director’s election. Therefore, abstentions and broker non-votes (which
occur if a broker or other nominee does not have discretionary authority and has not received instructions with respect to a particular
director nominee within ten days of the annual meeting) will not be counted in determining the number of votes cast with respect
to that director’s election.
Properly
executed proxies will be voted at the annual meeting in accordance with the instructions specified on the proxy; if no such instructions
are given, the persons named as agents and proxies in the enclosed form of proxy will vote such proxy “FOR” the election
of the nominees named herein. Should any nominee become unavailable for election, discretionary authority is conferred to the persons
named as agents and proxies in the enclosed form of proxy to vote for a substitute.
Pursuant
to the power provided to the Board of Directors in our Amended and Restated Bylaws (“Bylaws”), the Board has set the
number of directors that shall constitute the Board at nine. Proxies cannot be voted for a greater number of persons than the number
of nominees named on the enclosed form of proxy, and stockholders may not cumulate their votes in the election of directors.
THE
BOARD OF DIRECTORS RECOMMENDS
VOTING “FOR” EACH OF THE FOUR NOMINEES.
PROPOSAL 2
ADOPTION OF THE FIRST AMENDMENT TO THE 180 LIFE SCIENCES CORP. 2022
OMNIBUS INCENTIVE PLAN
General
The
share reserve under the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan (the “2022 OIP”) has been significantly
depleted and significantly reduced by the affects of the 1-for-20 Reverse Stock Split effective on December 19, 2022, discussed above
under “Reverse Stock Split”. If our stockholders do not approve an increase in the share reserve under the 2022 OIP, we may
not have sufficient shares to cover our annual equity award grants scheduled to be made in 2023, and we will lose access to an important
compensation tool that is key to our ability to attract, motivate, reward, and retain our key employees and directors.
Consequently,
on May 5, 2023, upon the recommendation of our Compensation Committee, our Board adopted the First Amendment (the “Amendment”)
to the 2022 OIP, subject to stockholder approval. The 2022 OIP, as amended by the Amendment, is hereinafter referred to as the “Amended
Plan.”
The
Amendment makes the following key changes to the 2022 OIP:
|
● |
Increase to the maximum number of shares that may be issued pursuant to the 2022 OIP, and the maximum number of shares which may be issued upon the exercise of incentive stock options, by 350,000 shares, to 470,000 shares; and |
|
|
|
|
● |
Update all of the share amounts set forth in the 2022 OIP to take into account the Reverse Stock Split. |
If
stockholders do not approve this Proposal 2, the Amendment will not become effective, the proposed additional shares will not become
available for issuance under the 2022 OIP, and the 2022 OIP will continue as in effect prior to the Amendment, subject to previously
authorized share limits.
A
copy of the Amendment is attached as Appendix A to this Proxy Statement, and a conformed copy of the 2022 OIP, as amended
by the Amendment, is attached as Appendix B to this Proxy Statement. Other than the limited amendments described herein,
we are not making other changes to the 2022 OIP.
Background
and Purpose of the Amended Plan
The
Compensation Committee and the Board are asking the Company’s stockholders to approve the Amendment because the Compensation Committee
and the Board believe that it is in the best interest of the Company and its stockholders to provide, through the Amended Plan, a comprehensive
equity and long-term compensation program designed to enable the Company to attract, retain, and reward employees, non-employee directors,
and other persons providing services to the Company. The Compensation Committee and the Board also believe that long-term equity compensation
is essential to link executive compensation with long-term stockholder value creation. Equity compensation represents a significant portion
of the compensation package for management. Since our equity awards generally vest over several years, the value ultimately realized
from these awards depends on the long-term value of our common stock. We strongly believe that granting equity awards motivates management
to think and act like owners, rewarding them when value is created for stockholders.
The
Amended Plan provides for a broad range of awards to enable the Company to respond to market trends and to structure incentives to align
to its business goals. In particular, the Amended Plan authorizes awards under the 2022 OIP in the form of performance awards, restricted
stock, restricted stock units, stock options, which may be either incentive stock options or non-qualified stock options, stock
appreciation rights, other stock-based awards and dividend equivalents, as discussed in greater detail below.
Current
Overview of Outstanding Equity Information
There
are only 16,747 shares available for future awards under the Company’s 2020 OIP and only 113,526 shares available for future awards
under the Company’s 2022 OIP.
The
Amended Plan authorizes an additional 350,000 shares for issuance of equity awards under the Amended Plan (representing approximately
6.6% of the outstanding shares of the Company common stock as of May 11, 2023). In setting and recommending to stockholders the number
of additional shares to authorize under the Amended Plan pursuant to the Amendment, the Compensation Committee and the Board considered
the historical number of equity awards granted under the 2020 OIP and 2022 OIP, as well as the Company’s average burn rate for
the preceding two fiscal years.
When
considering the number of additional shares to add to the 2022 OIP, the Compensation Committee and the Board reviewed, among other things,
the potential dilution to the Company’s current stockholders as measured by burn rate, projected future share usage, and projected
future forfeitures. The projected future usage of shares for long-term incentive awards under the 2022 OIP was reviewed under scenarios
based on a variety of assumptions. Depending on assumptions, the 350,000 shares to be added to the 2022 OIP pursuant to the Amendment,
in combination with the remaining authorized shares and shares added back to the 2022 OIP from forfeitures of awards granted under the
2022 OIP, are projected to satisfy the Company’s equity compensation needs for the next eighteen months. In light of the factors
considered by the Board and Compensation Committee, the Board and Compensation Committee believe that this number of shares represents
reasonable potential equity dilution and provides a significant incentive for officers, employees, and non-employee directors to increase
the value of the Company for all stockholders. The Compensation Committee is committed to effectively managing the number of shares reserved
for issuance under the Amended Plan while minimizing stockholder dilution.
In
light of the factors described above, and the fact that our ability to continue to grant equity and equity-based compensation is vital
to our ability to continue to attract and retain key personnel in the labor markets in which we compete, the Board has determined that
the size of the share reserve under the Amended Plan is reasonable and appropriate at this time.
Summary
of the Material Terms of the Amended Plan
The
following is a summary of the principal features of the Amended Plan. This summary does not purport to be a complete description
of all of the provisions of the Amended Plan. It is qualified in its entirety by reference to the full text of the Amended Plan,
following the approval of the Amendment (included as Appendix A to this proxy statement), which is included as Appendix
B to this proxy statement.
Purpose. The
purpose of the Amended Plan is to promote the interests of the Company and its subsidiaries and its stockholders by (i) attracting
and retaining directors, executive officers, employees and consultants of outstanding ability; (ii) motivating such individuals
by means of performance-related incentives to achieve the longer-range performance goals of the Company and its subsidiaries;
and (iii) enabling such individuals to participate in the long-term growth and financial success of the Company.
Administration. The
Board of Directors, and unless otherwise determined by our Board, our Compensation Committee of the Board, have the power and authority
to administer the Amended Plan (the “Administrator”). The Administrator has the authority to (i) determine the
type or types of awards to be granted to each participant; (ii) select the participants to whom awards may from time to time be
granted; (iii) determine all matters and questions related to the termination of service of a participant with respect to any award
granted to him or her; (iv) determine the number of awards to be granted and the number of shares to which an award will relate;
(v) approve forms of agreement for use under the Amended Plan; (vi) determine the terms and conditions of any awards; (vii) prescribe,
amend and rescind rules and regulations relating to the Amended Plan; (viii) determine whether, to what extent, and pursuant to
what circumstances an award may be settled in, or the exercise or purchase price of an award may be paid in, cash, stock, other awards,
or other property, or an award may be canceled, forfeited or surrendered; (ix) suspend or accelerate the vesting of any award granted
under the Amended Plan or waive the forfeiture restrictions or any other restriction or limitation regarding any awards or the shares
of stock relating thereto; (x) construe and interpret the terms of the Amended Plan and awards granted pursuant to the Amended Plan;
and (xi) make all other decisions and determinations that may be required pursuant to the Amended Plan or as it deems necessary
or advisable to administer the Amended Plan.
Eligibility. Employees,
non-employee directors, and consultants of the Company and its subsidiaries are eligible to participate in the Amended Plan. Incentive
stock options may be granted under the Amended Plan only to employees of our company and its subsidiaries. Employees, directors and consultants
of our company and its affiliates are eligible to receive all other types of awards under the Amended Plan.
Awards. Awards
under the Amended Plan may be made in the form of performance awards, restricted stock, restricted stock units, stock options, which
may be either incentive stock options or non-qualified stock options, stock appreciation rights, other stock-based awards and
dividend equivalents. Awards are generally non-transferable.
Shares
Subject to the Amended Plan. Subject to adjustment in connection with the payment of a stock dividend, a stock
split or subdivision or combination of the shares of common stock, or a reorganization or reclassification of the Company’s common
stock, the aggregate number of shares of common stock which may be issued pursuant to awards under the Amended Plan is 470,000. The 470,000 share
limit also applies to the total number of incentive stock options which may be awarded pursuant to the terms of the Amended Plan.
If
an award granted under the Amended Plan entitles a holder to receive or purchase shares of our common stock, then on the date of grant
of the award, the number of shares covered by the award (or to which the award relates) will be counted against the total number of shares
available for granting awards under the Amended Plan. As a result, the shares available for granting future awards under the Amended
Plan will be reduced as of the date of grant. However, certain shares that have been counted against the total number of shares authorized
under the Amended Plan in connection with awards previously granted under such Amended Plan will again be available for awards under
the Amended Plan as follows: shares of our common stock covered by an award or to which an award relates which were not issued because
the award terminated or was forfeited or cancelled without the delivery of shares will again be available for awards.
Shares
issued under the Amended Plan may be authorized but unissued shares or reacquired shares. Any shares covered by an award, or portion
of an award, granted under the Amended Plan that is forfeited, canceled, cash-settled, expired or otherwise terminated without the issuance
of shares, shall again be available for the grant of an award under the Amended Plan.
Award
Limitations on Non-Director Awards. The maximum number of shares subject to awards granted during
a single compensation year (that is from one annual meeting of stockholders to the next annual meeting) to any non-employee director,
taken together with any cash fees paid during the compensation year to the non-employee director, in respect of the director’s
service as a member of the Board during such year (including service as a member or chair of any committees of the Board), will not exceed
$500,000 in total value (calculating the value of any such awards based on the grant date fair value of such awards for financial reporting
purposes); provided that in the event such non-employee director is first appointed or elected to the Board during such compensation
year, and/or in the case that the non-employee director is serving as non-employee chairperson of the Board, such amount shall
not exceed $750,000 in total value.
Change
in Capitalization or Other Corporate Event. If and to the extent necessary or appropriate to reflect any stock
dividend, extraordinary dividend, stock split or share combination or any recapitalization, merger, consolidation, exchange of shares,
spin-off, liquidation or dissolution of the Company or other similar transaction affecting our common stock, the Administrator shall
adjust the number of shares of our common stock available for issuance under the Amended Plan, and the number, class and exercise price
or base price of any outstanding award, and/or make such substitution, revision or other provisions or take such other actions with respect
to any outstanding award or the holder or holders thereof, in each case as it determines to be equitable.
Terms
and Conditions of Options. An “incentive stock option” is an option that meets the requirements
of Section 422 of the U.S. Internal Revenue Code (the “Code”), and a “non-qualified stock
option” is an option that does not meet those requirements. An option granted will be exercisable only to the extent that it
is vested on the date of exercise. No option may be exercisable more than ten years from the grant date. In general, the exercise
price per share under each option granted under the Amended Plan may not be less than 100% of the fair market value of our common stock
on the option grant date, provided that stockholders who own greater than 10% of the Company’s voting stock cannot be granted incentive
stock options that have an exercise price less than 110% of the fair market value of the Company’s common stock on the date of
grant. For so long as our common stock is listed on an established stock exchange, the fair market value of the common stock will be
the closing price of our common stock on the exchange on which it is listed on the option grant date. If there is no closing price reported
on the option grant date, the fair market value will be deemed equal to the closing price for the common stock on the last market trading
day prior to the day of determination.
Terms
and Conditions of Stock Appreciation Rights. A “stock appreciation right” (or a “SAR”)
is the right to receive payment from the Company in cash and/or shares of common stock equal to the product of (i) the excess, if
any, of the fair market value of one (1) share of our common stock on the exercise date over a specified price fixed by the Administrator
on the grant date (which price may not be less than the fair market value of a share of our common stock on the grant date), multiplied
by (ii) a stated number of shares of common stock. A SAR will be exercisable only to the extent that it is vested on the date of
exercise. No SAR may be exercisable more than ten years from the grant date. SARs may be granted to participants in tandem with
options or on their own. Tandem SARs will generally have substantially similar terms and conditions as the options with which they are
granted.
Terms
and Conditions of Restricted Stock and Restricted Stock Units. “Restricted stock” is an
award of common stock on which certain restrictions are imposed over specified periods that subject the shares to a substantial risk
of forfeiture. A “restricted stock unit” is a unit, equivalent in value to a share of common stock, credited by means
of a bookkeeping entry in our books to a participant’s account, which is settled in stock or cash upon vesting. Subject to the
provisions of the Amended Plan, the Administrator will determine the terms and conditions of each award of restricted stock or restricted
stock units, including the restriction period for the award, and the restrictions applicable to the award. Restricted stock and restricted
stock units will vest based on a minimum period of service or the occurrence of events specified by the Administrator.
Terms
and Conditions of Performance Awards. A “performance award” is a contractual right to receive
shares of our common stock or a U.S.-denominated amount of cash which is earned (in whole or in part) based on the achievement of
specified performance goals. Vested performance awards may be settled in cash, stock or a combination of cash and stock, at the discretion
of the Administrator. Performance awards will vest based on the achievement of predetermined performance goals established by the Administrator.
Performance goals may be established on a company-wide basis, with respect to one or more business units, divisions, subsidiaries
or products or based on individual performance measures, and may be expressed in absolute terms or relative to other metrics including
internal targets or budgets, past performance of the Company, the performance of one or more similarly situated companies, performance
of an index, outstanding equity or other external measures. In the case of earning-based measures, performance goals may include
comparisons relating to capital (including but limited to, the cost of capital), stockholders’ equity, shares outstanding, assets
or net assets, or any combination thereof. Performance goals may also be subject to such other terms and conditions as the committee
may determine appropriate. The committee may also adjust the performance goals for any performance cycle as it deems equitable in recognition
of unusual or non-recurring events affecting the Company; changes in applicable tax laws or accounting principles; other extraordinary
events such as restructurings; discontinued operations; asset write-downs; significant litigation or claims, judgments or settlements;
acquisitions or divestitures; reorganizations or changes in the corporate structure or capital structure of the Company; foreign exchange
gains and losses; change in the fiscal year of the Company; business interruption events; unbudgeted capital expenditures; unrealized
investment gains and losses; impairments and/or such other factors as the committee may determine.
Other Stock-Based Awards. The
Compensation Committee or Board of Directors may make other equity-based or equity-related awards not otherwise described by
the terms of the plan.
Dividend
Equivalents. A dividend equivalent is the right to receive payments in cash or in stock, based on dividends
with respect to shares of stock. Dividend equivalents may be granted to participants in tandem with another award or on their own, but
not in respect of stock options or SARs. In general, dividend equivalents will be paid to participants with respect to an award when
the award becomes vested.
Termination
of Employment. All of the terms relating to the exercise, cancellation or other disposition of any award upon
a termination of employment or service with the Company of the participant, whether due to disability, death or under any circumstances
may be determined by the Administrator and described in each participant’s award agreement. Unless otherwise set forth in the applicable
agreement, the following provisions will apply:
Termination
for Cause; Post-Service Competitive Activity. If a participant’s employment or service terminates
for cause or a participant breaches any restrictive covenants (such as a non-competition or non-solicitation agreement) following
the participant’s termination of employment or service, all options and SARs, whether vested or unvested, and all other awards
that are unvested or unexercisable or otherwise unpaid (or were unvested or unexercisable or unpaid at the time of occurrence of cause
or such breach) will be immediately forfeited and canceled. If the participant breaches the restrictive covenants following the termination,
any portion of the participant’s awards that became vested after termination, and any shares or cash issued upon exercise or settlement
of such awards, will be immediately forfeited, canceled, and disgorged or paid to the Company together with all gains earned or accrued
due to the sale of shares issued upon exercise or settlement of such awards.
Termination
due to Death. If a participant’s employment or service terminates by reason of death, all options and
SARs (whether or not then otherwise exercisable) will become exercisable in full and may be exercised at any time prior to the earlier
of (i) the one-year anniversary of the participant’s death or (ii) the expiration of the term of the options or
SARs; provided that any in-the-money options and SARs that are still outstanding on the last day of their term will automatically
be exercised on such date, and all other awards will immediately vest in full, and restricted stock units and performance awards that
have not been settled or converted into shares prior to the participant’s death will immediately be settled in shares. Performance
awards will vest and be paid based on target levels of performance.
Termination
due to Disability. If a participant’s employment or service terminates by reason of disability, the
participant will be treated as though the participant continued in the employ or service of the Company and all unvested awards will
remain outstanding and vest, or in the case of options and SARs, vest and become exercisable, in accordance with the terms set forth
in the applicable award agreement. Any options or SARs that are or become exercisable may be exercised at any time prior to the earlier
of (i) the fifth anniversary of the participant’s termination for disability or (ii) the expiration of their term.
Involuntary
Termination Without Cause. If a participant’s employment or service is involuntarily terminated without
cause, all options and SARs that are unvested will be immediately forfeited and canceled, and all options and SARs that are vested will
remain outstanding and exercisable until the earlier of (i) 30 days after the termination date or (ii) the expiration
of their term, all restricted stock or restricted stock units that are unvested will be immediately forfeited and canceled, and provided
that the participant signs a general release and waiver of claims in the form provided by the Company and does not exercise any rights
to revoke such release, the participant will retain a pro-rated portion of any unvested performance awards granted earlier than
one year prior to the termination date, and be earned based on the attainment of the applicable performance goals (and any performance
awards that are not so earned will be forfeited and canceled).
Termination
for Any Other Reason. If a participant’s employment or service terminates for any reason other than
as set forth above, all options and SARs that are unvested will be immediately forfeited and canceled, and all options and SARs that
are vested will remain outstanding and exercisable until the earlier of (i) 30 days after the termination date or (ii) the
expiration of their term, and all other awards that are unvested or have not otherwise been earned shall be immediately forfeited and
canceled.
Change
in Control. Unless otherwise provided in an award agreement, and other than with respect to certain performance
awards (described in the next paragraph), no cancellation, acceleration or other payment will occur in connection with a change in control
of the Company if the Administrator reasonably determines in good faith, prior to the occurrence of the change in control, that the award
will be honored or assumed, or new rights substituted therefor following the change in control, provided that any such alternative award
must (i) give the participant rights and entitlements substantially equivalent to or better than the rights and terms applicable
under the award immediately prior to the change in control, (ii) have terms such that if a participant’s employment is involuntarily
or constructively terminated within the twenty-four months following the change in control at a time when any portion of the alternative
award is unvested, the unvested portion of the alternative award will immediately vest in full and the participant will receive either
(1) a cash payment equal in value to the excess (if any) of the fair market value of the stock subject to the alternative award
at the date of exercise or settlement over the price that the participant would be required to pay to exercise the alternative award,
or (2) or an equal value of publicly-traded shares or equity interests.
Unless
otherwise provided in an award agreement, upon a change in control, then-outstanding performance awards will be modified to replace
any performance goals with vesting solely based on the requirement of continued service through, as nearly as is practicable, the date(s) on
which the satisfaction of the performance goals would have been measured if the change in control had not occurred or, if applicable,
the later period of required service following such measurement date, with accelerated vesting if the participant’s employment
is involuntarily or constructively terminated within the twenty-four months following the change in control. The number of such
alternative awards will be equal to (i) if less than 50% of the performance cycle has elapsed, the target number of performance
awards, and (ii) if 50% or more of the performance cycle has elapsed, a number of awards based on actual performance through the
date of the change in control if determinable, or the target, if not determinable.
Except
as otherwise provided above or in an award agreement, upon a change in control: each vested and unvested option or SAR will be canceled
in exchange for a payment equal to the excess, if any, of the change in control price over the applicable exercise or base price, the
vesting restrictions applicable to all other unvested awards (other than freestanding dividend equivalents and performance awards) will
lapse, and such awards will be canceled in exchange for a payment equal to the change in control price, the alternative performance awards
will be canceled in exchange for a payment equal to the change in control price, all other awards (other than freestanding dividend equivalents)
that were vested prior to the change in control but that have not been settled or converted into shares prior to the change in control
will be canceled in exchange for a payment equal to the change in control price, and all freestanding dividend equivalents will be cancelled
without payment therefor.
To
the extent any portion of the change in control price is payable other than in cash and/or other than at the time of the change in control,
the award holders will receive the same value in respect of their awards (less any applicable exercise or base price) as is received
by the Company’s stockholders in respect of their shares. To the extent any portion of the change in control price is payable other
than at the time of the change in control, the committee will determine the time and form of payment to the award holders consistent
with Section 409A of the Code and other applicable laws. Upon a change in control the committee may cancel options and SARs for
no consideration if the fair market value of the shares subject to such options or such SARs is less than or equal to their exercise
or base price.
Forfeiture,
Cancellation or “Clawback” of Awards. Awards (and gains earned or accrued in connection
with awards) will be subject to such generally applicable policies as to forfeiture and recoupment as may be adopted by the Compensation
Committee or the Board. Participants will also forfeit and disgorge to the Company any awards granted or vested and any gains earned
or accrued due to the exercise of options or SARs or the sale of any shares of stock to the extent required by applicable law or as required
by any stock exchange or quotation system on which the stock is listed or quoted. Awards are also subject to any generally applicable
clawback policy adopted by the Administrator, the Board or the Company that is communicated to the participants or any such policy adopted
to comply with applicable law.
Amendment
or Termination of the Amended Plan. The Amended Plan may be wholly or partially amended or otherwise modified,
suspended or terminated at any time or from time to time by the Administrator; provided, that without the approval of the stockholders
of the Company, no amendment or modification to the Amended Plan may (i) except as otherwise expressly provided in the Amended Plan,
increase the number of shares subject to the Amended Plan; (ii) modify the class of persons eligible for participation in the Amended
Plan or (iii) materially modify the Amended Plan in any other way that would require stockholder approval under applicable law.
Except as otherwise expressly provided in the Amended Plan, neither the amendment, suspension nor termination of the Amended Plan shall,
without the written consent of the holder of the award, materially adversely alter or impair any rights or obligations under any award
theretofore granted. No award may be granted during any period of suspension nor after termination of the Amended Plan, and in no event
may any award be granted under the Amended Plan after the expiration of ten years from the original effective date of the Amended
Plan.
Amendment
of an Award. The Administrator may at any time, and from time to time, amend the terms of any one or more
existing award agreements, provided, however, that the rights of a participant under an award agreement may not be materially adversely
impaired without the participant’s written consent.
Federal
Income Tax Consequences
The
Code provides that a participant receiving a nonqualified stock option ordinarily does not realize taxable income upon the grant of the
stock option. A participant does, however, realize compensation income taxed at ordinary income tax rates upon the exercise of a nonqualified
stock option to the extent that the fair market value of the common stock on the date of exercise exceeds the stock option price. Subject
to the deduction limitation under Section 162(m) of the Code (which disallows a federal income tax deduction to any publicly
held corporation for compensation paid in excess of $1.0 million in any taxable year to certain “covered employees”,
which term includes the named executive officers of the Company), the Company is entitled to a federal income tax deduction for compensation
in an amount equal to the ordinary income so realized by the participant. When the participant sells the shares acquired pursuant to
a nonqualified stock option, any gain or loss will be capital gain or loss (this assumes that the shares represent a capital asset in
the participant’s hands), and there will be no tax consequences for the Company.
The
grant of an incentive stock option does not result in taxable income to a participant. The exercise of an incentive stock option also
does not result in taxable income, provided that the circumstances satisfy the employment requirements in the Code. However, the exercise
of an incentive stock option may give rise to alternative minimum tax liability for the participant. In addition, if the participant
does not dispose of the common stock acquired upon exercise of an incentive stock option during the statutory holding period, then any
gain or loss upon subsequent sale of the common stock will be a long-term capital gain or loss. This assumes that the shares represent
a capital asset in the participant’s hands. The statutory holding period lasts until the later of two years from
the date the stock option is granted and one year from the date the common stock is transferred to the participant pursuant to the exercise
of the stock option. If the employment and statutory holding period requirements are satisfied, the Company may not claim any federal
income tax deduction upon either the exercise of the incentive stock option or the subsequent sale of the common stock received upon
exercise. If these requirements are not satisfied (a “disqualifying disposition”), the amount of ordinary income taxable
to the participant is the lesser of the fair market value of the common stock on the date of exercise minus the stock option price and
the amount realized on disposition minus the stock option price. Any excess is long-term or short-term capital gain or loss,
assuming the shares represent a capital asset in the participant’s hands. Subject to the deduction limitation under Section 162(m) of
the Code, in the case of a disqualifying disposition, the Company is entitled to a federal income tax deduction in an amount equal to
the ordinary income realized by the participant.
The
exercise of a stock option through the exchange of previously-acquired stock will generally be treated as a non-taxable like-kind exchange
as to the number of shares given up and the identical number of shares received under the stock option. That number of shares will take
the same tax basis and, for capital gain purposes, the same holding period as the shares that are given up. The value of the shares received
upon such an exchange which are in excess of the number given up will be taxed to the participant at the time of the exercise as ordinary
income, taxed as compensation. The excess shares will have a new holding period for capital gains purposes and a tax basis equal to the
value of such shares determined at the time of exercise. If the tendered shares were acquired through the prior exercise of an incentive
stock option and do not satisfy the statutory two-year and one-year holding periods (“disqualified shares”),
then the tender will result in compensation income to the optionee taxed as ordinary income equal to the excess of the fair market value
of the disqualified shares, determined when the prior incentive stock option was exercised, over the exercise price of the disqualified
shares. The optionee will increase his tax basis in the number of shares received on exercise equal to the number of shares of disqualified
shares tendered by the amount of compensation income recognized by the optionee with respect to the disqualified shares. Generally, the
federal income tax consequences to the optionee are similar to those described above relating to the exercise of a stock option through
the exchange of non-disqualified shares.
If
an optionee exercises a stock option through the cashless exercise method by authorizing a broker to sell a specified number of the shares
to be acquired through the stock option exercise having a market value equal to the sum of the stock option exercise plus any transaction
costs (the “cashless shares”), the optionee should be treated as constructively receiving the full amount of stock
option shares, followed immediately by a sale of the cashless shares by the optionee. In the case of an incentive stock option, the cashless
exercise method would result in the cashless shares becoming disqualified shares and taxed in a manner described above for disqualified
shares.
In
the case of a nonqualified stock option, the cashless exercise method would result in compensation income to the optionee with respect
to both the cashless shares and remaining stock option shares as discussed above relating to nonqualified stock options. Since the optionee’s
tax basis in the cashless shares that are deemed received and simultaneously sold on exercise of the stock option is equal to the sum
of the exercise price and the compensation to the optionee, no additional gain should be recognized by the optionee upon the deemed sale
of the cashless shares.
Under
Section 83(b) of the Code, an employee may elect to include in ordinary income, as compensation at the time restricted stock
is first issued, the excess of the fair market value of the stock at the time of issuance over the amount paid, if any, by the employee.
In this event, any subsequent change in the value of the shares will be recognized for tax purposes as capital gain or loss upon disposition
of the shares, assuming that the shares represent a capital asset in the hands of the employee. An employee makes a Section 83(b) election
by filing the election with the IRS no later than 30 days after the restricted stock is transferred to the employee. If a Section 83(b) election
is properly made, the employee will not be entitled to any loss deduction if the shares with respect to which a Section 83(b) election
was made are later forfeited. Unless a Section 83(b) election is made, no taxable income will generally be recognized by the
recipient of a restricted stock award until the shares are no longer subject to the transfer restrictions or the risk of forfeiture.
When either the transfer restrictions or the risk of forfeiture lapses, the employee will recognize ordinary income, taxable as compensation,
in an amount equal to the excess of the fair market value of the common stock on the date of lapse over the amount paid, if any, by the
employee for the stock. Absent a Section 83(b) election, any cash dividends or other distributions paid with respect to the
restricted stock prior to the lapse of the transfer restrictions or risk of forfeiture will be included in the employee’s ordinary
income as compensation at the time of receipt and subsequent appreciation or depreciation will be recognized as capital gain or loss,
assuming that the shares represent a capital asset in the hands of the employee.
Generally,
an employee will not recognize any taxable income upon the grant of stock appreciation rights, performance shares, or other stock or
cash-based award. At the time the employee receives the payment for the stock appreciation right, performance shares, or other stock
or cash-based award, the fair market value of shares of common stock or the amount of any cash received in payment for such awards
generally is taxable to the employee as ordinary income, taxable as compensation.
Subject
to the deduction limitation under Section 162(m) of the Code, the Company or one of its subsidiaries will be entitled to a
deduction for federal income tax purposes at the same time and in the same amount that an employee recognizes ordinary income from awards
under the Amended Plan.
The
exercisability of a stock option or a stock appreciation right, the payment of a performance share or the elimination of restrictions
on restricted stock, may be accelerated, and special cash settlement rights may be triggered and exercised, as a result of a change in
control. If any of the foregoing occurs, all or a portion of the value of the relevant award at that time may be considered a parachute
payment under the Code. This is relevant for determining whether a 20% excise tax (in addition to income tax otherwise owed) is payable
by the participant as a result of the receipt of an excess parachute payment pursuant to the Code. The Company will not be entitled to
a deduction for that portion of any parachute payment which is subject to the excise tax.
Unanimous
Recommendation of the Board of Directors; Vote Required
This
proposal to approve the Amendment requires approval by the affirmative vote of a majority of the votes entitled to be cast at the annual
meeting by holders of voting capital stock who are present in person or by proxy.
OUR
BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS APPROVAL OF THE FIRST AMENDMENT TO THE 180 LIFE SCIENCES CORP. 2022 OMNIBUS INCENTIVE
PLAN.
Proposal
3
Approval of an Advisory Resolution on Named Executive Officer
Compensation
General
In
accordance with the requirements of Section 14A of the Exchange Act and the related rules of the SEC, our stockholders have the opportunity
to cast an advisory vote to approve the compensation of our named executive officers as disclosed pursuant to the SEC’s compensation
disclosure rules, which disclosure includes the executive compensation tables, and the narrative disclosures that accompany the executive
compensation tables.
Motivating
and retaining a talented and experienced leadership team is a key component of the Company’s long-term success. We are committed
to an effective executive compensation program that incorporates sound policies and best practices. The compensation realized by our
named executive officers in 2022 reflected our executive compensation program’s alignment with Company performance and shareholder
interests. We encourage shareholders to read the section entitled “Executive and Director Compensation,” above.
In
accordance with Section 14A of the Exchange Act, and as a matter of good corporate governance, stockholders will be asked at the annual
meeting to approve the following advisory resolution:
“RESOLVED,
that the compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including
the compensation tables and any related material disclosed in this proxy statement, is hereby APPROVED.”
As
an advisory vote, this proposal, commonly referred to as a “say on pay” resolution, is not binding on the Company, the Board,
or the Compensation Committee. However, the Compensation Committee and the Board value the opinions expressed by stockholders in their
votes on this proposal and will consider the outcome of the vote when making future compensation decisions regarding named executive
officers.
Although
the Compensation Committee will consider the outcome of the shareholder advisory vote on say on pay frequency in Proposal 4, we expect
the next advisory say on pay vote will occur at the 2024 annual meeting of shareholders.
Vote
Required
Approval
of Proposal 3 requires the affirmative vote of a majority of the shares present or represented by proxy and voting at the annual meeting.
THE
BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” THIS PROPOSAL.
Proposal
4
Recommendation on the Frequency of Future Advisory Votes on Named
Executive Officer Compensation
General
As
described in Proposal 3 above, our stockholders have the opportunity to cast an advisory vote to approve the compensation of our named
executive officers. In accordance with the requirements of Section 14A of the Exchange Act and the related rules of the SEC, this Proposal
4 affords stockholders the opportunity to cast an advisory vote on how often we should include a say on pay proposal in our proxy materials
for future annual shareholder meetings or any special shareholder meeting for which we must include executive compensation information
in the proxy statement for that meeting. Under this Proposal 4, stockholders may vote to have the say on pay vote every year, every two
years, or every three years.
Our
shareholders voted on a similar proposal in 2017 with the majority voting to hold the Say on Pay vote every year. Our Board and Compensation
Committee continue to believe that Say on Pay advisory votes should be conducted each year so that our shareholders may express their
views on our executive compensation program and the Compensation Committee can consider such views in its compensation planning for the
fiscal year following the Say on Pay advisory vote.
After
careful consideration, the Board has determined that holding the advisory vote on executive compensation every year is the most appropriate
policy for the Company at this time, and recommends that stockholders vote for future advisory votes on executive compensation to occur
every year. While the Company’s executive compensation programs are designed to promote a long-term connection between pay and
performance, the Board recognizes that executive compensation disclosures are made annually. Holding an annual advisory vote on executive
compensation provides the Company with more direct and immediate feedback on our compensation programs. However, stockholders should
note that because the advisory vote on named executive officer compensation occurs well after the beginning of the compensation year,
and because the different elements of our executive compensation programs are designed to operate in an integrated manner and to complement
one another, in many cases it may not be appropriate or feasible to change our executive compensation programs in consideration of any
single year’s advisory vote on named executive officer compensation by the time of the following year’s annual meeting of
stockholders. An annual advisory vote on named executive officer compensation also is consistent with the Company’s practice of
annually providing stockholders the opportunity to ratify the Audit Committee’s selection of independent auditors.
We
understand that our stockholders may have different views as to what is an appropriate frequency for “say-on-pay”
votes, and we will carefully review the voting results on this proposal. Stockholders will be able to specify one of four choices for
this proposal on the proxy card: every “1 year”, “2 years”, “3 years” or “abstain”.
This recommendation on the frequency of future advisory votes on named executive officer compensation is non-binding on the Board. Notwithstanding
the stockholders’ recommendation, the Board may in the future decide to conduct advisory votes on a more or less frequent basis
and may vary its practice based on factors such as discussions with stockholders and the adoption of material changes to our compensation
programs.
As
an advisory vote, this proposal is not binding on the Company, the Board, or the Compensation Committee. However, the Compensation Committee
and the Board value the opinions expressed by shareholders and will consider the outcome of the vote when making a decision regarding
the frequency of conducting a say on pay vote.
It
is expected that the next say on pay frequency vote will occur at the 2029 annual meeting of stockholders.
Vote
Required
The
voting frequency (that is, every “1 year”, “2 years”, or “3 years”) receiving
the greatest number of “for” votes cast by stockholders who are present, either in person or by proxy, at the annual
meeting and entitled to vote on the proposal will be the frequency recommended, on an advisory basis, by the stockholders.
THE
BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE FOR “1 YEAR” FOR THIS PROPOSAL.
PROPOSAL 5
RATIFICATION OF APPOINTMENT OF AUDITORS
General
Marcum
LLP (“Marcum”) has served as the independent registered public accounting firm for the Company since the closing
of the Business Combination on November 6, 2020. The Board of Directors has selected Marcum as the Company’s independent auditors
for the fiscal year ended December 31, 2023, and recommends that the stockholders vote to ratify such appointment.
The
Company does not anticipate a representative from Marcum to be present at the annual stockholders meeting. In the event that a representative
of Marcum is present at the annual meeting, the representative will have the opportunity to make a statement if he/she desires to do
so and the Company will allow such representative to be available to respond to appropriate questions.
Audit
Fees
The
following is a summary of fees paid or to be paid for audit, tax and related fees for services rendered during the periods indicated:
| |
For the Fiscal Year Ended December 31, | |
| |
2022 | | |
2021 | |
Marcum | |
| | |
| |
Audit Fees | |
$ | 682,951 | | |
$ | 538,408 | |
Audit-Related Fees | |
| — | | |
| — | |
Tax Fees | |
| 76,713 | | |
| 10,400 | |
All Other Fees | |
| — | | |
| | |
Total | |
$ | 759,664 | | |
$ | 548,808 | |
Audit
Fees. Audit fees consist of fees billed for professional services rendered for the audit of our annual
consolidated financial statements and services that are normally provided by Marcum, in connection with regulatory filings, including
for professional services rendered for the audit of our annual consolidated financial statements, review of the financial information
included in our Forms 10-Q for the respective periods and other required filings with the SEC for the applicable years. The
above amounts include interim procedures and audit fees, as well as attendance at Audit Committee meetings.
Audit-Related Fees. Audit-related services
consist of fees billed for assurance and related services that are reasonably related to performance of the audit or review of our consolidated
financial statements and are not reported under “Audit Fees.” These services include attest services that are not
required by statute or regulation and consultations concerning financial accounting and reporting standards.
Tax
Fees. Includes fees paid for tax return services.
All
Other Fees. Includes fees not included under “Audit Fees”, “Audit-Related Fees”
and “Tax Fees”.
Pre-Approval Policies
It
is the policy of our Board of Directors that all services to be provided by our independent registered public accounting firm, including
audit services and permitted audit-related and non-audit services, must be pre-approved by our Audit Committee. Our Audit
Committee pre-approved all services, audit and non-audit related, provided to us by Marcum for 2022 and 2021.
In
order to assure continuing auditor independence, the Audit Committee periodically considers the independent auditor’s qualifications,
performance and independence and whether there should be a regular rotation of our independent external audit firm. We believe the continued
retention of Marcum to serve as our independent auditor is in the best interests of the Company and its stockholders, and we are asking
our stockholders to ratify the appointment of Marcum as our independent auditor for the year ended December 31, 2023. While the
Audit Committee is responsible for the appointment, compensation, retention, termination and oversight of the independent registered
public accounting firm, the Audit Committee and our Board of Directors are requesting, as a matter of policy, that the stockholders ratify
the appointment of Marcum as our independent registered public accounting firm.
Vote
Required
Ratification
of this appointment shall be effective upon the affirmative vote of a majority of the shares present in person or represented by proxy
at the annual meeting and entitled to vote on, and who voted for, against, or expressly abstained with respect to, this proposal, provided
that a quorum exists at the annual meeting. Abstentions with respect to the ratification of this appointment will have the effect of
a vote “Against” ratification of this appointment. Properly executed proxies will be voted at the annual meeting in
accordance with the instructions specified on the proxy; if no such instructions are given, the persons named as agents and proxies in
the enclosed form of proxy will vote such proxy “For” the ratification of the appointment of Marcum.
The
Audit Committee is not required to take any action as a result of the outcome of the vote on this proposal. In the event stockholders
fail to ratify the appointment, the Audit Committee may reconsider this appointment. Even if the appointment is ratified, the Audit Committee,
in its discretion, may direct the appointment of a different independent accounting firm at any time during the year if the committee
determines that such a change would be in our and the stockholders’ best interests.
THE
BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” THIS PROPOSAL.
Proposal
6
Amend the Company’s SECOND Amended and Restated Certificate of Incorporation to Reflect New Delaware Law Provisions Regarding Officer
Exculpation
General
The
Company is incorporated in the State of Delaware and therefore subject to the Delaware General Corporation Law (“DGCL”).
The DGCL permits Delaware corporations to limit or eliminate the directors’ personal liability for monetary damages resulting from
a breach of the fiduciary duty of care, subject to certain limitations such as prohibiting exculpation for intentional misconduct or
knowing violations of the law. These provisions are referred to as “exculpatory provisions” or “exculpatory
protections.” Similar exculpatory provisions for directors are currently included in the Company’s Second Amended and
Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”).
Recently,
the Delaware legislature amended the DGCL to permit Delaware corporations to provide similar exculpatory protections for officers. This
decision was due in part to the recognition that both officers and directors owe fiduciary duties to corporations, and yet only directors
were protected by the exculpatory provisions. In addition, Delaware courts experienced an increase in litigation in which plaintiffs
attempted to exploit the absence of protection for officers to prolong litigation and extract settlements from defendant corporations.
As adopted, amended Section 102(b)(7) of the DGCL protects officers from personal monetary liability under limited circumstances as explained
below.
We
are proposing to amend the Certificate of Incorporation to add a provision exculpating certain of the Company’s officers from liability
in specific circumstances, as permitted by Delaware law. The new Delaware legislation only permits, and our proposed amendment would
only permit, exculpation for direct claims (as opposed to derivative claims made by stockholders on behalf of the corporation) and would
not apply to breaches of the duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing
violation of law, or any transaction in which the officer derived an improper personal benefit. The rationale for so limiting the scope
of liability is to strike a balance between stockholders’ interest in accountability and their interest in the Company being able
to attract and retain quality officers to work on its behalf.
The
Nominating and Corporate Governance Committee believes that there is a need for directors and officers to remain free of the risk of
financial ruin as a result of an unintentional misstep. Further, the Nominating and Corporate Governance Committee noted that the proposed
provision would not negatively impact stockholder rights. Therefore, taking into account the narrow class and type of claims for which
officers’ liability would be exculpated, and the benefits the Nominating and Corporate Governance Committee believes would accrue
to the Company and its stockholders in the form of an enhanced ability to attract and retain talented officers, the Nominating and Corporate
Governance Committee recommended to the Board an amendment to the Certificate of Incorporation to provide such exculpation to the extent
permitted by Delaware law. Based on this recommendation, the Board determined that it is in the best interests of the Company and our
stockholders to amend the Certificate of Incorporation as described herein.
Accordingly,
we ask our stockholders to vote on the following resolution:
The
full text of the amendment, subject to non-material technical, administrative or similar changes and modifications in the reasonable
discretion of the officers of the Company, is attached as Appendix C (the “Charter Amendment”). Appendix
D includes marked changes (items in bold with double underlines are additions and items in bold and strikethrough are deletions),
to the current wording of Section 8.1 of the Certificate of Incorporation.
“RESOLVED,
that the Company’s stockholders approve an amendment to the Company’s Second Amended and Restated Certificate of Incorporation
to amend and restate Section 8.1 thereof, which shall read in its entirety as follows:
“Section
8.1 Limitation of Director and Officer Liability. No Director or officer of the Corporation shall be personally liable to
the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, as applicable, to the
fullest extent permitted by the DGCL as the same now exists or hereafter may be amended. Any amendment, modification or repeal of the
foregoing sentence shall not adversely affect any right or protection of a director or officer of the Corporation hereunder in respect
of any act or omission occurring prior to the time of such amendment, modification or repeal.”
Conditions
and Limitations to Exculpation under DGCL Section 102(b)(7)
As
amended, Section 102(b)(7) of the DGCL provides important conditions and limitations on a corporation’s exculpation of its officers
for monetary damages from breaches of fiduciary duty and does not eliminate or limit the liability of:
(i)
A director or officer for any breach of the director’s or officer’s duty of loyalty
to the corporation or its stockholders;
(ii)
A director or officer for acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law;
(iii)
The liability of directors for unlawful payment of dividends or unlawful stock purchases or
redemptions;
(iv)
A director or officer for any transaction from which the director or officer derived an improper
personal benefit; or
(v)
An officer in any action by or in the right of the corporation.
Reasons
for the Proposal
The
Board believes that eliminating personal monetary liability for officers under certain circumstances is reasonable and appropriate. Claims
against corporations for breaches of fiduciary duties are expected to continue increasing. Delaware corporations that fail to adopt officer
exculpation provisions may experience a disproportionate amount of nuisance litigation and disproportionately increased costs in the
form of increased director and officer liability insurance premiums, as well as diversion of management attention from the business of
the corporation.
Further,
the Board anticipates that similar exculpation provisions are likely to be adopted by the Company’s peers and others with whom
the Company competes for executive talent. As a result, officer exculpation provisions may become necessary for Delaware corporations
to attract and retain experienced and qualified corporate officers.
A
Delaware corporation seeking to extend the benefits of the newly amended Section 102(b)(7) to its corporate officers must amend its certificate
of incorporation, as the protections do not apply automatically and must be embedded in the corporation’s certificate of incorporation
to be effective. Accordingly, the Board has determined it is advisable and in the best interests of the Company and its stockholders
to seek stockholders’ approval for the Charter Amendment.
Effect
of the Proposal if Approved
The
Charter Amendment would provide for the elimination of personal monetary liability for certain officers only in connection with direct
claims brought by stockholders, subject to the limitations described under the heading “Conditions and Limitations to Exculpation
under DGCL Section 102(b)(7)” above. As is the case with directors under the Certificate of Incorporation, the Charter Amendment
would not limit the liability of officers for any breach of the duty of loyalty to the Company or its stockholders, any acts or omissions
not in good faith or which involve intentional misconduct or a knowing violation of the law, or any transaction from which the officer
derived an improper personal benefit.
If
the Charter Amendment is approved by the stockholders at the annual meeting, it will become effective upon the filing of the Charter
Amendment with the Secretary of State of the State of Delaware. In accordance with the DGCL, however, the Board may abandon the Charter
Amendment without further action by the stockholders at any time prior to the effectiveness of the filing of the Charter Amendment with
the Secretary of State of the State of Delaware, notwithstanding stockholder approval.
Vote
Required
Approval
of the Charter Amendment to the Certificate of Incorporation shall be effective upon the affirmative vote of a majority of the shares
eligible to vote at the annual meeting. Abstentions and broker non-votes with respect to this proposal will have the effect of a vote
“Against” approval of the Charter Amendment to the Certificate of Incorporation. Properly executed proxies will be
voted at the annual meeting in accordance with the instructions specified on the proxy; if no such instructions are given, the persons
named as agents and proxies in the enclosed form of proxy will vote such proxy “For” the approval of the Amendment
to the Certificate of Incorporation.
THE
BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” THIS PROPOSAL.
OTHER
MATTERS
Proposals
for 2024 Annual Meeting of Stockholders and 2024 Proxy Materials
Proxy
Statement Proposals
Pursuant
to Rule 14a-8 under the Exchange Act, if a stockholder wants to submit a proposal for inclusion in our proxy materials
for the 2024 annual meeting of stockholders, it must be received by our Secretary by no later than [●], 2023, unless the date of
the 2024 annual meeting of stockholders is more than 30 days before or after [●], 2024, in which case the proposal must be
received at least ten (10) days before we begin to print and mail our proxy materials and must otherwise comply with Rule 14a-8
under the Exchange Act. In order to avoid controversy, stockholders should submit proposals by means, including electronic means, which
permit them to prove the date of delivery.
Other
Proposals and Nominations
For
any proposal or director nomination that is not submitted for inclusion in next year’s proxy statement pursuant to the process
set forth above, but is instead sought to be presented directly at the 2024 annual meeting of stockholders, stockholders are advised
to review our Amended and Restated Bylaws as they contain requirements with respect to advance notice of stockholder proposals and director
nominations. To be timely, the notice must be received at our principal executive offices not less than 90 days nor more than 120 days
prior to the first anniversary of the date of the prior year’s annual meeting of stockholders. Accordingly, any such stockholder
proposal or director nomination must be received between March 8, 2024 and the close of business on April 7, 2024, for the 2024 annual
meeting of stockholders. In the event that the 2024 annual meeting of stockholders is convened more than 45 days prior to or delayed
by more than 45 days after the anniversary of the 2023 annual meeting, notice by the stockholder, to be timely, must be received
no earlier than the 120th day prior to the 2024 annual meeting of stockholders and no later than the later of (i) the
90th day prior to the 2024 annual meeting of stockholders and (ii) the tenth day following the day on
which we publicly announce the date of the 2024 annual meeting of stockholders. All proposals should be sent to our principal executive
offices at 3000 El Camino Rd., Bldg. 4, Suite 200, Palo Alto, California 94306, Attention: Corporate Secretary. These advance notice
provisions are in addition to, and separate from, the requirements that a stockholder must meet in order to have a proposal included
in the proxy statement under the rules of the SEC.
A
proxy granted by a stockholder will give discretionary authority to the proxies to vote on any matters introduced pursuant to the above
advance notice bylaw provisions, subject to applicable rules of the SEC.
Copies
of our Amended and Restated Bylaws are filed as, or incorporated by reference as, an exhibit to our Annual Reports on Form 10-K,
which is available at www.sec.gov available by request to the Secretary at 3000 El Camino Rd., Bldg. 4, Suite 200,
Palo Alto, California 94306.
In
addition to satisfying the deadlines in the advance notice provisions of our Amended and Restated Bylaws, a stockholder who intends to
solicit proxies pursuant to Rule 14a-19 in support of nominees submitted under these advance notice provisions for the 2024 annual meeting
must notify our Secretary in writing not later than May 7, 2024 comply with the other requirements of Rule 14a-19(b).
All
submissions to, or requests from, the Secretary of the Company should be made to: 180 Life Sciences Corp., 3000 El Camino Real, Bldg. 4,
Suite 200, Palo Alto, CA, 94306.
The
chairman of the annual meeting of stockholders has the sole authority to determine whether any nomination or other proposal has been
properly brought before the meeting in accordance with our Amended and Restated Bylaws. If we receive a proposal other than pursuant
to Rule 14a-8 or a nomination for the 2024 annual meeting, and such nomination or other proposal is not delivered within the time frame
specified in our Amended and Restated Bylaws, then the person(s) appointed by the Board and named in the proxies for the 2024 annual
meeting may exercise discretionary voting power if a vote is taken with respect to that nomination or other proposal.
Annual
Report
Copies
of our Annual Report on Form 10-K (as amended) (including our audited financial statements) filed with the SEC may be obtained
without charge by writing to 180 Life Sciences Corp., 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, 94306, attention:
Secretary. Exhibits to the Form 10-K will be mailed upon similar request and payment of specified fees to cover the costs of
copying and mailing such materials.
Our
audited financial statements for the fiscal year ended December 31, 2022 and certain other related financial and business information
are contained in our 2022 Annual Report to stockholders, which is being made available to our stockholders along with this proxy statement,
but which is not deemed a part of the proxy soliciting material.
Additional
Filings
The
Company’s Forms 10-K, 10-Q, 8-K and all amendments to those reports are available without charge through
the Company’s website on the Internet, www.180lifesciences.com, as soon as reasonably practicable after they are
electronically filed with, or furnished to, the Securities and Exchange Commission. Information on our website does not constitute part
of this proxy statement.
The
Company will provide, without charge, to each person to whom a proxy statement is delivered, upon written or oral request of such person
and by first class mail or other equally prompt means within one business day of receipt of such request, a copy of any of the filings
described above. Individuals may request a copy of such information by sending a request to the Company, Attn: Corporate Secretary, 3000
El Camino Real, Bldg. 4, Suite 200, Palo Alto, California 94306.
Other
Matters to be Presented at the Annual Meeting
As
of the date of this proxy statement, our management has no knowledge of any business to be presented for consideration at the annual
meeting other than that described above. If any other business should properly come before the annual meeting or any adjournment thereof,
it is intended that the shares represented by properly executed proxies will be voted with respect thereto in accordance with the judgment
of the persons named as agents and proxies in the enclosed form of proxy.
The
Board of Directors does not intend to bring any other matters before the annual meeting of stockholders and has not been informed that
any other matters are to be presented by others.
Interest
of Certain Persons in or Opposition to Matters to Be Acted Upon:
| (a) | No
officer or director of us has any substantial interest in the matters to be acted upon, other than his or her role as an officer or director
of us, or as a stockholder of us. |
| (b) | No
director of us has informed us that he or she intends to oppose the action taken by us set forth in this proxy statement. |
Company
Contact Information
The
Board has established a process for stockholders to send communications to our Board or any individual director. Stockholders may send
written communications to the Board or any director to 180 Life Sciences Corp.:
180
Life Sciences Corp.
Attn:
Investor Relations
3000
El Camino Real, Bldg. 4, Suite 200, Palo Alto, California 94306
Appendix
A
FIRST
AMENDMENT TO
180 LIFE SCIENCES CORP.
2022 OMNIBUS INCENTIVE PLAN
This
First Amendment (“First Amendment”) to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan (the “2022
OIP”), is made and adopted by the Board of Directors of 180 Life Sciences Corp., a Delaware corporation (the “Company”),
on May 5, 2023, effective as of the date of the Annual Meeting that occurs in 2023, provided that it is approved by the Company’s
stockholders on that date (the “First Amendment Date”). Capitalized terms used in this First Amendment and not otherwise
defined herein shall have the meanings ascribed to such terms in the 2022 OIP.
RECITALS
|
A. |
The
Company currently maintains the 2022 OIP. |
|
|
|
|
B. |
The
Board believes it is in the best interests of the Company and its stockholders to amend the 2022 OIP to increase the Share Limit
and the ISO Limit and to incorporate the other terms and conditions set forth herein. |
AMENDMENT
The
2022 OIP is hereby amended as follows, effective as of the date of the Annual Meeting that occurs in 2023, provided that it is approved
by the Company’s stockholders on that date.
|
1. |
Section
3.1(a). Section 3.1(a) of the 2022 OIP is hereby deleted and replaced in its entirety
with the following:
“(a)
Subject to Section 3.3 and Section 3.6, the aggregate number of Shares which may be issued under this Plan shall be 470,000 (the “Share
Limit”). All of the Shares reserved under the Plan may be issued in the form of Incentive Stock Options under the Plan,
subject to the limitation set forth in Section 3.6. The Shares issued under the Plan may be authorized but unissued, or reacquired
Company Common Stock. No provision of this Plan shall be construed to require the Company to maintain the Shares in certificated
form. Unless the Administrator shall determine otherwise, (x) Awards may not consist of fractional shares and shall be rounded down
to the nearest whole Share, and (y) fractional Shares shall not be issued under the Plan (and shall instead also be rounded as aforesaid).”
|
|
2. |
Section
3.6. Section 3.6 of the 2022 OIP is hereby deleted and replaced in its entirety with
the following:
“Section
3.6 Maximum Number of Incentive Stock Options. Notwithstanding the Share Limit, and subject to adjustment in accordance
with Section 3.3 hereof, the maximum number of Shares that may be granted in connection with, and issued pursuant to the exercise
of, Incentive Stock Options granted under this Plan is 470,000 shares (the “ISO Limit”).”
|
|
3. |
This
First Amendment shall be and, as of the First Amendment Date, is hereby incorporated in and forms a part of the 2022 OIP. |
|
|
|
|
4. |
Except
as expressly provided herein, all terms and conditions of the 2022 OIP shall remain in full force and effect. |
Appendix
B
FIRST
AMENDED AND RESTATED
180
LIFE SCIENCES CORP.
2022
OMNIBUS INCENTIVE PLAN
Originally Adopted by the Board of Directors
on April 26, 2022 and the Stockholders on June 14, 2022
Amended and Restated by the Stockholders on July
11, 2023
PURPOSES
This
First Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive Plan, as may be amended from time to time (the “Plan”),
is intended to promote the interests of 180 Life Sciences Corp. (the “Company”) and its Subsidiaries (as defined
below) and its stockholders by (i) attracting and retaining directors, executive officers, employees and consultants of outstanding ability;
(ii) motivating such individuals by means of performance-related incentives to achieve the longer-range performance goals of the Company
and its Subsidiaries; and (iii) enabling such individuals to participate in the long-term growth and financial success of the Company.
Article
I
Definitions
Whenever
the following terms are used in this Plan, they shall have the meanings specified below unless the context clearly indicates to the contrary.
Section
1.1 “Administrator” means the Board or the Compensation Committee, as determined by the Board from time to
time. In exercising its discretion hereunder, the Board shall endeavor to cause the Administrator to satisfy any requirements applicable
to qualify for an exemption available under Rule 16b-3 promulgated under the Exchange Act or any other regulatory or administrative requirements
that may be applicable with respect to Awards granted hereunder.
Section
1.2 “Affiliate” means, with respect to any Person, any other Person directly or indirectly controlling, controlled
by or under common control with, such Person where “control” (including the terms “controlling,” “controlled
by,” and “under common control with”) means the possession, direct or indirect, of the power to direct or cause the
direction of the management and policies of a Person, whether through the ownership of securities, by contract, or otherwise.
Section
1.3 “Alternative Award” has the meaning set forth in Section 10.1.
Section
1.4 “Alternative Performance Awards” has the meaning set forth in Section 10.2.
Section
1.5 “Award” means any Option, Restricted Stock, Restricted Stock Unit, Performance Award, SAR, Dividend Equivalent
or other Stock-Based Award granted to a Participant pursuant to the Plan, including an Award combining two or more types of Awards into
a single grant.
Section
1.6 “Award Agreement” means any written agreement, contract or other instrument or document evidencing an Award,
including through an electronic medium. The Administrator may provide for the use of electronic, internet or other non-paper Award Agreements,
and the use of electronic, internet or other non-paper means for the Participant’s acceptance of, or actions under, an Award Agreement
unless otherwise expressly specified herein.
Section
1.7 “Board” means the Board of Directors of the Company.
Section
1.8 [Reserved]
Section
1.9 “Cause” means, unless otherwise provided in the Award Agreement, any of the following: (A) the Participant’s
commission of a crime involving fraud, theft, false statements or other similar acts or commission of any crime that is a felony (or
comparable classification in a jurisdiction that does not use these terms); (b) the Participant’s engaging in any conduct that
constitutes an employment disqualification under applicable law with respect to a material portion of the Participant’s work duties;
(c) the Participant’s willful or grossly negligent failure to perform his or her material employment-related duties for the Company
Group, or willful misconduct in the performance of such duties; (d) the Participant’s material violation of any Company or Subsidiary
policy as in effect from time to time; (e) the Participant’s engaging in any act or making any public statement that materially
impairs, impugns, denigrates, disparages or negatively reflects upon the name, reputation or business interests of the Company or its
Subsidiaries; or (f) the Participant’s material breach of any Award Agreement, employment agreement, or noncompetition, nondisclosure
or nonsolicitation agreement to which the Participant is a party or by which the Participant is bound; provided that
in the case of any Participant who, as of the date of determination, is a party to an effective services, severance, consulting or employment
agreement with the Company or any Subsidiary of the Company that employs such individual, “Cause” has the meaning, if any,
specified in such agreement. A termination for Cause shall be deemed to include a determination by the Administrator following a Participant’s
termination of employment that circumstances existing prior to such termination would have entitled the Company or one of its Subsidiaries
to have terminated such Participant’s employment for Cause. All rights a Participant has or may have under the Plan shall be suspended
automatically during the pendency of any investigation by the Administrator or its designee, or during any negotiations between the Administrator
or its designee and the Participant, regarding any actual or alleged act or omission by the Participant of the type described in the
applicable definition of Cause.
Section
1.10 “Change in Control” means the first to occur of any of the following events after the Effective Date:
(a)
any Person becomes the beneficial owner (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 30% or more of
either (x) the then-outstanding shares of common stock of the Company (the “Outstanding Company Common Stock”)
or (y) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election
of directors (the “Outstanding Company Voting Securities”);
(b)
the individuals who constitute the Board as of the Effective Date (the “Incumbent Board”) cease for any reason
to constitute at least a majority of the Board; provided, however, that any individual becoming a Director subsequent
to the Effective Date whose election, or nomination for election, by the Company’s stockholders, was approved by a vote of at least
a majority of the Directors then comprising the Incumbent Board shall be considered as though such individual was a member of the Incumbent
Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened
election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents
by or on behalf of a Person other than the Board; or
(c)
the consummation of a reorganization, merger, statutory share exchange or consolidation or similar transaction involving the Company
or any of its Subsidiaries, a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition
of assets or stock of another entity by the Company or any of its Subsidiaries (each, a “Business Combination”),
in each case, unless, following such Business Combination, (i) all or substantially all of the individuals and entities that were the
beneficial owners of the Outstanding Company Common Stock and the Outstanding Company Voting Securities immediately prior to such Business
Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock (or, for a non-corporate
entity, equivalent securities) and the combined voting power of the then-outstanding voting securities entitled to vote generally in
the election of Directors (or, for a non-corporate entity, equivalent governing body), as the case may be, of the entity resulting from
such Business Combination (including, without limitation, an entity that, as a result of such transaction, owns the Company or all or
substantially all of the Company’s assets either directly or through one or more Subsidiaries) in substantially the same proportions
as their ownership immediately prior to such Business Combination of the Outstanding Company Common Stock and the Outstanding Company
Voting Securities, as the case may be, (ii) no Person (excluding any corporation resulting from such Business Combination or any employee
benefit plan (or related trust) of the Company or such corporation resulting from such Business Combination) beneficially owns, directly
or indirectly, 30% or more of, respectively, the then-outstanding shares of common stock (or, for a non-corporate entity, equivalent
securities) of the entity resulting from such Business Combination or the combined voting power of the then-outstanding voting securities
of such entity entitled to vote generally in the election of directors (or, for a non-corporate entity, equivalent securities), except
to the extent that such ownership existed prior to the Business Combination, and (iii) at least a majority of the members of the board
of directors (or, for a non-corporate entity, equivalent governing body) of the entity resulting from such Business Combination were
members of the Incumbent Board at the time of the execution of the initial agreement or of the action of the Board providing for such
Business Combination;
in
each case, provided that, as to Awards subject to Section 409A of the Code, the payment or settlement of which will
occur by reason of the Change in Control, such event also constitutes a “change in control” within the meaning of Section
409A of the Code. In addition, notwithstanding the foregoing, a “Change in Control” shall not be deemed to occur if the Company
files for bankruptcy, liquidation or reorganization under the United States Bankruptcy Code or as a result of any restructuring that
occurs as a result of any such proceeding.
Section
1.11 “Change in Control Price” means the price per share of Company Common Stock paid in conjunction with any
transaction resulting in a Change in Control. If any part of the offered price is payable other than in cash, the value of the non-cash
portion of the Change in Control Price shall be determined in good faith by the Administrator as constituted immediately prior to the
Change in Control.
Section
1.12 “Code” means the Internal Revenue Code of 1986, as amended.
Section
1.13 “Company Common Stock” means the common stock, par value $0.0001 per share, of the Company and such other
stock or securities into which such common stock is hereafter converted or for which such common stock is exchanged.
Section
1.14 “Company Group” means the Company and its direct or indirect Subsidiaries.
Section
1.15 “Compensation Year” means the period from one annual meeting of stockholders to the next following annual
meeting of stockholders.
Section
1.16 “Competitive Activity” means a Participant’s material breach of restrictive covenants relating to
noncompetition, nonsolicitation (of customers or employees) or preservation of confidential information or other covenants having the
same or similar scope, included in an Award Agreement or other agreement to which the Participant and the Company or any of its Affiliates
is a party.
Section
1.17 “Corporate Event” means, as determined by the Administrator, any transaction or event described in Section
3.3(a) or any unusual or infrequently occurring transaction or event affecting the Company, any Subsidiary of the Company, or the financial
statements of the Company or any of its Subsidiaries, or changes in applicable laws, regulations or accounting principles (including,
without limitation, a recapitalization of the Company).
Section
1.18 “Director” means a member of the Board or a member of the board of directors of any Subsidiary.
Section
1.19 “Disability” means (x) for Awards that are not subject to Section 409A of the Code, “disability”
as such term is defined in the long-term disability insurance plan or program of the Company or any Subsidiary then covering the Participant,
and (y) for Awards that are subject to Section 409A of the Code, “disability” has the meaning set forth in Section 409A(a)(2)(c)
of the Code; provided that with respect to Awards that are not subject to Section 409A, in the case of any Participant
who, as of the date of determination, is a party to an effective services, severance, consulting or employment agreement with the Company
or any Subsidiary of the Company that employs such individual, “Disability” has the meaning, if any, specified in such agreement.
Section
1.20 “Dividend Equivalent” means the right to receive payments, in cash or in Shares, based on dividends paid
with respect to Shares.
Section
1.21 “Eligible Representative” for a Participant means such Participant’s personal representative or
such other person as is empowered under the deceased Participant’s will or the then applicable laws of descent and distribution
to represent the Participant hereunder.
Section
1.22 “Employee” means any individual classified as an employee by the Company or one of its Subsidiaries.
Section
1.23 “Exchange Act” means the Securities Exchange Act of 1934, as amended.
Section
1.24 “Executive Officer” means each person who is an officer or employee of the Company or any of its Subsidiaries
and who is subject to the reporting requirements under Section 16(a) of the Exchange Act.
Section
1.25 “Fair Market Value” means, unless otherwise determined by the Administrator from time to time, the closing
transaction price of a Share as reported on the NASDAQ Stock Market LLC on the date as of which such value is being determined or, if
Shares are not listed on the NASDAQ Stock Market LLC, the closing transaction price of a Share on the principal national stock exchange
on which Shares are traded on the date as of which such value is being determined or, if there shall be no reported transactions for
such date, on the next preceding date for which transactions were reported; provided, however, that if Shares are not listed on a national
stock exchange or if Fair Market Value for any date cannot be so determined, Fair Market Value shall be determined by the Administrator
by whatever means or method as the Administrator, in the good faith exercise of its discretion, shall at such time deem appropriate and
in compliance with Section 409A of the Code.
Section
1.26 “Good Reason” means, unless otherwise provided in the Award Agreement, a material reduction in the Participant’s
base salary or a material reduction in the Participant’s target annual cash incentive compensation opportunity, in each case, other
than (a) any isolated or inadvertent failure by the Company or the applicable Subsidiary that is not in bad faith and is cured within
thirty (30) business days after the Participant gives the Company or the applicable Subsidiary notice of such event or (b) a reduction
of 10% or less which is applicable to all employees in the same salary grade as the Participant; provided that in the
case of any Participant who, as of the date of determination, is a party to an effective services, severance, consulting or employment
agreement with the Company or any Subsidiary of the Company that employs such individual, “Good Reason” has the meaning,
if any, specified in such agreement.
Section
1.27 “Incentive Stock Option” means an Option which qualifies under Section 422 of the Code and is expressly
designated as an Incentive Stock Option in the Award Agreement.
Section
1.28 “Non-Qualified Stock Option” means an Option that is not an Incentive Stock Option.
Section
1.29 “Option” means an option to purchase Company Common Stock granted under the Plan. The term “Option”
includes both an Incentive Stock Option and a Non-Qualified Stock Option.
Section
1.30 “Participant” means any Service Provider who has been granted an Award pursuant to the Plan.
Section
1.31 “Performance Award” means a Performance Shares or a Performance Unit.
Section
1.32 “Performance Cycle” means the period of time selected by the Administrator during which performance is
measured for the purpose of determining the extent to which a Performance Award has been earned or vested.
Section
1.33 “Performance Goals” means the objectives established by the Administrator for a Performance Cycle pursuant
to Section 6.5 for the purpose of determining the extent to which a Performance Award has been earned or vested.
Section
1.34 “Performance Share” means an Award granted pursuant to Article VI of the Plan of a Share or a contractual
right to receive a Share (or the cash equivalent thereof) upon the achievement, in whole or in part, of the applicable Performance Goals.
Section
1.35 “Performance Unit” means a U.S. Dollar-denominated unit (or a unit denominated in the Participant’s
local currency) granted pursuant to Article VI of the Plan, payable in cash or in Shares upon the achievement, in whole or in part, of
the applicable Performance Goals.
Section
1.36 “Person” means an individual, partnership, corporation, limited liability company, business trust, joint
stock company, trust, unincorporated association, joint venture, governmental authority or any other entity of whatever nature.
Section
1.37 “Replacement Awards” means Shares or Awards issued in assumption of, or in substitution for, any outstanding
awards of any entity acquired in any form or combination by the Company or any of its Subsidiaries.
Section
1.38 “Restricted Stock” means an Award granted pursuant to Section 5.1.
Section
1.39 “Restricted Stock Unit” means an Award granted pursuant to Section 5.2.
Section
1.40 “Securities Act” means the Securities Act of 1933, as amended.
Section
1.41 “Service Provider” means an Employee, Director or consultant of the Company or any of its Subsidiaries.
Section
1.42 “Share” means a share of Company Common Stock.
Section
1.43 “Stock Appreciation Right” or “SAR” means the right to receive a payment from
the Company in cash and/or Shares equal to the excess, if any, of the Fair Market Value of one Share on the exercise date over a specified
price (the “Base Price”) fixed by the Administrator on the grant date (which specified price shall not be less
than the Fair Market Value of one Share on the grant date).
Section
1.44 “Subsidiary” means any entity that is directly or indirectly controlled by the Company or any entity in
which the Company directly or indirectly has at least a 50% equity interest.
Section
1.45 “Termination of employment,” “termination of service” and any similar term or
terms means, with respect to a Director who is not an Employee of the Company or any Subsidiary, the date upon which such Director ceases
to be a member of the Board or of the board of directors of any Subsidiary, with respect to a consultant of the Company or any of its
Subsidiaries, the date upon which such consultant ceases to provide services to the Company and its Subsidiaries and, with respect to
an Employee, the date he or she ceases to be an Employee; provided that with respect to any Award subject to Section
409A of the Code, such terms shall mean “separation from service,” as defined in Section 409A of the Code and the rules,
regulations and guidance promulgated thereunder. Unless otherwise determined by the Administrator, a “termination of employment”
or “termination of service” shall not occur if an Employee, consultant or Director, immediately upon ceasing to provide services
in such capacity, commences to or continues to provide services to the Company or any of its Affiliates in another of such capacities.
Article
II
ADMINISTRATION
Section
2.1 Powers of the Administrator. The Plan shall be administered by the Administrator. The Administrator shall have the sole
and complete authority and discretion to: (i) determine the type or types of Awards to be granted to each Participant; (ii) select the
Service Providers to whom Awards may from time to time be granted; (iii) determine all matters and questions related to the termination
of service of a Service Provider with respect to any Award granted to him or her; (iv) determine the number of Awards to be granted and
the number of Shares to which an Award will relate; (v) approve forms of agreement for use under the Plan, which need not be identical
for each Service Provider; (vi) determine the terms and conditions of any Awards (including, without limitation, the exercise price,
the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture
restrictions and any restriction or limitation regarding any Award or the Company Common Stock relating thereto) based in each case on
such factors as the Administrator shall determine; (vii) prescribe, amend and rescind rules and regulations relating to the Plan, including
rules and regulations relating to Subplans (as defined in Section 2.4) established for the purpose of satisfying applicable foreign laws;
(viii) determine whether, to what extent, and pursuant to what circumstances an Award may be settled in, or the exercise or purchase
price of an Award may be paid in, cash, Company Common Stock, other Awards, or other property, or an Award may be canceled, forfeited
or surrendered; (ix) suspend or accelerate the vesting of any Award granted under the Plan or waive the forfeiture restrictions or any
other restriction or limitation regarding any Awards or the Company Common Stock relating thereto; (x) construe and interpret the terms
of the Plan and Awards granted pursuant to the Plan; and (xi) make all other decisions and determinations that may be required pursuant
to the Plan or as the Administrator deems necessary or advisable to administer the Plan. Any determination made by the Administrator
under the Plan, including, without limitation, under Section 3.3, shall be final, binding and conclusive on all Participants and other
persons having or claiming any right or interest under the Plan. The Administrator’s determinations under the Plan need not be
uniform and may be made by the Administrator selectively among persons who receive, or are eligible to receive, Awards under the Plan,
whether or not such persons are similarly situated.
Section
2.2 Delegation by the Administrator. The Administrator may delegate, subject to such terms or conditions or guidelines as
it shall determine, to any officer or group of officers, or Director or group of Directors of the Company or its Subsidiaries any portion
of its authority and powers under the Plan with respect to Participants who are not Executive Officers or non-employee directors of the
Board; provided that any delegation to one or more officers of the Company shall be subject to and comply with applicable
law.
Section
2.3 Expenses, Professional Assistance, No Liability. All expenses and liabilities incurred by the Administrator in connection
with the administration of the Plan shall be borne by the Company. The Administrator may elect to engage the services of attorneys, consultants,
accountants or other persons. The Administrator, the Company and its officers and Directors shall be entitled to rely upon the advice,
opinions or valuations of any such persons. The Administrator (and its members) shall not be personally liable for any action, determination
or interpretation made with respect to the Plan or the Awards, and the Administrator (and its members) shall be fully protected by the
Company with respect to any such action, determination or interpretation.
Section
2.4 Participants Based Outside the United States. To conform with the provisions of local laws and regulations, or with local
compensation practices and policies, in foreign countries in which the Company or any of its Subsidiaries operate, but subject to the
limitations set forth herein regarding the maximum number of shares issuable hereunder and the maximum award to any single Participant,
the Administrator may (i) modify the terms and conditions of Awards granted to Employees employed and consultants who provide services
outside the United States (“Non-U.S. Awards”), (ii) establish subplans with such modifications as may be necessary
or advisable under the circumstances (“Subplans”) and (iii) take any action which it deems advisable to obtain,
comply with or otherwise reflect any necessary governmental regulatory procedures, exemptions or approvals with respect to the Plan.
The Administrator’s decision to grant Non-U.S. Awards or to establish Subplans is entirely voluntary, and at the complete discretion
of the Administrator. The Administrator may amend, modify or terminate any Subplans at any time, and such amendment, modification or
termination may be made without prior notice to the Participants. The Company, Affiliates and members of the Administrator shall not
incur any liability of any kind to any Participant as a result of any change, amendment or termination of any Subplan at any time. The
benefits and rights provided under any Subplan or by any Non-U.S. Award (x) are wholly discretionary and, although provided by either
the Company or an Affiliate of the Company, do not constitute regular or periodic payments and (y) except as otherwise required under
applicable laws, are not to be considered part of the Participant’s salary or compensation under the Participant’s employment
with the Participant’s local employer for purposes of calculating any severance, resignation, redundancy or other end of service
payments, vacation, bonuses, long-term service awards, indemnification, pension or retirement benefits, or any other payments, benefits
or rights of any kind. If a Subplan is terminated, the Administrator may direct the payment of Non-U.S. Awards (or direct the deferral
of payments whose amount shall be determined) prior to the dates on which payments would otherwise have been made, and determine if such
payments may be made in a lump sum or in installments.
Article
III
SHARES SUBJECT TO PLAN
Section
3.1 Shares Subject to Plan.
(a)
Subject to Section 3.3 and Section 3.6, the aggregate number of Shares which may be issued under this Plan shall be 470,000 (the “Share
Limit”). All of the Shares reserved under the Plan may be issued in the form of Incentive Stock Options under the Plan,
subject to the limitation set forth in Section 3.6. The Shares issued under the Plan may be authorized but unissued, or reacquired Company
Common Stock. No provision of this Plan shall be construed to require the Company to maintain the Shares in certificated form. Unless
the Administrator shall determine otherwise, (x) Awards may not consist of fractional shares and shall be rounded down to the nearest
whole Share, and (y) fractional Shares shall not be issued under the Plan (and shall instead also be rounded as aforesaid).
(b)
If any Award or portion thereof under this Plan is for any reason forfeited, canceled, cash-settled, expired or otherwise terminated
without the issuance of Shares, the Shares subject to such forfeited, canceled, cash-settled, expired or otherwise terminated Award,
or portion thereof, shall again be available for grant under the Plan. If Shares are tendered or withheld from issuance with respect
to an Award by the Company in satisfaction of any Exercise Price, Base Price or tax withholding or similar obligations, such tendered
or withheld Shares shall again be available for grant under the Plan. Notwithstanding the foregoing, and except to the extent required
by applicable law, Replacement Awards shall not be counted against Shares available for grant pursuant to this Plan.
Section
3.2 Limitation on Non-Employee Director Awards. The maximum number of Shares subject to Awards granted during a single Compensation
Year to any non-employee Director, taken together with any cash fees paid during the Compensation Year to the non-employee Director,
in respect of the Director’s service as a member of the Board during such year (including service as a member or chair of any committees
of the Board), shall not exceed (i) $500,000 in total value; or (ii) in the event such non-employee Director is first appointed or elected
to the Board during such Compensation Year, $750,000 in total value, or (iii) in the event such non-employee Director is serving
as non-employee Chairperson (or co-Chairperson) of the Board, $750,000 in total value, in each case calculating the value of any equity
awards based on the grant date fair value of such equity awards for financial reporting purposes.
Section
3.3 Changes in Company Common Stock; Disposition of Assets and Corporate Events.
(a)
If and to the extent necessary or appropriate to reflect any stock dividend, extraordinary dividend, stock split or share combination
or any recapitalization, merger, consolidation, exchange of shares, spin-off, liquidation or dissolution of the Company or other similar
transaction affecting the Company Common Stock (each, a “Corporate Event”), the Administrator shall adjust
the number of shares of Company Common Stock available for issuance under the Plan, the ISO Limit, and the number, class and Exercise
Price (if applicable) or Base Price (if applicable) of any outstanding Award, and/or make such substitution, revision or other provisions
or take such other actions with respect to any outstanding Award or the holder or holders thereof, in each case as it determines to be
equitable. Without limiting the generality of the foregoing sentence, in the event of any such Corporate Event, the Administrator shall
have the power to make such changes as it deems appropriate in (i) the number and type of shares or other securities covered by outstanding
Awards, (ii) the prices specified therein (if applicable), (iii) the securities, cash or other property to be received upon the
exercise, settlement or conversion of such outstanding Awards or otherwise to be received in connection with such outstanding Awards
and (iv) any applicable Performance Goals. After any adjustment made by the Administrator pursuant to this Section 3.3, the number of
shares subject to each outstanding Award shall be rounded down to the nearest whole number of whole or fractional shares (as determined
by the Administrator), and (if applicable) the Exercise Price or Base Price thereof shall be rounded up to the nearest cent.
(b)
Any adjustment of an Award pursuant to this Section 3.3 shall be effected in compliance with Section 424 and 409A of the Code to
the extent applicable.
Section
3.4 Award Agreement Provisions. The Administrator may include such provisions and limitations in any Award Agreement as it
shall determine, subject to the terms of the Plan.
Section
3.5 Prohibition Against Repricing. Except to the extent (i) approved in advance by the stockholders of the Company or (ii)
pursuant to Section 3.3 as a result of any Corporate Event or pursuant to Article XI in connection with a Change in Control, the Administrator
shall not have the power or authority to reduce, whether through amendment or otherwise, the Exercise Price of any outstanding Option
or Base Price or any outstanding SAR or to grant any new Award, or make any cash payment, in substitution for or upon the cancellation
of Options or SARs previously granted and as to which the Exercise Price or Base Price thereof is in excess of the then-current Fair
Market Value of Share.
Section
3.6 Maximum Number of Incentive Stock Options. Notwithstanding the Share Limit, and subject to adjustment in accordance with
Section 3.3 hereof, the maximum number of Shares that may be granted in connection with, and issued pursuant to the exercise of, Incentive
Stock Options granted under this Plan is 470,000 shares (the “ISO Limit”).
Article
IV
OPTIONS AND SARS
Section
4.1 Grant of Options and SARs. The Administrator is authorized to make Awards of Options and/or SARs to any Service Provider
in such amounts and subject to such terms and conditions as determined by the Administrator, consistent with the Plan. SARs may be granted
in tandem with Options or may be granted on a freestanding basis, not related to any Option. Excluding Replacement Awards, the per Share
purchase price of the Shares subject to each Option (the “Exercise Price”) and the Base Price of each SAR shall
be not less than 100% of the Fair Market Value of a Share on the date such Option or SAR is granted. Each Option and each SAR shall be
evidenced by an Award Agreement.
Section
4.2 Exercisability and Vesting; Exercise. Each Option and SAR shall vest and become exercisable according to the terms and
conditions as determined by the Administrator. Except as otherwise determined by the Administrator, SARs granted in tandem with an Option
shall become vested and exercisable on the same date or dates as the Options with which such SARs are associated vest and become exercisable.
SARs that are granted in tandem with an Option may only be exercised upon the surrender of the right to exercise such Option for an equivalent
number of Shares, and may be exercised only with respect to the Shares for which the related Option is then exercisable. The Administrator
shall specify the manner of and any terms and conditions of exercise of an exercisable Option or SAR, including but not limited to net-settlement,
delivery of previously owned stock and broker-assisted sales.
Section
4.3 Settlement of SARs. Upon exercise of a SAR, the Participant shall be entitled to receive payment in Shares, or such other
form as determined by the Administrator, having an aggregate value equal to the Fair Market Value of one Share on the exercise date over
(ii) the Base Price of such SAR; provided, however, that on the grant date, the Administrator may establish a
maximum amount per Share that may be payable upon exercise of a SAR.
Section
4.4 Expiration of Options and SARs. No Option or SAR may be exercised after the expiration of ten (10) years from the
date the Option or SAR was granted, unless a longer or shorter period is set forth in the Award Agreement. Notwithstanding the foregoing,
in the event that on the last business day of the term of the Option or SAR (x) the exercise of the Option or SAR is prohibited by applicable
law or (y) Shares may not be purchased or sold by certain employees or directors of the Company due to the “black-out period”
of a Company policy or a “lock-up” agreement undertaken in connection with an issuance of securities by the Company, the
term of the Option or SAR shall be extended but not beyond a period of thirty (30) days following the end of the legal prohibition, black-out
period or lock-up agreement (to the extent permissible under Section 409A of the Code) and provided further that no extension will be
made if the applicable Exercise Price or Base Price at the date the initial term would otherwise expire is below the Fair Market Value
on such date.
Article
V
Restricted Stock Awards AND RESTRICTED STOCK UNIT AWARDS
Section
5.1 Restricted Stock. The Administrator is authorized to make Awards of Restricted Stock to any Service Provider selected
by the Administrator in such amounts and subject to such terms and conditions as determined by the Administrator. All Awards of Restricted
Stock shall be evidenced by an Award Agreement. Restricted Stock shall be subject to such restrictions on transferability and other restrictions
as the Administrator may impose. These restrictions may lapse separately or in combination at such times, pursuant to such circumstances,
in such installments, or otherwise, as the Administrator determines at the time of the grant of the Award or thereafter. The issuance
of Restricted Stock granted pursuant to the Plan may be evidenced in such manner as the Administrator shall determine.
Section
5.2 Restricted Stock Units. The Administrator is authorized to make Awards of Restricted Stock Units to any Service Provider
selected by the Administrator in such amounts and subject to such terms and conditions as determined by the Administrator. The Administrator
may specify any conditions to vesting as it deems appropriate. For the avoidance of doubt, the Administrator may grant Restricted Stock
Units that are fully vested and nonforfeitable when granted. At the time of grant, the Administrator shall specify the settlement date
applicable to each grant of Restricted Stock Units. Unless otherwise provided in an Award Agreement, on the settlement date, the Company
shall, subject to the terms of this Plan, transfer to the Participant one Share (or a cash amount equal to the then Fair Market Value
of a Share) for each Restricted Stock Unit scheduled to be paid out on such date and not previously forfeited. A Participant shall
not be, nor have any of the rights or privileges of, a stockholder in respect of Restricted Stock Units awarded pursuant to the Plan
unless and until the Shares attributable to such Restricted Stock Units have been issued to such Participant. Notwithstanding the foregoing,
unless otherwise determined by the Administrator, the Restricted Stock Units awarded pursuant to the Plan will receive Dividend Equivalents
in accordance with Article VIII.
Article
VI
Performance AWARDS
Section
6.1 Grant of Performance Awards. The Administrator is authorized to make Performance Awards to any Participant selected by
the Administrator in such amounts and subject to such terms and conditions as determined by the Administrator. All Performance Shares
and Performance Units shall be evidenced by an Award Agreement.
Section
6.2 Issuance and Restrictions. The Administrator shall have the authority to determine the Participants who shall receive
Performance Awards; the number of Performance Shares, the number and value of Performance Units; the cash entitlement of any Participant
with respect to any Performance Cycle; and the Performance Goals applicable in respect of such Performance Awards for each Performance
Cycle. The Administrator shall determine the duration of each Performance Cycle (the duration of Performance Cycles may differ from one
another), and there may be more than one Performance Cycle in existence at any one time. An Award Agreement evidencing the grant of Performance
Shares or Performance Units shall specify the number of Performance Shares and the number and value of Performance Units awarded to the
Participant, the Performance Goals applicable thereto, and such other terms and conditions as the Administrator shall determine. Unless
the Administrator shall determine otherwise, no Company Common Stock will be issued at the time an Award of Performance Shares is made.
The Company shall not be required to set aside a fund for the payment of Performance Awards.
Section
6.3 Earned Performance Awards. Performance Awards shall become earned, in whole or in part, based upon the attainment of
specified Performance Goals or the occurrence of any event or events, as the Administrator shall determine or as set forth in an Award
Agreement. In addition to the achievement of the specified Performance Goals, the Administrator may condition payment of Performance
Awards on such other conditions as the Administrator shall determine. The Administrator may also provide in an Award Agreement for the
completion of a minimum period of service (in addition to the achievement of any applicable Performance Goals) as a condition to the
vesting of any Performance Award.
Section
6.4 Rights as a Stockholder. A Participant shall not have any rights as a stockholder in respect of Performance Awards (including,
without limitation, the right to vote on any matter submitted to the Company’s stockholders) until such time as the Shares attributable
to such Performance Awards have been issued to such Participant or his or her beneficiary. Performance Shares as to which Shares are
issued prior to the end of the Performance Cycle shall, during such period, be subject to such restrictions on transferability and other
restrictions as the Administrator may impose. Notwithstanding the foregoing, unless otherwise determined by the Administrator, the Performance
Awards awarded pursuant to the Plan will receive Dividend Equivalents settled in Shares in accordance with Article VIII.
Section
6.5 Performance Goals and Related Provisions. The Administrator shall establish the Performance Goals that must be satisfied
in order for a Participant to receive an Award for a Performance Cycle or for a Performance Award to be earned or vested. The Administrator
may provide for a threshold level of performance below which no amount of compensation will be paid and a maximum level of performance
above which no additional amount of compensation will be paid under the Plan, and it may provide for the payment of differing amounts
of compensation for different levels of performance. Performance Goals may be established on a Company-wide basis, with respect to one
or more business units, divisions, Subsidiaries or products or based on individual performance measures, and may be expressed in absolute
terms or relative to other metrics including internal targets or budgets, past performance of the Company, the performance of one or
more similarly situated companies, performance of an index, outstanding equity or other external measures. In the case of earning-based
measures, performance goals may include comparisons relating to capital (including but limited to, the cost of capital), stockholders’
equity, shares outstanding, assets or net assets, or any combination thereof. Performance Goals may also be subject to such other terms
and conditions as the Administrator may determine appropriate. The Administrator may also adjust the Performance Goals for any Performance
Cycle as it deems equitable in recognition of unusual or non-recurring events affecting the Company; changes in applicable tax laws or
accounting principles; other extraordinary events such as restructurings; discontinued operations; asset write-downs; significant litigation
or claims, judgments or settlements; acquisitions or divestitures; reorganizations or changes in the corporate structure or capital structure
of the Company; foreign exchange gains and losses; change in the fiscal year of the Company; business interruption events; unbudgeted
capital expenditures; unrealized investment gains and losses; impairments and/or such other factors as the Administrator may determine.
Section
6.6 Determination of Attainment of Performance Goals. As soon as practicable following the end of a Performance Cycle and
prior to any payment or vesting in respect of such Performance Cycle, the Administrator shall determine the number of Performance Shares
or other Performance Awards and the number and value of Performance Units or the amount of any cash entitlement, in each case that has
been earned or vested.
Section
6.7 Payment of Awards. Payment or delivery of Company Common Stock with respect to earned Performance Shares, earned Performance
Units and earned cash entitlements shall be made to the Participant or, if the Participant has died, to the Participant’s Eligible
Representative, as soon as practicable after the expiration of the Performance Cycle and the Administrator’s determination under
Section 6.6 above and (unless an applicable Award Agreement shall set forth one or more other dates) in any event no later than the earlier
of (i) ninety (90) days after the end of the fiscal year in which the Performance Cycle has ended and (ii) ninety (90) days after the
expiration of the Performance Cycle. The Administrator shall determine and set forth in the applicable Award Agreement whether earned
Performance Shares and the value of earned Performance Units are to be distributed in the form of cash, Shares or in a combination thereof,
with the value or number of Shares payable to be determined based on the Fair Market Value of the Company Common Stock on the date of
the Administrator’s determination under Section 6.6 above or such other date specified in the Award Agreement. The Administrator
may, in an Award Agreement with respect to the Award or delivery of Shares, condition the vesting of such Shares on the performance of
additional service.
Section
6.8 Newly Eligible Participants. Notwithstanding anything in this Article VI to the contrary, the Administrator shall be
entitled to make such rules, determinations and adjustments as it deems appropriate with respect to any Participant who becomes eligible
to receive Performance Shares, Performance Units or other Performance Awards after the commencement of a Performance Cycle.
Article
VII
OTHER Stock-Based Awards
Section
7.1 Grant of Stock-Based Awards. The Administrator is authorized to make Awards of other types of equity-based or equity-related
awards and fully vested stock awards, including grants of fully vested Shares (collectively, “Stock-Based Awards”)
not otherwise described by the terms of the Plan in such amounts and subject to such terms and conditions as the Administrator shall
determine, including without limitation the payment of cash bonuses or other incentives in the form of Stock-Based Awards. Unless otherwise
determined by the Administrator, all Stock-Based Awards shall be evidenced by an Award Agreement. Such Stock-Based Awards may be granted
as an inducement to enter the employ of the Company, any Affiliate or any Subsidiary or in satisfaction of any obligation of the Company,
any Affiliate or any Subsidiary to an officer or other key employee, whether pursuant to this Plan or otherwise, that would otherwise
have been payable in cash or in respect of any other obligation of the Company. Such Stock-Based Awards may entail the transfer of actual
Shares, or payment in cash or otherwise of amounts based on the value of Shares and may include, without limitation, Awards designed
to comply with or take advantage of the applicable local laws of jurisdictions other than the United States.
Article
VIII
Dividend Equivalents
Section
8.1 Generally. Dividend Equivalents may be granted to Participants at such time or times as shall be determined by the Administrator.
Dividend Equivalents may be granted in tandem with other Awards, in addition to other Awards, or freestanding and unrelated to other
Awards. Notwithstanding the terms of this Section 8.1, no Dividend Equivalents shall be granted with respect to Options or SARs. The
grant date of any Dividend Equivalents will be the date on which the Dividend Equivalent is awarded by the Administrator, or such other
date permitted by applicable laws as the Administrator shall determine. Dividend Equivalents may, at the discretion of the Administrator,
be fully vested and nonforfeitable when granted or subject to such vesting conditions as determined by the Administrator; provided,
that, unless the Administrator shall determine otherwise in an Award Agreement, Dividend Equivalents with respect to Awards shall not
be fully vested until the Awards have been earned and shall be forfeited if the related Award is forfeited. Dividend Equivalents shall
be evidenced in writing, whether as part of the Award Agreement governing the terms of the Award, if any, to which such Dividend Equivalent
relates, or pursuant to a separate Award Agreement with respect to freestanding Dividend Equivalents, in each case, containing such provisions
not inconsistent with the Plan as the Administrator shall determine, including customary representations, warranties and covenants with
respect to securities law matters.
Article
IX
Termination and Forfeiture
Section
9.1 Termination for Cause; Post-Service Competitive Activity. Unless otherwise set forth in the Award Agreement, if a Participant’s
employment or service terminates for Cause or a Participant engages in Competitive Activity following the Participant’s termination
of employment or service, all Options and SARs, whether vested or unvested, and all other Awards that are unvested or unexercisable or
otherwise unpaid (or were unvested or unexercisable or unpaid at the time of occurrence of Cause or engagement in Competitive Activity)
shall be immediately forfeited and canceled, effective as of the date of the termination or engagement in Competitive Activity. If the
Participant engages in Competitive Activity following the termination, any portion of the Participant’s Awards that became vested
after termination, and any Shares or cash issued upon exercise or settlement of such Awards, shall be immediately forfeited, canceled,
and disgorged or paid to the Company together with all gains earned or accrued due to the sale of Shares issued upon exercise or settlement
of such Awards.
Section
9.2 Termination due to Death. Unless otherwise set forth in the Award Agreement, if a Participant’s employment or service
terminates by reason of death:
(a)
All Options and SARs (whether or not then otherwise exercisable) shall become exercisable in full and the Participant’s Eligible
Representative may exercise all such Options and SARs at any time prior to the earlier of (i) the one-year anniversary of the Participant’s
death or (ii) the expiration of the term of the Options or SARs; provided that any in-the-money Options and SARs that
are still outstanding on the last day of the time period specified in this Section 9.2(a) shall automatically be exercised on such date;
and
(b)
All other Awards shall immediately vest in full upon the Participant’s death, and Restricted Stock Units and Performance Awards
that have not been settled or converted into Shares prior to the Participant’s death shall immediately be settled in Shares. Any
Performance Awards that vest as a result of this Section 9.2(b) shall vest and be paid based on target levels of performance.
Section
9.3 Termination due to Disability. Unless otherwise set forth in the Award Agreement, if a Participant’s employment
or service terminates by reason of Disability, the Participant shall be treated for purposes of the treatment of the Participant’s
Awards under this Section 9.3 as though the Participant continued in the employ or service of the Company and all unvested Awards shall
remain outstanding and vest, or in the case of Options and SARs, vest and become exercisable, in accordance with the terms set forth
in the applicable Award Agreement. Any Options or SARs granted to such Participant that are exercisable at the date of termination by
reason of Disability or that thereafter become exercisable by reason of the operation of the immediately preceding sentence may be exercised
at any time prior to the earlier of (i) the fifth anniversary of the Participant’s termination for Disability or (ii) the expiration
of the term of such Options or SARs.
Section
9.4 Involuntary Termination Without Cause. Unless otherwise set forth in the Award Agreement, if a Participant’s employment
or service is involuntarily terminated without Cause:
(a)
All Options and SARs that are unvested shall be immediately forfeited and canceled, effective as of the date of the termination, and
all Options and SARs that are vested shall remain outstanding and exercisable until the earlier of (i) 30 days after the effective date
of the termination under this Section 9.4 or (ii) the expiration of the term of such Options or SARs; and
(b)
All Awards of Restricted Stock or Restricted Stock Units that are unvested shall be immediately forfeited and canceled, effective as
of the date of the termination; and
(c)
Provided that the Participant signs a general release and waiver of claims in the form provided by the Administrator and does not exercise
any rights to revoke such release, the Participant shall retain a portion of any unvested Performance Awards granted earlier than one
year prior to the termination under this Section 9.4 equal to, for each grant of Performance Awards, the number of Performance Shares
or Performance Units specified in the Award Agreement multiplied by the quotient of (i) the number of full months elapsed between the
grant date in respect of such Performance Awards and the effective date of the termination under this Section 9.4 over (ii) the total
number of months in the Performance Cycle. Such retained Performance Awards will remain outstanding and vest subject to the attainment
of the applicable Performance Goals in respect thereof. Any Performance Awards that do not vest pursuant to this Section 9.4(c) shall
be immediately forfeited and canceled, effective as of the date of the termination.
Section
9.5 Termination for Any Other Reason. Unless otherwise set forth in the Award Agreement, if a Participant’s employment
or service terminates for any reason other as set forth in Sections 9.1 (other than post-service Competitive Activity) through 9.4:
(a)
All Options and SARs that are unvested shall be immediately forfeited and canceled, effective as of the date of the termination, and
all Options and SARs that are vested shall remain outstanding and exercisable until the earlier of (i) 30 days after the effective date
of the termination under this Section 9.5 or (ii) the expiration of the term of such Options or SARs; and
(b)
All other Awards that are unvested or have not otherwise been earned shall be immediately forfeited and canceled, effective as of the
date of termination.
Section
9.6 Post-Termination Informational Requirements. Before the settlement of any Award following termination of employment or
service, the Administrator may require the Participant (or the Participant’s Eligible Representative, if applicable) to make such
representations and provide such documents as the Administrator deems necessary or advisable to effect compliance with applicable law
and the provisions of this Plan.
Section
9.7 Forfeiture and Recoupment of Awards. Awards granted under this Plan (and gains earned or accrued in connection with Awards)
shall be subject to such generally applicable policies as to forfeiture and recoupment (including, without limitation, upon the occurrence
of material financial or accounting errors, financial or other misconduct or Competitive Activity) as may be adopted by the Administrator
or the Board from time to time. Any such policies may (in the discretion of the Administrator or the Board) be applied to outstanding
Awards at the time of adoption of such policies, or on a prospective basis only. Participants shall also forfeit and disgorge to the
Company any Awards granted or vested and any gains earned or accrued due to the exercise of Options or SARs or the sale of any Company
Common Stock to the extent required by applicable law or as required by any stock exchange or quotation system on which the Company Common
Stock is listed or quoted, in each case in effect on or after the Effective Date, including but not limited to Section 304 of the Sarbanes-Oxley
Act of 2002 and Section 10D of the Exchange Act. The implementation of policies and procedures pursuant to this Section 9.7 and any modification
of the same shall not be subject to any restrictions on amendment or modification of Awards.
Section
9.8 Clawbacks. Awards shall be subject to any generally applicable clawback policy adopted by the Administrator, the Board
or the Company that is communicated to the Participants or any such policy adopted to comply with applicable law.
Article
X
CHANGE IN CONTROL
Section
10.1 Alternative Award. Unless otherwise provided in an Award Agreement, and other than with respect to the Performance Award
Conversion, no cancellation, acceleration or other payment shall occur in connection with a Change in Control pursuant to Section 10.3
with respect to any Award or portion thereof as a result of the Change in Control if the Administrator reasonably determines in good
faith, prior to the occurrence of the Change in Control, that such Award shall be honored or assumed, or new rights substituted therefor
following the Change in Control (such honored, assumed or substituted award, an “Alternative Award”), provided that
any Alternative Award must (i) give the Participant who held the Award rights and entitlements substantially equivalent to or better
than the rights and terms applicable under the Award immediately prior to the Change in Control, including an equal or better vesting
schedule and that Alternative Awards that are stock options have identical or better methods of payment of the exercise price thereof
and a post-termination exercise period extending until at least the fifth anniversary of the Participant’s termination (or, if
earlier, the expiration of the term of such stock options); (ii) have terms such that if a Participant’s employment is involuntarily
(i.e., by the Company or its successor other than for Cause) or constructively (i.e., by the Participant with Good Reason)
terminated within the twenty-four (24) months following a Change in Control at a time when any portion of the Alternative Award is unvested,
the unvested portion of such Alternative Award shall immediately vest in full and such Participant shall receive (as determined by the
Board prior to the Change in Control) either (1) a cash payment equal in value to the excess (if any) of the fair market value of the
stock subject to the Alternative Award at the date of exercise or settlement over the price (if any) that such Participant would be required
to pay to exercise such Alternative Award or (2) publicly-traded shares or equity interests equal in value (as determined by the Administrator)
to the value in clause (1).
Section
10.2 Performance Award Conversion. Unless otherwise provided in an Award Agreement, upon a Change in Control, then-outstanding
Performance Awards shall be modified to remove any Performance Goals applicable thereto and to substitute, in lieu of such Performance
Goals, vesting solely based on the requirement of continued service through, as nearly as is practicable, the date(s) on which the satisfaction
of the Performance Goals would have been measured if the Change in Control had not occurred (or, if applicable, the later period of required
service following such measurement date) (such Awards, the “Alternative Performance Awards”), with such service-vesting
of the Alternative Performance Awards to accelerate upon the termination of service of the holder prior to such vesting date(s) thereof,
if such termination of service satisfies the requirements of clause (ii) of Section 10.1 hereof. The number of Alternative Performance
Awards shall be equal to (i) if less than 50% of the Performance Cycle has elapsed, the target number of Performance Awards, and (ii)
if 50% or more of the Performance Cycle has elapsed, a number of Performance Awards based on actual performance through the date of the
Change in Control if determinable, or the target, if not determinable (with the Administrator as constituted prior to the Change in Control
making any determinations necessary to determine performance and the vesting date(s) thereof). The conversion of the Performance Awards
into Alternative Performance Awards is referred to herein as the “Performance Award Conversion”. Following
the Performance Award Conversion, the Alternative Performance Awards shall either remain outstanding as Alternative Awards consistent
with this Section 10.2 or shall be treated as provided in Section 10.3.
Section
10.3 Accelerated Vesting and Payment. Except as otherwise provided in this Article X or in an Award Agreement, upon a Change
in Control:
(a)
each vested and unvested Option or SAR shall be canceled in exchange for a payment equal to the excess, if any, of the Change in Control
Price over the applicable Exercise Price or Base Price;
(b)
the vesting restrictions applicable to all other unvested Awards (other than (x) freestanding Dividend Equivalents not granted in connection
with another Award and (y) Performance Awards) shall lapse, all such Awards shall vest and become non-forfeitable and be canceled in
exchange for a payment equal to the Change in Control Price;
(c)
the Alternative Performance Awards shall be canceled in exchange for a payment equal to the Change in Control Price;
(d)
all other Awards (other than freestanding Dividend Equivalents not granted in connection with another Award) that were vested prior to
the Change in Control but that have not been settled or converted into Shares prior to the Change in Control shall be canceled in exchange
for a payment equal to the Change in Control Price; and
(e)
all freestanding Dividend Equivalents not granted in connection with another Award shall be cancelled without payment therefor.
To
the extent any portion of the Change in Control Price is payable other than in cash and/or other than at the time of the Change in Control,
Award holders under the Plan shall receive the same value in respect of their Awards (less any applicable Exercise Price, Base Price
or similar feature) as is received by the Company’s stockholders in respect of their Company Common Stock (as determined by the
Administrator), and the Administrator shall determine the extent to which such value shall be paid in cash, in securities or other property,
or in a combination of cash and securities or other property, consistent with applicable law. To the extent any portion of the Change
in Control Price is payable other than at the time of the Change in Control, the Administrator shall determine the time and form of payment
to the Award holders consistent with Section 409A of the Code and other applicable laws. Upon a Change in Control the Administrator may
cancel Options and SARs for no consideration if the Fair Market Value of the Shares subject to such Options or such SARs is less than
or equal to the Exercise Price of such Options or the Base Price of such SARs.
Article
XI
OTHER PROVISIONS
Section
11.1 Awards Not Transferable. Except as otherwise determined by the Administrator, no Award or interest or right therein
or part thereof shall be liable for the debts, contracts or engagements of the Participant or his or her successors in interest or shall
be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition
be voluntary or involuntary or by operation of law, by judgment, levy, attachment, garnishment or any other legal or equitable proceedings
(including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect; provided, however,
that nothing in this Section 11.1 shall prevent transfers by will, by the applicable laws of descent and distribution or pursuant to
the beneficiary designation procedures approved by the Company pursuant to Section 11.13 or, with the prior approval of the Company,
estate planning transfers.
Section
11.2 Amendment, Suspension or Termination of the Plan or Award Agreements.
(a)
The Plan may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Administrator; provided,
that without the approval of the stockholders of the Company, no amendment or modification to the Plan may (i) except as otherwise expressly
provided in Section 3.3, increase the number of Shares subject to the Plan; (ii) modify the class of persons eligible for participation
in the Plan or (iii) materially modify the Plan in any other way that would require stockholder approval under applicable law. Except
as otherwise expressly provided in the Plan, neither the amendment, suspension or termination of the Plan shall, without the written
consent of the holder of the Award, materially adversely alter or impair any rights or obligations under any Award theretofore granted.
(b)
The Administrator at any time, and from time to time, may amend the terms of any one or more existing Award Agreements, provided, however,
that the rights of a Participant under an Award Agreement shall not be materially adversely impaired without the Participant’s
written consent. The Company shall provide a Participant with notice of any amendment made to a Participant’s existing Award Agreement.
(c)
No Award may be granted during any period of suspension nor after termination of the Plan, and in no event may any Award be granted under
this Plan after the expiration of ten (10) years from the Effective Date.
Section
11.3 Effect of Plan upon Other Award and Compensation Plans. The adoption of this Plan shall not affect any other compensation
or incentive plans in effect for the Company or any of its Affiliates. Nothing in this Plan shall be construed to limit the right of
the Company or any of its Affiliates (a) to establish any other forms of incentives or compensation for Service Providers or (b) to grant
or assume options or restricted stock other than under this Plan in connection with any proper corporate purpose, including, but not
by way of limitation, the grant or assumption of options or restricted stock in connection with the acquisition by purchase, lease, merger,
consolidation or otherwise, of the business, stock or assets of any corporation, firm or association.
Section
11.4 At-Will Employment. Nothing in the Plan or any Award Agreement hereunder shall confer upon the Participant any right
to continue as a Service Provider of the Company or any of its Affiliates or shall interfere with or restrict in any way the rights of
the Company or any of its Affiliates, which are hereby expressly reserved, to discharge any Participant at any time for any reason whatsoever,
with or without Cause.
Section
11.5 Conformity to Securities Laws. The Plan is intended to conform to the extent necessary with all provisions of the Securities
Act and the Exchange Act and any and all regulations and rules promulgated under any of the foregoing, to the extent the Company, any
of its Affiliates or any Participant is subject to the provisions thereof. Notwithstanding anything herein to the contrary, the Plan
shall be administered, and Awards shall be granted and may be exercised, only in such a manner as to conform to such laws, rules and
regulations. To the extent permitted by applicable law, the Plan and Awards granted hereunder shall be deemed amended to the extent necessary
to conform to such laws, rules and regulations.
Section
11.6 Term of Plan. The Plan was approved by the Board of Directors of the Company on April 26, 2022 (the “Adoption
Date”), subject to stockholder approval. The Plan shall be effective on the date of its approval by the stockholders of
the Company at the 2022 annual meeting of stockholders (the “Effective Date”) in accordance with applicable
law. No awards shall be issued or granted under this Plan until or unless this Plan is approved by stockholders. The Plan shall continue
in effect, unless sooner terminated pursuant to Section 11.2, until the tenth (10th) anniversary of the Adoption Date.
The provisions of the Plan shall continue thereafter to govern all outstanding Awards.
Section
11.7 Governing Law. To the extent not preempted by federal law, the Plan shall be construed in accordance with and governed
by the laws of the State of Delaware regardless of the application of rules of conflict of law that would apply the laws of any other
jurisdiction.
Section
11.8 Severability. In the event any portion of the Plan or any action taken pursuant thereto shall be held illegal or invalid
for any reason, the illegality or invalidity shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced
as if the illegal or invalid provisions had not been included, and the illegal or invalid action shall be null and void.
Section
11.9 Governing Documents. In the event of any express contradiction between the Plan and any Award Agreement or any other
written agreement between a Participant and the Company or any Affiliate that has been approved by the Administrator, the express terms
of the Plan shall govern, unless it is expressly specified in such Award Agreement or other written document that such express provision
of the Plan shall not apply.
Section
11.10 Withholding Taxes. In addition to any rights or obligations with respect to the federal, state, local or foreign income
taxes, withholding taxes or employment taxes required to be withheld under applicable law, the Company or any Affiliate employing a Service
Provider shall have the right to withhold from the Service Provider, or otherwise require the Service Provider or an assignee to pay,
any such required withholding obligations arising as a result of grant, exercise, vesting or settlement of any Award or any other taxable
event occurring pursuant to the Plan or any Award Agreement, including, without limitation, to the extent permitted by law, the right
to deduct any such withholding obligations from any payment of any kind otherwise due to the Service Provider or to take such other actions
(including, without limitation, withholding any Shares or cash deliverable pursuant to the Plan or any Award) as may be necessary to
satisfy such withholding obligations.
Section
11.11 Section 409A. To the extent applicable, the Plan and Award Agreements shall be interpreted in accordance with Section
409A of the Code and Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation
any such regulations or other guidance that may be issued after the adoption of the Plan. Notwithstanding any provision of the Plan to
the contrary, in the event that following the adoption of the Plan, the Administrator determines that any Award may be subject to Section
409A of the Code and related regulations and Department of Treasury guidance (including such Department of Treasury guidance as may be
issued after the adoption of the Plan), the Administrator may adopt such amendments to the Plan and the applicable Award Agreement or
adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions,
that the Administrator determines are necessary or appropriate to (a) exempt the Award from Section 409A of the Code and/or preserve
the intended tax treatment of the benefits provided with respect to the Award, (b) comply with the requirements of Section 409A of the
Code and related Department of Treasury guidance or (c) comply with any correction procedures available with respect to Section 409A
of the Code. Notwithstanding anything else contained in this Plan or any Award Agreement to the contrary, if a Service Provider is a
“specified employee” at the time of the Service Provider’s “separation from service” (as determined
under Section 409A of the Code) then, to the extent necessary to comply with, and avoid imposition on such Service Provider of any
tax penalty imposed under, Section 409A of the Code, any payment required to be made to a Service Provider hereunder upon or following
his or her separation from service shall be delayed until the first to occur of (i) the six-month anniversary of the Service Provider’s
separation from service and (ii) the Service Provider’s death. Should payments be delayed in accordance with the preceding sentence,
the accumulated payment that would have been made but for the period of the delay shall be paid in a single lump sum during the ten (10)
day period following the lapsing of the delay period. No provision of this Plan or an Award Agreement shall be construed to indemnify
any Service Provider for any taxes incurred by reason of Section 409A (or timing of incurrence thereof), other than an express indemnification
provision therefor.
Section
11.12 Notices. Except as provided otherwise in an Award Agreement, all notices and other communications required or permitted
to be given under this Plan or any Award Agreement shall be in writing and shall be deemed to have been given if delivered personally,
sent by email or any other form of electronic transfer approved by the Administrator, sent by certified or express mail, return receipt
requested, postage prepaid, or by any recognized international equivalent of such delivery, (i) in the case of notices and communications
to the Company, to its current business address and to the attention of the Corporate Secretary of the Company or (ii) in the case of
a Participant, to the last known address, or email address or, where the individual is an employee of the Company or one of its Subsidiaries,
to the individual’s workplace address or email address or by other means of electronic transfer acceptable to the Administrator.
All such notices and communications shall be deemed to have been received on the date of delivery, if sent by email or any other form
of electronic transfer, at the time of dispatch or on the third business day after the mailing thereof.
Section
11.13 Beneficiary Designation. Each Participant under the Plan may from time to time pursuant to procedures approved by the
Company name any beneficiary or beneficiaries by whom any right under the Plan is to be exercised in case of such Participant’s
death.
Appendix
C
FORM
OF
CERTIFICATE OF AMENDMENT
OF
SECOND AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
180 LIFE SCIENCES CORP.
180
Life Sciences Corp., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware
(the “Company”), DOES HEREBY CERTIFY:
FIRST: The
name of the corporation is 180 Life Sciences Corp.
SECOND: The
original name of the Company was KBL Merger Corp. IV. The date on which the Company’s original Certificate of Incorporation
was filed with the Secretary of State of the State of Delaware is September 7, 2016. The Amended and Restated Certificate of Incorporation
of the Company was filed with the Secretary of State of the State of Delaware on June 2, 2017. The Second Amended and Restated Certificate
of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on November 6, 2020.
THIRD: The
Board of Directors of the Company (the “Board”), acting in accordance with the provisions of Sections
141 and 242 of the General Corporation Law of the State of Delaware (the “DGCL”),
adopted resolutions approving and deeming advisable an amendment to the Company’s Second Amended and Restated Certificate of Incorporation,
as amended (the “Restated Certificate”), as follows:
RESOLVED: That
Section 8.1 of the Second Amended and Restated Certificate of Incorporation of the Corporation be and it hereby is amended and
restated to provide as follows:
“Section
8.1 Limitation of Director and Officer Liability. A director or officer (as defined in Section 102(b)(7) of DGCL) of the Corporation
shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director
or officer, as applicable, to the fullest extent permitted by the DGCL, as the same now exists or hereafter may be amended, except to
the extent such exemption from liability or limitation thereof is not permitted under the DGCL as the same exists or may hereafter be
amended. Any amendment, modification or repeal of the foregoing sentence shall not adversely affect any right or protection of an officer
of the corporation hereunder in respect of any act or omission occurring prior to the time of such amendment, modification or repeal.”
FOURTH: The
foregoing amendment was submitted to the stockholders of the Company for their approval at a meeting of stockholders which was duly called
and held, upon notice in accordance with Section 222 of the DGCL, at which meeting the necessary number of shares
as required by statute were voted in favor of the amendment. Accordingly, said amendment was duly adopted in accordance with the provisions
of Section 242 of the DGCL.
FIFTH: This
Certificate of Amendment shall become effective on [_____], 2023 at [_____] Eastern Time.
IN
WITNESS WHEREOF, 180 Life Sciences Corp. has caused this certificate to be signed by Ozan Pamir, its Chief Financial Officer, this day
of , 2023.
180
LIFE SCIENCES CORP. |
|
By: |
|
|
Its: |
|
|
Appendix
D
Section
8.1. Limitation of Director and Officer Liability. A director
No Director or officer of the Corporation shall not
be personally liable to the Corporation or its stockholders
for monetary damages for breach of fiduciary duty as a director, exceptdirector
or officer, as applicable, to the fullest extent such
exemption from liability or limitation thereof is not permitted under
by the DGCL as the same now exists
or may hereafter may be amended. Any
amendment, modification or repeal of the foregoing sentence
shall not adversely affect any right or protection of a director or
officer of the Corporation hereunder in respect of any act or omission occurring prior to the time of such amendment,
modification or repeal.
180 LIFE SCIENCES CORP.
THIS
PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
ANNUAL
MEETING OF STOCKHOLDERS – THURSDAY, JULY 6, 2023 AT 9 A.M. PACIFIC TIME |
|
|
|
|
|
CONTROL ID: |
|
|
|
|
|
|
|
REQUEST ID: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The undersigned stockholder of 180 Life Sciences
Corp., a Delaware corporation (the “Company”), hereby acknowledges receipt of the Notice of Annual Meeting of Stockholders
and Proxy Statement of the Company, each dated on or around May [●], 2023, and hereby appoints James N. Woody, M.D., Ph.D. and Ozan
Pamir (the “Proxies”) or any one of them, with full power of substitution and resubstitution, and authority to act in the
absence of the other, each as proxies and attorneys-in-fact, to cast all votes that the undersigned is entitled to cast at, and with all
powers that the undersigned would possess if personally present at, the Annual Meeting of Stockholders of the Company, to be held virtually
on Thursday, July 6, 2023, at 9 a.m. Pacific Time, virtually via live audio webcast at https://agm.issuerdirect.com/atnf (please
note this link is case sensitive), and at any adjournment or postponement thereof, and to vote all shares of the Company that the undersigned
would be entitled to vote if then and there personally present, on the matters set forth on the reverse side, and all such other business
as may properly
come before the meeting. I/we hereby revoke all proxies previously
given. |
|
|
(CONTINUED AND TO BE SIGNED ON REVERSE SIDE.) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
VOTING INSTRUCTIONS |
|
|
|
|
|
|
If you vote by phone, fax or internet, please DO NOT mail your proxy card. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MAIL: |
Please mark, sign, date, and return this Proxy Card promptly using the enclosed envelope. |
|
|
|
|
|
|
FAX: |
Complete the reverse portion of this Proxy Card and Fax to 202-521-3464. |
|
|
|
|
|
|
INTERNET: |
https://www.iproxydirect.com/atnf |
|
|
|
|
|
|
PHONE: |
1-866-752-VOTE(8683) |
|
|
|
|
|
|
|
|
|
|
|
|
|
ANNUAL
MEETING OF THE STOCKHOLDERS OF
180 LIFE SCIENCES CORP |
PLEASE
COMPLETE, DATE, SIGN AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.
PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE: ☒ |
THE
BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR ALL” FOR PROPOSAL ONE, “FOR” PROPOSALS TWO,
THREE, FIVE, AND SIX, AND FOR “1 YEAR” FOR PROPOSAL FOUR. |
|
PROXY
SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS |
|
|
|
Proposal
1 |
|
à |
FOR
ALL |
|
WITHHOLD
ALL |
|
FOR
ALL
EXCEPT |
|
|
|
|
Election of Directors |
|
☐ |
|
☐ |
|
|
|
|
|
|
Lawrence
Steinman, |
|
|
|
|
|
☐ |
|
|
|
|
James
N. Woody, |
|
|
|
|
|
☐ |
|
CONTROL ID: |
|
|
Russell
T. Ray |
|
|
|
|
|
☐ |
|
REQUEST
ID: |
|
|
Francis
Knuettel II |
|
|
|
|
|
☐ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposal 2 |
|
à |
FOR |
|
AGAINST |
|
ABSTAIN |
|
|
|
|
Approval of
the adoption of the First Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan |
|
☐ |
|
☐ |
|
☐ |
|
|
|
Proposal 3 |
|
à |
FOR |
|
AGAINST |
|
ABSTAIN |
|
|
|
|
Advisory vote
to approve named executive officer compensation, as described in the 180 Life Sciences Corp. Proxy Statement. |
|
☐ |
|
☐ |
|
☐ |
|
|
|
Proposal 4 |
|
à |
1 Year |
|
2
Years |
|
3
Years |
|
4
Years |
|
|
Advisory Vote
on the frequency of future advisory votes to approve named executive officer compensation. |
|
☐ |
|
☐ |
|
☐ |
|
☐ |
|
Proposal 5 |
|
à |
FOR |
|
AGAINST |
|
ABSTAIN |
|
|
|
|
Ratification
of the appointment of Marcum LLP, as the company’s independent auditors for the fiscal year ending December 31, 2023. |
|
☐ |
|
☐ |
|
☐ |
|
|
|
Proposal 6 |
|
à |
FOR |
|
AGAINST |
|
ABSTAIN |
|
|
|
|
Approval of
an Amendment to the Company’s Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers
of the Company. |
|
☐ |
|
☐ |
|
☐ |
|
|
|
|
|
|
|
|
MARK “X”
HERE IF YOU PLAN TO ATTEND THE MEETING: ☐ |
This
Proxy, when properly executed will be voted as provided above, or if no contrary direction is indicated, it will be voted “For
All” for Proposal One, “For” Proposals Two, Three, Five, and Six, and for “1 Year” for Proposal Four,
and for all such other business as may properly come before the meeting in the sole determination of the Proxies. |
|
|
|
MARK
HERE FOR ADDRESS CHANGE ☐ New Address (if applicable):
____________________________
____________________________
____________________________
IMPORTANT: Please
sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor,
administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate
name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized
person.
Dated:
________________________, 2023 |
|
|
(Print
Name of Stockholder and/or Joint Tenant) |
|
(Signature of
Stockholder) |
|
(Second Signature
if held jointly) |
KBL Merger Corporation IV (NASDAQ:KBLM)
過去 株価チャート
から 8 2024 まで 9 2024
KBL Merger Corporation IV (NASDAQ:KBLM)
過去 株価チャート
から 9 2023 まで 9 2024